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Delivery of drugs via the intranasal olfactory route is a non-invasive and practical method 
of bypassing the blood-brain barrier (BBB). However, targeted delivery and retention of 
drugs to the olfactory region is a significant challenge due to the geometrical complexity of 
the nasal cavity and mucociliary clearance. Formulating drugs into particulate-carriers, 
specifically, carriers with mucoadhesive properties can potentially overcome this challenge 
by enabling targeted deposition and retention of the drug onto the olfactory epithelium for 
subsequent nose-to-brain transport. Recent modeling data indicates that particles around 
10 μm in size show maximum deposition in the olfactory region, the target site for nose-to-
brain drug absorption. Therefore, the primary objectives of this thesis was to develop and 
characterize 10 μm-sized mucoadhesive microparticles for selective drug deposition in the 
olfactory region and enhanced nose-to-brain delivery. Furthermore, recently several drug 
delivery devices that aim to target drug formulations to the olfactory region in the nasal 
cavity are making their way to the market. Therefore, the second objective of this thesis was 
to explore if the formulative approach of making particles to a specific size and combining 
it with a targeting device could augment olfactory targeting and further enhance 
nose-to-brain delivery of therapeutic molecules. Consequently, the effect of particle size 
combined with a bi-directional delivery technique on the olfactory deposition of 
microparticles in the human nasal cavity was investigated. 
A naturally occurring mucoadhesive polymer, tamarind seed polysaccharide (TSP), was 
spray-dried with model drugs, FITC-Dextrans of molecular weight (MW) 3 to 40 kDa. The 
spray-drying process was optimized by the Box-Behnken experimental design to produce 
particles with 10 µm size. In-vitro and ex-vivo characterization demonstrated mucoadhesive 
potential and successful drug loading of TSP-microparticles. Particles of 10 µm in size 
demonstrated higher olfactory deposition compared to 2 µm sized particles in a 3D-human 
nasal replica, at standard inhalation airflow rate. The nose-to-brain delivery efficiency of the 
mucoadhesive TSP-microparticles was tested in-vivo in a rodent model. An anti-epileptic 
drug (AED) phenytoin was loaded into TSP-microparticles and administered intranasally to 
rats with an insufflator. The analysis of phenytoin concentrations in the rat brain revealed a 
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three-fold greater direct transport of phenytoin with the TSP-microparticles compared to the 
intranasal solution at the end of 60 min. The results from this study demonstrated the 
potential of TSP-microparticles to improve direct transport of drugs to the brain by 
enhancing the nasal residence time of phenytoin due to mucoadhesion. 
In-silico computational fluid and particle dynamics (CFPD) techniques were utilized to 
identify the variability in olfactory deposition of microparticles between three human 
subjects with the inhalational delivery technique. Three normal human nasal cavities 
reconstructed using computerized tomography (CT)-scans were used to study the deposition 
of particles. The results identified that particles around 10 µm have consistently high 
deposition in the olfactory regions of three human subjects without any significant 
inter-subject variability. CFPD techniques were also used to study the effect of particle size 
in combination with a novel bi-directional delivery technique (used in the ‘OPTINOSE®’ 
targeting device) on the deposition of particles in the human nasal cavities. The deposition 
of particles in the olfactory region was found to be a function of particle size. The bi-
directional delivery technique demonstrated significantly higher deposition of particles in 
the olfactory region compared to standard inhalation. The results identified a particle size 
range of 14 to 18 µm can significantly enhance the olfactory deposition of particles when 
administered with bi-directional delivery technique without any inter-subject variability.  
In summary, this thesis demonstrated that formulation strategies can augment olfactory 
deposition and enhance nose-to-brain delivery of therapeutic molecules. This thesis 
integrated data from in-vitro, in-vivo and in-silico studies to refine and optimize a size 
tailored mucoadhesive microparticle delivery system that has promising potential in the 
nose-to-brain drug delivery. 
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1.1  Rationale 
The blood-brain barrier (BBB) serves as a barrier to restrict the entry of potential drugs 
from the systemic circulation into the central nervous system (CNS). The discovery of direct 
drug transport pathways found in the olfactory region of the nasal cavity that can bypass the 
BBB has provided a non-invasive approach to treat complex CNS disorders. However, 
exploiting these direct nose-to-brain pathways and translating them into effective treatment 
strategies for CNS disorders has been challenging. In last 20 years, the vast amount of 
literature published on direct nose-to-brain delivery has led to approximately 165 clinical 
trials, and from this, only five drugs have been approved by the US food and drug 
administration (FDA) for use in the clinic (Appendix A). One of the main reasons behind 
the failure to translate the preclinical research to the clinical stage has been the 
subtherapeutic concentration of drugs reaching the brain following intranasal administration. 
There has been intensive research and development in innovative drug formulation 
technologies to address the inadequate therapeutic drug levels in the brain. Much of this 
research has resulted in the evolution of polymer-based, mucoadhesive, microparticle and 
nanocarrier drug delivery systems. Each of these systems has been shown to deliver higher 
drug concentrations to the brain by sustained release and improved residence time of drugs 
in the nasal cavity. However, to obtain sufficient therapeutic drug levels in the brain, it is 
necessary for a delivery system to target the site of nose-to-brain transport (the olfactory 
region) in the nasal cavity. 
The complex geometry and narrow airways (Figure 1.1) of the nasal cavity makes 
targeted delivery of drug formulations to the olfactory mucosa a significant challenge1. 
Drugs administered as solutions often cannot be retained by the upper, neuron-containing, 
region of the nasal passage and are instead cleared by nasal mucociliary clearance or 
swallowed or lost to dripping2. Drugs formulated as mucoadhesive microparticles might 
have advantages in targeting and retaining the drugs in the olfactory region due to their size 
  Chapter 1 
2 
 
and mucoadhesive properties. Therefore, the overall focus and aim of this thesis is the 
development of an olfactory-targeted mucoadhesive microparticulate delivery system, with 
the idea that this will offer an improved nose-to-brain delivery of drugs. 
1.2 Nose-to-brain drug delivery 
Considering the potential advantages microparticles can offer in nose-to-brain drug 
delivery, it may be hard to understand their poor representation in the pharmaceutical market. 
Nasal formulations intended for nose-to-brain delivery are predominantly available as liquid 
formulations, for example, Fentanyl citrate nasal spray (Lazanda®), Ketorolac tromethamine 
(Sprix®), Zolmitriptan (Zomig®) and Sumatriptan nasal spray (Imitrex®) to treat pain and/or 
a migraine3. To facilitate the discussion on the application of microparticles to overcome the 
challenges of nose-to-brain delivery, some fundamental concepts will be introduced first. 
1.2.1 Anatomical and physiological aspects 
The physiology of the human nose is intended for warming and moistening of inspired 
air and olfaction. The nasal cavity is divided into two separate passages by the nasal septum. 
Each nasal passage ends anteriorly in a nostril and posteriorly at the nasopharynx. The nasal 
passage contains comma-shaped, bony turbinates protruding into the cavity allowing only a 
narrow pathway for the inspired air4,5 as shown in Figure 1.1 B. These geometrically 
complex airways act as a filter for inhaled particles at the same time and help in conditioning 
the inhaled air so that air reaching the lungs is warm and moist6.





Figure 1.1 A. A sagittal view of human nasal cavity displaying the location of the olfactory region and turbinates. B. Transparent view of human 
nasal cavity revealing the narrow airways for the inhaled air. Figure modified with permissions from Fasiolo et al.7
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The nose is a direct entry point to our internal body. To help protect our body from the 
inhaled material, the nasal cavity is lined with mucosa along the nasal passage. Depending 
on where we look in the nasal cavity, three different mucosae are present, which serve 
different purposes. Near to the nostrils, stratified squamous epithelium is found and 
gradually transforms into a pseudostratified columnar epithelium (respiratory mucosa). The 
respiratory mucosa is innervated by the trigeminal nerve and covers most of the nasal cavity. 
The pseudostratified columnar epithelium in the olfactory region (olfactory mucosa) 
contains olfactory neurons responsible for the detection of smell4,8. The intranasal 
administration of drugs provides access to the olfactory neurons in the olfactory mucosa and 
trigeminal nerves in the respiratory mucosa. 
The olfactory region is situated in the upper deep posterior region of the nasal passage 
as shown in Figure 1.1. The surface area of the olfactory region is small and covers 
approximately 10 cm2 of the total nasal cavity8. Due to curved, narrow airways and the 
location of the olfactory region situated deep in the nasal cavity, it is difficult for inhaled 
particles to reach this region. The CNS opens into the nasal cavity through the olfactory 
neurons in the olfactory mucosa as shown in Figure 1.2 A. The olfactory neurons contain 
several non-motile cilia with odorant receptors that extend into the overlying mucus. The 
unmyelinated axons from olfactory neurons extend through the basal lamina and converge 
with axons from other olfactory neurons to form nerve bundles called fila olfactoria. 
Olfactory ensheathing cells and fibroblasts enclose fila olfactoria to form a perineural like a 
sheath. These ensheathed fila olfactoria form the olfactory nerve and travel through the 
cribriform plate into the mitral, periglomerular, and tufted cells in glomeruli of the olfactory 
bulb. Axons from the olfactory bulb project to a number of rostral areas in the brain including 
piriform cortex, amygdala, and entorhinal cortex, forming a channel from the olfactory 
region within the nasal cavity to the brain9–11. The olfactory mucosa also contains supporting 
cells, microvillar cells secured in the basement membrane. The submucosa under the 
basement membrane is highly vascularized, it contains Bowman glands and a variety of other 
cells including progenitor cells such as globose and horizontal basal cells12–15. 
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In addition to the olfactory neurons, the CNS opens into the nasal cavity through 
trigeminal nerve endings in the respiratory mucosa. The free trigeminal nerve endings are 
extended into the respiratory region as shown in Figure 1.2 B. The axons of the trigeminal 
nerve project into the brainstem through the pons and enter into the forebrain through the 
cribriform plate16. Therefore the trigeminal nerve connects to both the caudal and rostral 
parts of the brain, consequently, forming a channel from the respiratory mucosa in the nasal 
cavity to the CNS16,17. The respiratory region contains ciliated and non-ciliated columnar 
cells, mucus-producing goblet cells with tight junctions. The movements of cilia in the 
respiratory region are responsible for the mucociliary clearance in the nasal cavity. The 
submucosa is highly vascularized9.





Figure 1.2 A. Drug transport pathways and organization of the olfactory mucosa B. Trigeminal innervation and the organization of the respiratory 
mucosa. Figure modified with permissions from Thorne et al9
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The trigeminal nerve and olfactory bulb were reported to be connected by the sensory 
endings of the trigeminal ganglion cells located in the nasal epithelium. The sensory endings 
were found to send collaterals directly into the olfactory bulb18. Along with trigeminal and 
olfactory nerves, the nasal passage also contains the nervus terminalus and the vomeronasal 
nerve. However, their role in drug transport to CNS has not been established9. 
1.2.2 Pathways and mechanisms for nose-to-brain transport of drugs 
The exact pathways and mechanisms of direct drug transport into the brain following 
intranasal administration have not been fully characterized. However, specific pathways 
through olfactory, trigeminal nerves, and nasal mucosa have been proposed by experimental 
evidence obtained from published literature. 
1.2.2.1 Neuronal pathways 
Intracellular uptake of molecules into olfactory neurons and trigeminal nerves leads to 
axonal transport of the molecules that have been taken up into the brain. Large protein 
molecules such as horseradish peroxidase and wheat germ agglutinin-horseradish peroxidase 
have been previously reported to be taken up into olfactory neurons via pinocytosis and 
adsorptive endocytosis19. Wheat germ agglutinin-horseradish peroxidase is also reported to 
be endocytosed into the trigeminal nerves and transported to the brain stem by axonal 
transport20,21. Endocytosis of proteins, viruses, and bacteria by the olfactory and trigeminal 
nerves and their subsequent intracellular transport to the brain has been previously 
reported22–26. 
  





Figure 1.3 Nose-to-brain direct pathways from olfactory and respiratory mucosa via olfactory nerve 
and trigeminal nerves. Figure adapted with permissions from Thorne et al9 
The olfactory and trigeminal pathways potentially occur in the olfactory and respiratory 
regions of the nasal cavity. The olfactory neuronal transport target the rostral area of the 
brain and the trigeminal transport target both the rostral and caudal areas of the brain27 as 
shown in Figure 1.3. Specifically, olfactory pathway contributes a vital role in direct nose-
to-brain transport, hence targeting drugs to olfactory mucosa/region can aid nose-to-brain 
delivery28. 
1.2.2.2 Mucosal pathways 
In addition to neuronal pathways, drugs can also cross nasal mucosa in the olfactory 
region to access the perineural space and thereby reach the brain via extracellular pathways 
(Figure 1.2 B). Transcytosis and paracellular diffusion across the nasal mucosa have been 
proposed as the extracellular pathways29–32. 
Receptor-mediated endocytosis is involved in the transcytosis pathway. Size of the 
molecule determines the mechanism of endocytosis, for example, molecules less than 
200 nm follow clathrin-dependent endocytosis and molecules with 100-200 nm are 
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transported by caveolae-mediated endocytosis33,34. Cell type, surface charge, and 
concentration are the other important factors that influence the mechanism of endocytosis in 
transcytosis35. 
Paracellular transport involves opening of tight junctions between the cells in the 
olfactory and respiratory mucosa. The continuous turnover of basal cells as a part of the life 
cycle of biological membranes causes loosening and the opening of tight junctions and 
promotes paracellular transport36,37. Drugs crossing nasal mucosa via extracellular pathways 
may enter the systemic circulation or lymphatic system or can access the perineural spaces. 
Perineural distribution of potassium ferrocyanide, ammonium citrate and fluorescein-
Dextran (3 kDa) in olfactory nerve bundles and their subsequent entry into the brain 
following the intranasal administration was reported38,39. 
Distribution of drugs to the different areas of the brain from the site of entry occurs by 
bulk flow within perivascular spaces of cerebral blood vessels27,40. Wider distribution of 
fluorescent liposomes in the brain parenchyma with increased blood pressure after 
intrastriatal injection demonstrated the role of bulk flow in the distribution of the drug 
molecules41. Cerebrospinal fluid (CSF) flow also plays a role in distributing the drug into 
widespread areas of the brain. Rapid distribution following tracer application into the CSF 
was reported42,43. Drugs reaching the perineural spaces are distributed to the CSF, and the 
flow of CSF can further transport the drug to more distant sites of the brain. However, the 
barrier between the perineural space and CSF is shown to be selective27, and the 
physiological aspects of this distribution are yet to be completely understood. 
1.2.3 Mucociliary clearance of drugs in nasal passages 
The nasal passage is covered with mucus produced by submucosal glands and goblet 
cells in the respiratory mucosa. The mucus in nasal passages are composed of >90 % water, 
0.5-5 % mucus glycoproteins, 1-2 % salts and 0.5-1 % free proteins and is slightly acidic 
with a pH of 5.5-6.56,44. The overlying mucus is between 10-20 µm in depth and consists of 
two distinct layers, a lower less viscous (sol) and an upper high viscous (gel) layer45,46. 
Mucus glycoproteins are responsible for the gel-like structure of the mucus; they are formed 
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from a protein core surrounded by carbohydrate chains47. Many columnar cells in the 
respiratory mucosa possess hair-like protrusions called cilia that are around 5-10 µm long 
and width from 0.1-0.3 µm extending into the sol layer. The number of cilia per cell is 
approximately 30048,49. The synchronized movement of cilia in the sol layer causes the 
transport of the upper gel layer towards the nasopharynx where it is swallowed50,51. The 
human nasal cilia beat with a frequency of 10 Hz, and the average velocity of the mucus 
transport is around 8 mm/min and can vary between 3-25 mm/min52,53. Airborne particles 
entering the nasal passages are entrapped in the mucus layer and get transported along with 
it to the nasopharynx and are eventually cleared from the nasal cavity. The combined action 
of the cilia and mucus layers is called mucociliary clearance. 
Mucociliary clearance is an essential physiological defense mechanism to protect the 
nasal cavity against noxious inhaled particles. On the other hand, it is responsible for the 
rapid clearance of the drugs and formulations after intranasal administration. The average 
nasal clearance half-life for drugs is about 12-15 mm/min. Mucociliary clearance decreases 
the contact time with the nasal mucosa, ultimately leading to decreased drug delivery to the 
brain54,48. 
1.2.4 Current status of nose-to-brain drug delivery 
Conventionally, the nasal route has been used for the systemic delivery of drugs, but now 
it has become an increasingly popular method to bypass the BBB and blood circulation to 
deliver neurotherapeutics to the brain/CNS24,55. The published literature now includes 
substantial evidence for the advantages of nose-to-brain delivery over the other routes of 
administration. Most importantly, a wide range of therapeutic agents including proteins, 
plasmids, gene vectors and stem cells have been shown to reach the brain following 
intranasal administration via olfactory and trigeminal pathways32,56–58. 
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1.2.4.1 Small molecular drugs 
Over the decades, intranasal administration of small molecular drugs has been explored 
for enhancing systemic bioavailability. However, small molecules have relatively easy 
access to the paracellular pathways compared with macromolecules due to their size and can 
directly reach the brain via perineural spaces of olfactory and trigeminal nerves59. All of the 
currently marketed drugs for nose-to-brain delivery are small molecules and are used for the 
management of migraine and/or pain as shown in Table 160. 
Table 1. Currently marketed drugs intended for nose-to-brain drug delivery. 
Drug Molecular weight 
(Da) 
Indication 
ketorolac tromethamine (Sprix®) 255 Moderate to severe pain  
Zolmitriptan (Zomig®) 287 Migraine 
sumatriptan nasal spray (Imitrex®) 295 Migraine 
fentanyl citrate (Lazanda®) 336 Cancer pain 
sumatriptan powder (Onzetra Xsail®) 295 Migraine 
 Several other small molecules have been reported to be promising in animal CNS 
disease models. For example, deferoxamine (MW = 561 Da) exhibits neuroprotection in 
Parkinson’s disease61, Alzheimer’s disease62 and ischemic stroke63. Losartan (MW = 
423 Da) decreased inflammation and amyloid β plaques in Alzheimer’s disease64. Other 
small molecules such as Remoxipride (MW = 371 Da), which are glycine receptor 
antagonists (MW = 369-611 Da) were shown to have high brain concentrations following 
intranasal administration65,66. Small molecules such as Sumatriptan (with permeation 
enhancer)67,68, lidocaine69, Zolmitriptan70, glutathione71, are at the clinical trial stage and are 
expected pipeline drugs. 
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1.2.4.2 Macromolecular drugs 
Macromolecular drugs like proteins and peptides have limited permeation across 
biological membranes and are prone to metabolic degradation in the blood and tissues. 
Intranasal administration provides a promising route for such molecules. Melanocortin, 
arginine-vasopressin and insulin were among the first peptides determined in CSF following 
intranasal administration, all these peptides were detected within 30 min in CSF of human 
volunteers72. Detectable brain concentrations of growth factors73–76, neuropeptides77,78, 
neurotrophic factors79,80,81 and other macromolecules82 have been reported following 
intranasal administration in animal models. Higher CNS levels of intranasal insulin 
compared to subcutaneous injection were reported in mice. Highest levels were found in the 
trigeminal nerve and olfactory bulbs suggesting the transport to the CNS through neuronal 
pathways83. Clinical trials in Alzheimer’s disease patients showed intranasal insulin 
improved memory and preserved general cognition84,85 and had rapid action86. Efficacy of 
intranasal insulin in treating obesity in humans and mice has been reported87. Intranasal 
administration of sleep-related peptide orexin-A has shown improved brain metabolic 
activity in rhesus monkeys and stabilized REM sleep in humans88–90. 
An increasing number of protein drugs for the treatment of CNS diseases and recent 
discoveries of essential brain functions have stimulated this area of research. Analysis of the 
literature shows a doubling of the number of publications on nose-to-brain peptide delivery 
reporting in-vivo studies in the last seven years (55 versus 120 reports [pubmed database]). 
Currently, many intranasal peptide and protein drugs are undergoing clinical trials and 
represent the most promising group of pipeline drugs to treat complex CNS diseases. Insulin 
is under clinical trials for the treatment of Schizophrenia (Phase I)91, Alzheimer’s disease 
(Phase I and Phase III)92–95, obesity (Phase II)96 and major depressive disorder (Phase II)97. 
Oxytocin is being examined for the treatment of schizophrenia (Phase I)98–100, autism 
spectrum disorder (Phase I and Phase III)101–103 and post-traumatic stress disorder (Phase I, 
II and Phase III)104–106. The efficacy of Arginine-vasopressin in the treatment of cognitive 
and behavior disorders (Phase I)107,108, Neuropeptide Y in the treatment of obesity 
(Phase I)96, insulin-like growth factor-I in the treatment of obesity and diabetes (Phase I)109 
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are also being investigated. Other potential peptide drugs such as melanocortin, 
cholecystokinin, NAP neuropeptide and hexarelin are also under clinical trials for nose-to-
brain delivery82. Although intranasal administration is a potential route for peptide drugs, 
many reported studies use simple drug solutions and the drugs are failing to reach the 
brain/CNS in therapeutic concentrations. Nevertheless, the trend is now changing to the 
carrier-based formulation of peptide drugs to improve the efficacy of such drugs. 
1.2.4.3 Cell-based therapies 
Targeting of stem cells to the brain via intranasal endocytic neuronal pathways represents 
the most recent group of intranasal drugs. Mesenchymal cells administered intranasally in 
mice have shown therapeutic potential in Parkinson’s disease and several models of 
stroke110–113. Fluorescently labeled mesenchymal stem cells has been transported to the brain 
via neuronal pathways 1 h after intranasal delivery in mice64. The therapeutic potential of 
intranasal neural stem/progenitor cells has been recently identified; with intranasal delivery 
providing direct transport of neural stem/progenitor cells to intracerebral gliomas in six h58. 
Finally, intranasal administration of genetically engineered T-cells has been successful in 
suppressing the inflammation in mouse models of multiple sclerosis114. The potential of such 
cell-based therapies has only recently been identified and is yet to be fully explored. 
1.2.5 Challenges and strategies for efficient nose-to-brain drug delivery 
As discussed in the previous sections, nose-to-brain administration has excellent 
potential for delivery of novel therapies for brain diseases. However, achieving sufficient 
therapeutic drug levels in the brain is still a challenge. In addition to the fast mucociliary 
clearance and loss of drug to the systemic and lymphatic circulation, targeting drugs to 
neuronal rich regions like the olfactory region in the nasal cavity and facilitating the transport 
across mucosal membrane are the significant challenges for attaining therapeutic drug levels 
in the brain via nose-to-brain delivery. Hydrophilic small molecular drugs have a 
bioavailability of 10 %, and peptide and protein drugs have a bioavailability of about 1 % 
following intranasal administration115. Therefore, to achieve efficient absorption and 
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therapeutic efficacy, approaches to target the olfactory region in the nasal cavity, increase 
the contact time of drugs with nasal mucosa, and facilitate the transport of drugs across the 
mucosa are required. 
 Many strategies such as, use of permeation enhancers to facilitate the drug transport 
across the nasal mucosa, use of vasoactive agents (bradykinin) to chemically disturb the 
BBB116,117, use of microbubble facilitated focus ultrasound waves to open the BBB118, 
implanting polymeric wafers119,120 & programmable microchips121, and chemically 
modifying the drug to increase the permeability and water solubility122,123, to improve the 
drug delivery to the brain are being researched upon. As stated in Section 1.1, much of the 
research has led to development of nano/microparticle delivery systems. The objective of 
this thesis is not, however, to review the many exciting aspects of these strategies as many 
of them are either invasive28 or associated with side effects124. Nevertheless, a brief 
comparison of the strengths and weaknesses of non-particle approaches to 
nano/microparticle delivery systems to increase drug transport across the nasal mucosa is 
presented here.  
Administration of drug solutions with permeation enhancers to open the tight junctions 
in the epithelial cells and enhance the transport across the nasal mucosa has been reported115. 
However, the permeation enhancers used in the studies such as surfactants, phospholipids, 
bile acids, etc. are reported to produce toxic effects on the nasal mucosa including decreased 
ciliary beat frequency, tissue damage, and irreversible ciliotoxicity125. On the contrary, 
nanoparticles can provide enhanced transport across the nasal mucosa without the use of an 
enhancer due to their size. Nanoparticles less than 20 nm can pass the epithelial tight 
junctions, while larger nanoparticles can cross the mucosal barrier transcellularly, by 
entering into the cell by the process of endocytosis or phagocytosis115. 
Another strategy, is to chemically modify the drug to improve solubility and permeability 
which has been reported for nose-to-brain delivery126. Producing prodrugs by chemical 
modification of a drug to change its lipophilicity to increase permeability and water solubility 
has been reported127–129. However, prodrug synthesis requires challenging skills involving 
reduction of polar groups or linking a lipophilic moiety to the drugs and in general is not 
fruitful28. On the contrast, nano/microparticles can be produced by single step processes like 
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spray-drying and have given promising results in pre-clinical studies to improve the brain 
delivery of a variety of drugs such as brimocriptine130, rokitamycin131, rivastigimin132, 
venlafaxine133,134, tizanidine135. 
Formulating drugs as nano/microparticle delivery systems, in general, has numerous 
advantages for nose-to-brain delivery of drugs. These delivery systems can control the 
release of drugs at a predetermined rate and desired drug levels can be maintained136. 
Nano\microparticles can prevent drug loss and degradation and improve drug solubility137 in 
the nasal cavity28. Nano/microparticle delivery systems can reduce the mucociliary 
clearance, increase residency time, enhance the permeation of drug through nasal mucosa, 
and promote large molecular138/phytochemical139 drug delivery across the nasal cavity28. 
Due to their advantages, these delivery systems are being extensively researched and are 
delivering promising results in pre-clinical studies28,140. 
Although nano\microparticle delivery systems have several advantages, a few limitations 
of these delivery systems exist in nose-to-brain delivery. Mucosal damage, nasal irritation, 
the effect of patients position during administration on brain uptake, low entrapment 
efficiency and storage related problems need to be addressed by further investigations to 
exploit the full potential of these delivery systems28,115. 
1.3 Delivery systems for nose-to-brain drug delivery 
Drug delivery systems intended for nose-to-brain delivery are designed to transport the 
drug to the brain, attain a desired therapeutic level and maintain the drug concentration 
within the therapeutic window. Furthermore, the desired characteristics of an ideal drug 
delivery system are to reduce the dose of the drug, have minimal side effects and ease of 
administration. Based on the size, drug delivery systems for nose-to-brain can be divided 
into nanocarriers and microparticles. Nanocarriers and microparticles have a potential to 
achieve the desired therapeutic level of drug in the brain by controlling and/or sustaining the 
release rate of encapsulated drug and nasal residence time141. 
  Chapter 1 
16 
 
Nanocarrier drug delivery system include polymeric nanoparticles, nanoemulsions, 
micelles, liposomes and nanogels. These delivery systems provide a versatile platform with 
great potential in overcoming the challenges associated with nose-to-brain delivery. 
However, the focus of this thesis is microparticles and not the nanocarriers; nonetheless, a 
short introduction on the impact of the nanocarrier drug delivery system will be provided to 
facilitate further discussions. 
1.3.1 Nanocarrier drug delivery systems 
The rapid increase in the number of publications reporting nanocarrier systems for 
nose-to-brain delivery demonstrates the enormous potential of such delivery systems in 
recent times142. Polymeric nanoparticles (NPs) have been successful in the delivery of small 
molecules to the brain. For example, chitosan NPs were shown to increase the concentration 
of two small MW drugs rasagiline and bromocriptine significantly in the brain after 
intranasal administration compared to intravenous (IV) adminsitation143,130. Use of other 
polymers such as polyethylene glycol (PEG), PLGA, poly (lactic acid) (PLA) and gelatin to 
formulate the NPs has also been reported28,82,144. 
Polymeric NPs have also been reported for their success in encapsulating and delivering 
macromolecular protein and peptide drugs such as a thyrotropin-releasing hormone, which 
when encapsulated in PLA NPs successfully suppressed seizures in epileptic rats145,146. Other 
peptides and protein drugs such as leucine–encephalin147, osteopontin148, and vasoactive 
intestinal peptide149 were reported to show higher brain concentrations with polymeric 
NPs82. Similarly, the ability of other nanocarrier systems such as nanoemulsions150, 
micelles151,152, liposomes153,154, and nanogels155 to enhance nose-to-brain delivery has been 
reported. Polymers employed in the preparation of nanoparticles and their size are found to 
be two critical factors that influence drug targeting to the brain after intranasal 
administration156. 
As implied above, nanocarrier systems could be an excellent platform for drug delivery 
to treat CNS diseases. However, still, no nanocarrier delivery system has reached the clinical 
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development phase. More conclusive studies, pharmacokinetic and pharmacodynamic data 
are required to unveil the full potential of such nanocarrier delivery systems. 
1.3.2 Microparticle drug delivery system 
As the name suggests, microparticles are tiny particles with size ranging from 
1 to 1000 µm. In the drug delivery field, microparticles are vesicles made up of a polymer 
into which drugs can be loaded for protection, transport, targeting, and release. Due to their 
size, microparticles provide an increased surface area which is advantageous for drug 
delivery. The high surface area of microparticles can aid faster drug diffusion into the 
external environment. Also, by changing the characteristics of the polymer drug release from 
the microparticles can be tuned to meet therapeutic requirements157. 
Microparticles can encapsulate many types of drugs including small molecules and 
peptide and protein drugs. They are biocompatible and can provide sustained release of the 
drug over long periods of time. For example, the commercially available PLGA 
microparticle products Nutropin Depot® and Lupron Depot® can sustain the release of 
macromolecular drugs somatropin and leuprolide respectively, for over a month replacing 
the need for daily injections158. 
Microparticle formulations can be administered as suspensions or solids (powders), and 
are administered via oral159, pulmonary160 and parenteral (intramuscular (IM)161, 
Subcutaneous159) routes. However, for nasal administration, solid particles can have good 
patient compliance, deposition in the nasal cavity and provide high dose without the 
necessity of a liquid vehicle162,163. Also, solid particles can enhance drug diffusion and 
absorption across the mucosa164. Many studies have reported in-vivo the advantage of 
administering drugs formulated as solid microparticles for intranasal administration, a few 
examples are reported in Table 2. 
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Polymer Observation Ref 
Carvedilol Rabbits 20 to 50  Chitosan 
Microparticles enhanced 
bioavailability (72.29 %) after 
intranasal administration vs 
IV (67.87 %) 
165 





Intranasal administration of 
microparticles produced a 
prolonged hypoglycemic 
effect (2-6 h) vs. IV (1 h) 
166 





enhanced the bioavailability 
of gentamicin by two-fold 
compared to the intranasal 
solution 
167 




produced 4-5 fold higher 
bioavailability compared to 
the control (mannitol), and the 
hypoglycemic effect lasted for 
more than 2 h vs. IV (15 min) 
168 
Verapamil  Rabbits 21 to 53 Chitosan 
Intranasal microparticles 
produced higher 
bioavailability (58.6 %) than 




1.3.3 Nanocarrier versus microparticles for nose-to-brain drug delivery 
It is an important question to reflect on as to why microparticles but not nanocarriers are 
used in this thesis for nose-to-brain delivery, especially, after having presented the success 
of nanocarrier delivery systems. In this case, it’s a matter of size perhaps literally, as will be 
discussed in Section 1.3.5.1.1. This section compares microparticles and nanocarrier 
delivery systems for nose-to-brain delivery of drugs. 
  Chapter 1 
19 
 
Estimation of drug transported through direct neuronal pathways as a function of the 
formulation can represent the efficiency of the formulation. Nose-to-brain direct transport 
percentage (%DTP) is the amount of the drug dose that is estimated to reach the brain via 
direct routes. The %DTP offers an interpretation of drug fraction transported through the 
neuronal pathways and has been used to represent the efficiency of formulations and delivery 
systems142,170,171. The values of %DTP can range from -∞ to 100, values between -∞ to 0 
indicate the drug transport is only through IV route, higher than 0 indicates drug transport 
through direct nose-to-brain neuronal pathways171. 




∗ 100  |𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 1 
Where AUC is the area under the curve representing drug concentration variation over 




∗ AUCblood intranasal  |𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 2 
With an aim to compare the efficiencies of nanoparticle systems and microparticles, 
%DTP values from the reported literature of the respective delivery systems were calculated. 
Initially, scientific publications reporting quantitative data on drugs by nose-to-brain 
delivery of microparticle delivery systems were identified. Specific keywords were used to 
search the PubMed database, and the search resulted in 303 articles. Further screening was 
performed based on their title, abstract and subsequently full text to identify publications 
reporting in-vivo brain or CSF concentrations of the drug. A total of 45 publications were 
identified reporting the formulation of drugs into microparticles for nose-to-brain delivery, 
out of which only seven had quantitative brain/CSF drug concentrations. The %DTP values 
were calculated using the Equation 1 and Equation 2. The %DTP values for nanocarrier 
systems were obtained from a recently published scientific article by Pires C.P and Santos 
O.A.142. 
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Microparticles containing hydrophobic drugs had relatively low %DTP values as 
their efficiency to reach the brain after IV administration was higher which decreased the 
“F” value and thereby the %DTP131,172. Higher %DTP were observed for microparticles 
loaded with hydrophilic drugs indicating their difficulty in permeating the BBB173–175. 













Figure 1.4 Comparison of drug delivery efficacy via neuronal pathways of nanocarriers and 
microparticles. Lines represent the arithmetic mean for the individual delivery systems. Statistical 
analysis was done by applying Mann-Whitney U test, **P =0.0037. Data for individual studies are 
reported in Appendix B. 
The %DTP of the microparticles calculated from the identified publications and the 
%DTP of nanocarriers obtained are grouped according to the delivery system and presented 
in Figure 1.4. The statistical analysis resulted in a significant difference between the delivery 
systems. The %DTP of microparticles was significantly higher than the nanocarrier systems 
(P = 0.0037) indicating direct transport of drugs to the brain from the microparticle delivery 
system is higher than the nanocarrier delivery system. Although the %DTP is a good 
indicator of nose-to-brain drug delivery, this comparison alone may not provide conclusive 
evidence to confirm microparticles are more advantageous than nanocarriers. This is due to 
the fact that this study compares only one parameter, but critical factors such as 
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pharmacological efficacy, toxicity, and therapeutic outcomes must be compared to prove the 
advantage of microparticles over nanocarrier systems. 
This comparison of %DTP values also has its own limitations. For instance, the 
difference in number of reports being compared between microparticles and nanocarriers 
(7 vs. 56) and the presence of outliers with very low %DTP values for certain nanocarrier 
systems176–178 are two major downsides of the study. In addition, formulation and delivery 
factors such as differences among administered formulations (suspension, powder etc.), 
difference among the size of nanoparticles (100 nm-1 µm), variety of drug delivery methods 
and apparatus employed for drug delivery to animals and site of drug delivery (tip of the 
nostril/inside the nasal cavity) might have affected the %DTP values. Also, a variety of 
animal models employed, variable factors among the animals that can affect the drug kinetics 
such as age, body weight, breed, etc. might have contributed to the %DTP values. In 
summary, consideration of more factors and data from extensive studies are required to 
identify the ideal delivery system for nose-to-brain delivery of drugs. However, in this thesis, 
a microparticle delivery system is studied due to its size as will be discussed in 
Section 1.3.5.1.1 
Interestingly, this study revealed a very low number of preclinical studies utilizing the 
microparticle delivery system for the nose-to-brain delivery of drugs, identifying shortage in 
critical pharmacokinetic and pharmacodynamic data required for clinical translation of 
microparticle systems. Though many scientific articles reported formulation and in-vitro 
characterization of drugs for nose-to-brain delivery of drugs, only a few reported results from 
in-vivo studies. This study could not identify the exact reason for this poor translation of 
microparticles compared to nanocarriers in nose-to-brain drug delivery. However, based on 
the literature, a few assumptions can be made. The advantageous characteristics of 
nanocarriers in nose-to-brain delivery such as the high surface area to volume, ability to 
bypass biological barriers (enhanced drug absorption) due to size and ability to enter cells 
by pinocytosis (enhances drug absorption)179 might have contributed to their comparatively 
better translation into preclinical studies.  
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Despite the advantages of microparticle delivery systems as stated in previous sections, 
the absence of well-distributed data indicates that this is an area where more research is 
needed to fully characterize and exploit its potential in nose-to-brain delivery of drugs.  
1.3.4 Microparticles for nose-to-brain delivery 
As stated in the previous section, few scientific articles are identified in the published 
literature reporting microparticles intended for nose-to-brain delivery. Among these, 51 % 
reported only in-vitro data and only one article reported the extent of pharmacological 
effects180, which represents the significant lack of critical data in this field.  
Among the studies reporting in-vivo pharmacokinetic data, only seven studies quantified 
the drug concentrations in the brain/CSF. However, these studies reported encouraging 
results, for example, the antiviral prodrug zidovudine formulated into chitosan and stearic 
acid microparticles had a six-fold increase in CSF uptake through the neuronal 
pathways181,174. Faster CSF uptake of the antimigraine drug zolmitriptan and reduction in the 
peripheral drug levels have been reported from chitosan and hydroxypropyl methylcellulose 
(HPMC) microparticles182. Enhanced CSF uptake of deferoxamine mesylate from 
methyl-β-cyclodextrin microparticles has been reported as the first formulative approach to 
increase the nose-to-brain transport of deferoxamine mesylate175. Also, increased CSF 
uptake of N6-cyclopentyladenosine, rokitamycin from mannitol-lecithin, chitosan and 
chitosan glutamate microparticles has been reported131,173. Most of these studies report that 
the presence of mucoadhesive polymers like chitosan and HPMC increase the residence time 
of the formulations in the nasal cavity and lead to enhanced brain/CSF drug transport. The 
mechanism of mucoadhesion and its effect on the bioavailability of drugs will be described 
in detail in Section 1.3.5.2. 
Mucoadhesive microparticles have been studied in three in-vivo studies in humans183 and 
rabbits184,185. These studies reported increased residence time of microparticle formulations 
in the nasal cavity due to the mucoadhesive nature of the polymers used. One study reported 
increased accumulation of the analgesic tramadol in the brain by HPMC microparticles. The 
mucoadhesive strength of HPMC microparticles retained tramadol in the rabbit nasal cavity 
  Chapter 1 
23 
 
for extended time periods consequently increasing tramadol accumulation in the brain as 
observed by gamma scintigraphy studies186. Sustained drug release resulting in constant 
plasma profiles of the antiemetic drug ondansetron was also reported with chitosan, PLA, 
and PLGA microparticles187,188. Rapid absorption of the drug and high bioavailability was 
reported with carbamazepine loaded chitosan glutamate microparticles189 and lorazepam95. 
Only one study reported no difference in the bioavailability of drug between starch 
microparticles and control in a rabbit model190. Moreover, one study has emphasized the 
importance of drugs reaching the olfactory region for obtaining therapeutically sufficient 
brain concentration. Sun et al. reported that methotrexate loaded chitosan microparticles 
enhanced brain tissue uptake of the drug. However, the levels were still not therapeutic due 
to low amounts of drug reaching the olfactory region172. A substantial fraction of the reported 
in-vivo studies focused on the formulation of small MW drugs (232-827 Da), with 
insulin191,192 and α-corobotoxin180 being the only two macromolecules reported. 
Drug and characteristics of polymers have been shown to have a significant impact on 
nose-to-brain delivery of microparticles. Although particle size and method of 
manufacturing can impact drug loading and delivery efficiencies, their effect has not been 
discussed extensively in the reported literature. Spray-drying is the most popular method of 
microparticle preparation, and chitosan is the most used polymer for the formulation of 
microparticles intended for nose-to-brain delivery. Almost half of the reported studies used 
chitosan and/or chitosan derivatives and this can be attributed to mucoadhesive nature. A 
summary of formulation properties is given in Table 3. 
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Table 3: Summary of microparticle formulation properties from the literature intended for the 
nose-to-brain delivery. 
Drug Polymer Particle 
Size (µm) 
Method Ref 






Ethyl Cellulose and 
chitosan 




5-8 Spray-drying 195 
Lorazepam HPMC and Carbomer 2-3 Spray-drying 196 
Rokitamycin Chitosan 2-5 Spray-drying 197 
Zolmitriptan Chitosan 1-4 Spray-drying 198 
Rokitamycin Chitosan derivatives 1-6 Spray-drying 199 
Sumatriptan HPMC 20-35 Spray-drying 200 





Chitosan and Alginate 1-3 Spray-drying 202 





















Granisetron Sodium CMC 7-15 Freeze drying 206 
Lysozyme 
as model protein 
HPMC and water-
soluble chitosan 
7-12 Freeze drying 207 












Sodium alginate and 
Chitosan 





2 Spray-drying 210 
Metoclopramide Gellan gum 9-10 Spray-drying 211 
Tacrine 
hydrochloride 
Chitosan/pectin 1-19 Spray-drying 212 
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1.3.5 Application of microparticles to overcome the challenges of nose-to-brain 
delivery 
As described in Section 1.2.5, targeting drug to the olfactory region, overcoming 
mucociliary clearance and facilitating drug transport across the mucosal membrane remain 
significant challenges for nose-to-brain drug delivery. In this thesis, formulating drugs into 
microparticles is investigated as a strategy to address these delivery challenges. 
1.3.5.1 Targeting the olfactory region 
1.3.5.1.1 Effect of particle size 
It has been reported that the size of a particle defines its aerodynamics and deposition in 
the geometrically complex human nasal cavity. Particles larger than 20 µm show preferential 
deposition in the anterior part of the nasal cavity due to high inertial impaction, while the 
majority of particles less than 5 µm escape the nasal cavity, following the air streamlines, 
and deposit in the lungs as shown by low deposition fraction in the nasal cavity213. 
With the advancements in computational power, recently, in-silico modeling has become 
a critical tool in characterizing various factors affecting deposition of particles in the nasal 
cavity. Recent modeling data from two reports suggested that particles around 10 µm in size 
show high deposition in the olfactory region when administered intranasally at normal 
inhalation rates of around 20 L/min214,215. Figure 1.5 shows the deposition of particles in the 
olfactory region as a function of size in one human subject from a modeling study. These 
studies have triggered the idea of controlling particle size to target specific sites in the nasal 
cavity. Therefore, this thesis postulates that formulating microparticles which are around 
10 µm in size and loaded with drugs can potentially target the drug to the olfactory mucosa 
after inhalation. 




Figure 1.5 Deposition of microparticles in the olfactory region as a function of particle size. The 
particles with size around 10 µm are shown to enhance the particle deposition in the olfactory region. 
Solid line represents computational simulation modeling studies and diamond symbols represent the 
study in a 3D human nasal cast. Figure adapted with permissions from Schroeter et al214 
1.3.5.1.2 Targeting devices 
Use of novel and effective drug delivery device technologies for targeting drug 
formulations to the olfactory region are reported in the literature. Among such systems, 
pressurized olfactory delivery technology (POD, Impel neuropharma), controlled particle 
dispersion technology (Kurve) and breath powered bi-directional technology (OPTINOSE) 
have shown potential for nose-to-brain drug delivery216–218. 




Figure 1.6 Delivery devices to target drug to the olfactory region in the human nasal cavity. 
Images are taken from http://impelnp.com/, http://www.kurvetech.com/devices.asp, and 
https://www.optinose.com 
Preclinical studies in rats with POD technology show high deposition of drug in the 
olfactory region. Studies have reported pain relief by morphine216, the prolonged 
anti-depressant effect by a peptide drug219 and a 13.6 fold increase of nelfinavir 
brain-to-blood ratio220. Kurve technology has shown increased olfactory deposition in 
five human subjects217 and promising results in Phase II clinical trials with insulin for the 
treatment of Alzheimer’s disease and Amnestic Mild Cognitive Impairment84. Finally, due 
to the ability to deposit high amounts of drug in the olfactory region, OPTINOSE technology 
was shown to decrease the dose of oxytocin required to produce the cognitive responses in 
trials with healthy humans218. Recently, the FDA approved sumatriptan powder (Onzetra 
Xsail®), which utilizes this technology for delivery of sumatriptan into the anterior part of 
the nasal cavity, for treatment of migraine. 
All these delivery devices target the olfactory region by dispersing the drug into micron 
size particles. Because particle deposition in the nasal cavity is known to be affected by 
particle size, it would be interesting to explore if the combination of controlled particle size 
with a targeting device can further enhance the olfactory targeting of the drugs. 




In addition to targeting the olfactory region, it is helpful if the drug formulation is 
retained in the olfactory region long enough for absorption to take place. Many polymers 
used in microparticle formulations can adhere to mucus, therefore, prolonging the residence 
time of drug in the olfactory region. 
Two critical steps in the mucoadhesion process are the initial contact stage and then the 
consolidation stage. For solid microparticles, the contact stage is most likely achieved by 
water movement from the mucosa into the formulation and hydration of polymer chains221. 
Consequently, the nasal mucosa de-hydrates causing the mucus viscosity to increase. In the 
second stage, consolidation between polymer and mucin happens by interpenetration of 
polymer chains into mucin to form entanglements, the formation of van der Waals, hydrogen 
and/or electrostatic bonds such as disulfide bonds222. These chemical bonds and molecular 
entanglements create regions where mucus viscosity is further increased leading to high 
resistance to the ciliary movement, resulting in decreased mucociliary clearance223–225 and 
providing a prolonged contact time for the drug in the nasal cavity. As solid microparticles 
can de-hydrate the nasal mucosa leading to an increase in mucous viscosity, they would 
lower the usual requirements for the formation of secondary chemical bonds compared to 
the pre-hydrated suspensions54,226. Hence, solid microparticles engineered with 
mucoadhesive polymers are exceptionally well suited for nose-to-brain drug delivery. 
1.3.5.3 Facilitating transport across the mucosa 
Solid microparticles are shown to increase the paracellular absorption of drugs loaded 
into them by opening tight junctions. For example, dry starch microparticles containing 
insulin temporarily opened tight junctions between epithelial cells and enhanced the 
absorption of insulin compared to pre-hydrated microparticles227–229. The opening of tight 
junctions by dry starch microparticles was thought to be caused by the initial dehydration of 
the mucosa which was not required in the case of the pre-hydrated microparticles230. Also, 
polymers such as chitosan and polycarbophil used for microparticle preparation were shown 
to open the tight junctions reversibly by inducing changes in transmembrane proteins and 
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chelation of calcium ions respectively and may have potential to increase extracellular 
transport along neurological pathways into the brain231,232. Finally, solid microparticles can 
increase absorption due to the higher concentration gradient of the drugs released to external 
environments as a virtue of their high surface area. Considering the advantages of solid 
particles in nasal delivery and the ability of 10 µm sized particles to target the olfactory 
region, formulating drugs as solid microparticles for nose-to-brain delivery can be beneficial. 
1.4 Size tailored, mucoadhesive microparticles for nose-to-brain drug 
delivery 
The introduction highlighted the potential of microparticles as one promising strategy to 
provide enhanced drug delivery to the brain, with the potential to treat complex CNS 
disorders. The versatility of microparticle delivery systems, i.e., the ability to tailor their size 
and choice of mucoadhesive polymers, therefore poses the research question of whether such 
microparticles can be optimized to deliver drugs efficiently to the brain through the intranasal 
route.  




This thesis will explore the following hypotheses 
1. That a combined formulative approach of packaging drugs into solid mucoadhesive 
microparticles and size tailoring them to 10 µm can enhance deposition and retention 
in the olfactory region and increase brain uptake of the encapsulated drug. 
2. That inter-subject variability does not affect the preferential deposition of 10 µm 
particles in the human nasal cavity. 
3. Combination of controlled particle size with an intranasal device can further enhance 
the olfactory targeting of microparticles. 
1.5.1 Aims 
In order to investigate the above hypotheses, the aims of this thesis are 
1. To develop mucoadhesive 10 µm sized microparticles and characterize their 
olfactory deposition in-vitro. 
2. To develop a model drug-loaded mucoadhesive 10 µm sized microparticles and 
investigate its brain uptake of the drug in a rat model. 
3. To evaluate inter-subject variability in olfactory deposition of particles in-silico. 
4. To identify the effect of particle size on olfactory deposition in the human nasal 
cavity combined with a delivery device in-silico.
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2 General Materials and Methods  
2.1 Materials 
Mucin (bovine submaxillary glands Type I-S, M3895), cellulose acetate membrane (MW 
cut off 50,000 Da), propylene glycol (PG), three-way stopcock, phenytoin sodium, 
5-(4-methyl phenyl)-5-phenyl-hydantoin, 5-(4-hydroxyphenyl)-5-phenyl-hydantoin and 
fluorescein isothiocyanate (FITC)-labelled dextrans with MW of 3-5, 10, 20 and 40 kDa 
were purchased from Sigma-Aldrich (New Zealand). Tamarind gum powder was purchased 
from Xi’an Jiatian Biotechnology (China). HPLC-grade acetonitrile, ethanol, and methanol 
were purchased from Merck KGaA (Darmstadt, Germany). A manual anemometer (N1287) 
was purchased from Digitech (Australia). Water was ion-exchanged distilled and passed 
through a Milli-Q water purification system (Millipore, Bedford, MA, USA) and was used 
for all the studies, sample preparation and HPLC analysis. 
2.2 Isolation of Tamarind seed polysaccharide  
A naturally mucoadhesive Tamarind seed polysaccharide (TSP) was used as the polymer 
in this thesis. A detailed discussion on the purpose and advantages of TSP as a polymer in 
drug delivery is provided in Chapter 3, Section 3.1.1. TSP was isolated from tamarind gum 
powder using methods described by Rao et al233. Tamarind gum powder (20 g) was 
dispersed in 200 mL of Milli-Q water to obtain a slurry, which was then mixed with a further 
800 mL of Milli-Q water and boiled for 20 min under constant stirring (800 rpm). This 
dispersion was kept overnight to allow proteins and fibers to sediment and subsequently 
centrifuged at 5000 rpm for 20 min. The supernatant was separated and mixed with twice 
the volume of absolute ethanol under constant stirring. Since the TSP is soluble in water and 
insoluble in most of the organic solvents234,235 this led to a precipitate of TSP, which was 
washed with Milli-Q water and dried at 60 °C for 12 h to obtain a film of TSP. The film was 
crushed using a mortar and pestle to a fine powder and stored in a desiccator at room 
temperature until required. 
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2.3 In-vitro and ex-vivo studies 
2.3.1 Preparation of TSP-FITC-Dextran microparticles 
All microparticle formulations in the study were prepared by spray-drying methods 
based on literature203,236,237 using a laboratory-scale mini Spray Dryer (Büchi B-290, Büchi 
Labortechnik AG, Switzerland). 
The effect of the spray-drying process variables; atomizing air flow, aspiration air flow 
rate, FITC-Dextran concentration and inlet temperature (independent factors) on the mode 
size of microparticles (response) was determined using a 4 factor (independent factors), 
3 level (low (-1), base (0) and high (+1)) Box-Behnken design238,239 (Table 4). A total of 
29 experiments were designed and analyzed using Design-Expert® Software Version 9 
(Stat-Ease Inc., MN, USA). The effect of independent variables upon the responses was 
modeled using a linear mathematical model. One-way Analysis of Variance (ANOVA) was 
applied to determine the significance of the model (P < 0.05). The optimized spray-drying 
conditions for producing 10 µm sized particles was determined by applying the numerical 
optimization methodology using Design-Expert® Software. The microparticles were 
prepared, and their size was measured to validate the optimized spray-drying conditions 
obtained from Design Expert®. 
Table 4. Actual and coded values of independent factors used in the Box-Behnken design. 
Independent factor 
Coded level 
Low (-1) Base (0) High (+1) 
Atomizing air flow (L/h) 246 494 742 
Aspiration air flow rate (%) 50 60 70 
Amount of FITC-Dextran 
(%w/w) 
0.10 0.25 0.50 
Inlet temperature (°C) 100 110 120 
Feed solutions for spray-drying were prepared as follows. TSP was dissolved in water 
under constant stirring at 60 oC for 2 h and cooled to room temperature. To this solution 
different amounts of FITC-Dextrans were added and mixed for a further 1 h. The total 
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amount of solids in the feed solution was 2 % w/w. The solutions were spray-dried with a 
standard nozzle cap with an orifice diameter of 0.7 mm and feed solution flow rate of 
2 mL/min. The dried microparticles were collected and stored in a desiccator until required. 
2.3.2 Preparation of TSP-phenytoin sodium microparticles 
The feed solutions were obtained as follows; Phenytoin sodium was dissolved in the 
water and different amounts of propylene glycol (PG) mixture by sonicating for 8 min. 
Different amounts of this solution was added to the TSP solution (prepared as described 
above) under stirring at room temperature and allowed to mix for 1 h. The total amount of 
solids in the feed solution was 1.5 % w/w. These solutions were spray-dried, and the 
microparticles were collected and stored in a desiccator at room temperature until further 
analysis. 
2.3.3 Particle size analysis 
The sizes of all microparticle formulations were determined using laser diffraction 
(Horiba™ Particle LA-950V2, HORIBA, Ltd. Kyoto, Japan). A 5 mg sample of 
microparticles was dispersed in ethanol (5 mL), from which a 200 µL aliquot was diluted 
with 10 mL of ethanol prior to analysis. Mode size (most common size in the particle 
population) of each formulation was determined and reported. All measurements were 
performed at 25 °C and results are presented as the mean ± standard deviation (SD) of at 
least three independent experiments. 
2.3.4  Morphology of microparticles  
Microparticles were adhered to double-sided adhesive carbon tape on metallic stubs, 
coated with a thin layer of platinum-palladium (Emtech K575X, Quorum Technologies Ltd, 
UK) and viewed under a scanning electron microscope (Zeiss Sigma VP variable-pressure 
scanning electron microscope (Carl Zeiss Inc, Oberkocken, Germany) fitted with a HKL 
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INCA Premium Synergy Integrated ED/EBSD system (Oxford Instruments, Oxfordshire, 
UK)) with an electron beam at an acceleration voltage of 1 kV. 
2.3.5 Determination of FITC-Dextran content  
To determine the amount of FITC-Dextran incorporated into TSP-microparticles, 5 mg 
of microparticles were dissolved in 10 mL of Milli-Q water under constant stirring at 60°C 
for 2 h. A 1 mL sample was collected and filtered through a membrane filter (0.45 μm). The 
filtrates were diluted to 10 mL with Milli-Q water, and the amount of FITC-Dextran 
quantified by spectrofluorometry (Hitachi F-7000 Spectrophotometer, High-Technologies 
Corporation, Japan) using an excitation and emission wavelength of 498 nm and 520 nm, 
respectively. Samples were quantified against calibration curves constructed of standard 
FITC-Dextran solutions in the range of 0.5−100 μg (n = 3, r2 > 0.999). The standards were 
made by processing the blank TSP-microparticles, which do not contain FITC-Dextran, and 
spiking with a known amount of FITC-Dextran to normalize the interference of TSP on 
fluorescence. FITC-Dextrans were reported to be stable at the temperatures employed in the 
study240,241. 
2.3.6 Determination of phenytoin sodium content  
For the TSP-Phenytoin sodium (referred to as phenytoin from this point onwards) 
microparticles, 25 mg of microparticles were dissolved in 3 mL of Milli-Q water under 
constant stirring at 60 °C for 2 h. The solution was allowed to cool down to room temperature 
while stirring, then sufficient amount of methanol was added to make it a 70 % methanol 
solution with a total volume of 10 mL. A 3 mL aliquot of the solution was collected and 
centrifuged at 13000 rpm for 5 min. A 1 mL sample was collected and filtered through a 
0.22 µm syringe filter, and the amount of phenytoin was quantified by high-performance 
liquid chromatography (HPLC), according to a validated method (Younus et al, unpublished 
data) developed from modification of published method242 as described below. 
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A reverse phase HPLC-system (Agilent 1200 series) with UV detector coupled with 
EZChrom Elite software, version 3.2.0 (Agilent Technologies, California, USA), a C-18 
(150 X 4.6 mm) column (5 µm particle size) with a C-18 guard cartridge (5 X 4.6 mm) 
(Phenomenex, California, USA) kept at 25 ºC were used for the analysis. An isocratic 
method was used to quantify the phenytoin. The mobile phase consisted of 70 % (v/v) 
methanol and 25 % (v/v) HPLC-grade water with a flow rate of 1 mL/min. A mixture of 
methanol and water (90:10, v/v) was used to perform needle wash. The injection volume was 
20 μL and detection was at 254 nm resulting in a retention time of 4.3 min for phenytoin. 
The standard curve range was 5 to 100 μg/ml (r2 = 1) and a new standard curve was prepared 
each day. 
2.3.7 Drug loading and Encapsulation efficiency 
Drug loading (DL) and encapsulation efficiency (EE) of microparticles were calculated 
by using Equation 3 and 4, respectively. 
DL ( %) =
D (actual)
Weight of TSP–microparticles
× 100  |𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 3 
 
EE ( %) =
D (actual)
D (theoretical)
× 100  |𝐸𝑞𝑢𝑎𝑖𝑡𝑜𝑛 4 
Where D (actual) and D (theoretical) are the actual and theoretical amounts of FITC-
Dextran/phenytoin in microparticles, respectively. 
2.3.8 Fluorescence microscopy 
Fluorescence microscopy was used to confirm the incorporation of the FITC-Dextran in 
the microparticle formulations. Samples were prepared by dispersing microparticles (5 mg) 
in ethanol (2 mL). A sample of dispersed microparticles was added on to a glass slide and 
examined under an inverted microscope with a fluorescence illuminator with a U-FBN filter 
block (bandpass = 470-495, barrier filter = 510 (IF) and dichroic mirror = 505) (Olympus 
IX53, Olympus Corporation, Japan). Images were captured with cellSensTM software. 
  Chapter 2 
38 
 
2.3.9 In-vitro mucoadhesion under breathing conditions 
Mucoadhesion of TSP-microparticles under simulated breathing conditions was 
determined in-vitro using a method modified from Gavini et al209. The amount of 
FITC-Dextran/phenytoin containing TSP-microparticles adhering to a piece of filter paper 
saturated with mucin after application of an air load was quantified. The mucin from bovine 
submaxillary glands was compared to human airway mucus in the literature due to its 
similarities and is used in this thesis243,244. The schematic representation of the experimental 
set-up is shown in Figure 2.1. A 3D printed mucoadhesion apparatus as shown in Figure 
2.2 was designed to emulate the human nasal cavity. 
 
Figure 2.1 Schematic representation of the apparatus used for the evaluation of in-vitro 
mucoadhesion. LI, Left inlet; RI, Right inlet, RH, removable hatch. Arrows indicate the direction of 
airflow. Filter paper saturated with mucin and adhered microparticles is shown in the inset. 
The filter paper (d = 1.5 cm, A = 1.78 cm2) was soaked in a solution of mucin (2 % w/v 
in distilled water) for 20 min to saturate the filter paper with mucin solution. A 5 mg sample 
of microparticles containing FITC-Dextran or phenytoin was placed on the filter paper 
saturated with mucin as shown in the inset of Figure 2.1. The filter paper was fixed to the 
roof of the apparatus with the help of a removable hatch, and the hatch was sealed as shown 
in Figure 2.1. A stream of air with a flux of 6.37 ms-1 was applied over the microparticles 
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for 5 sec from the left inlet and then repeated from the right inlet. Since the microparticles 
contained FITC-Dextran or phenytoin, the amount of microparticles that remained adhered 
to the filter paper after the applied air load was quantified by spectrofluorometry or HPLC 
respectively. Mucoadhesion of microparticles was expressed as the percentage of 
FITC-Dextran or phenytoin remaining on the filter paper after exposure to the air stream as 
a function of the FITC-Dextran or phenytoin deposited. Mucoadhesion of unformulated 
FITC-Dextran or phenytoin powders was used as a control. 
 
Figure 2.2 Cast used for in-vitro mucoadhesion experiments (A) side view showing the cast and 
removable hatch (B) top view showing the setup of the removable hatch. 
2.3.10 Ex-vivo mucoadhesion 
2.3.10.1 Isolation of porcine nasal mucosa 
Nasal mucosa was isolated from porcine snouts obtained from a local slaughterhouse. 
The snouts were opened by a longitudinal incision to expose the septum and conchae, and 
the nasal mucosa was carefully removed from the underlying bone, transferred to ice-cold 
PBS (pH 7.4) and immediately frozen in liquid nitrogen and stored at – 81 ºC until use. 
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2.3.10.2 Mucoadhesion strength 
Measurement of tensile strength to assess mucoadhesion of powders has been previously 
reported by Kockish et al.245 and was used in the current study to measure mucoadhesion of 
TSP-microparticles. Briefly, microparticles were attached to the moving cylindrical probe 
(Stable Microsystems, United Kingdom) of a texture analyzer (TA HD plus) with a 
mucoadhesion rig using industrial grade adhesive epoxy. A section of the porcine nasal 
mucosa was fixed onto the stationary mucoadhesion rig. TSP-microparticles or unformulated 
FITC-Dextran/phenytoin powders (control) were brought into contact with the mucosa for 
30 sec and retracted at a constant speed of 1 cm/min. The force required to disrupt the 
adhesive bond between microparticles and the mucosa was measured and is reported as 
mucoadhesion strength in the present study. The tensile strength apparatus and 
mucoadhesion rig used for these studies are shown in Appendix C. 
2.3.11 Cryogenic field emission scanning electron microscopy (cryo-FESEM). 
The interaction of TSP-microparticles with mucin over time was investigated using cryo-
FESEM. Approximately 30 µL of mucin solution (2 % w/v) was spread on the flat surface 
of metallic stubs to create an artificial mucus layer. TSP-microparticles were distributed over 
the mucus layers of the stubs, which were subsequently plunge-frozen in liquid nitrogen at 
time 0, 15, 30 and 60 min, respectively. The samples were then transferred into the cryo-
chamber (Gatan, Alto 2500, UK) of the microscope (JEOL, JSM-6700F, Japan), which was 
maintained at −140 °C. The samples were sublimed at −90 °C for 2–5 min to remove any 
surface frost and viewed at −140 °C at an acceleration voltage of 3 kV and a working 
distance of 6 mm. 
2.3.12 Crystallinity of microparticles 
Crystallinity of the TSP, FITC-Dextrans, and phenytoin and microparticle formulations 
was examined using an X-ray diffractometer (PANalytical X’Pert PRO MPD PW3040/60 
XRD) equipped with a rapid real-time multistrip X’Celerator detector. Approximately 
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5-10 mg of the powder sample was loaded into the sample holder as a thin layer, and x-ray 
powder diffraction (XRPD) patterns were recorded over an angular range of 5−35° (2θ) using 
Cu Kα radiation operating at a generator power of 40 kV and current of 40 mA at ambient 
room conditions. The results were analyzed using the PANalytical High Score software. 
2.3.13 Thermal behavior of microparticles 
Thermal behavior of TSP, FITC-Dextrans, phenytoin and microparticle formulations 
was analyzed using Differential scanning calorimetry (DSC) Q1000 (TA Instruments, USA) 
calibrated with indium (calibration standard, purity > 99.9 %). Approximately 5 mg of the 
powder sample was weighed into a standard aluminum pan (TA instruments) and press 
sealed with the standard aluminum lid. All the samples were scanned at 1°C/min from 30°C 
to 500°C under a nitrogen gas flow (50 mL/min). An empty aluminum pan with lid served 
as a control. 
2.3.14 Moisture content of microparticles 
Moisture content of the microparticles was determined by the oven dry method246,247. 
250 mg of freshly prepared TSP-microparticles containing phenytoin were accurately 
weighed (W1). Microparticles were placed in a glass petri dish and kept in a hot air oven at 
110 ºC overnight to dry. The dried microparticles were accurately weighed (W2). The 
% moisture content was determined by the following formula. 
2.3.15 Stability studies 
Stability studies for the TSP-microparticles containing phenytoin were performed 
according to the international conference on harmonization (ICH) guidelines for stability 
testing of finished pharmaceutical products248. 
Moisture content ( %) =
𝑊1 − 𝑊2
𝑊1
 × 100 |𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 5 
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Freshly spray-dried TSP-microparticles containing phenytoin were placed in two glass 
Petri dishes (2 g each) and stored at 25 °C ± 2 °C and 60 % ± 5 % relative humidity (RH) 
and 40 °C ± 2 °C and 75 % ± 5 % RH in two separate incubators for six months. A sample 
of 250 mg of TSP-microparticles was collected on day 1, 30, 60, 90 and 180 from each 
incubator. The samples were analyzed for the encapsulation efficiency, moisture content, 
and crystallinity as described before. The storage conditions were monitored during the six 
month storage time, and any deviations were recorded. Phenytoin has been reported to be 
stable at temperatures employed in stability studies249. 
2.3.16 In-vitro release studies 
Release studies were conducted across a cellulose acetate membrane (MW cut-off 
50 kDa) using vertical static diffusion cells with an effective diffusion area of 1.77 cm2 and 
a receptor chamber volume of 7 mL. The cellulose acetate membrane was saturated with 
phosphate buffer (PBS) (pH7.4) for 30 min and then mounted onto a vertical diffusion cell. 
Microparticles containing the equivalent of 1 mg of FITC-Dextran or phenytoin were spread 
over the membrane as evenly as possible. The receptor compartment was filled with PBS 
(pH 7.4), and the temperature was maintained at 37 °C using a thermostatic water bath. The 
PBS in the receptor compartment was magnetically stirred to maintain sample homogeneity. 
A 1 mL sample was withdrawn at predetermined time intervals from the receptor 
compartment and replaced with the same quantity of fresh PBS. The samples were diluted 
with 9 mL of PBS, and the content of FITC-Dextran or phenytoin were quantified using 
methods described in Sections 2.3.5 and 2.3.6 and plotted against time. The samples 
obtained from blank TSP microparticles were used as a reference to normalize any 
interference caused by TSP. The first 60 min of the drug release data were analyzed against 
zero-order, first-order, and Higuchi and Korsymeyers-Peppas models to determine the 
mechanism of drug release from TSP-microparticles. 
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2.3.17 Ex-vivo permeation studies 
The porcine nasal mucosa was isolated as described in Section 2.3.10.1, and permeability 
to FITC-Dextrans or phenytoin were quantified using methods described in Sections 2.3.5 
and 2.3.6. The cumulative amount of FITC-Dextrans or phenytoin permeating through the 
nasal mucosa per cm2 over time was plotted, and the steady-state flux (Jss) was calculated 





  |𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 6 
Where Jss is the steady-state flux, dQ/dt is the slope of the cumulative amount of FITC-
Dextran permeated versus time curve, and A is the diffusional cross-sectional area of the 
mucosa. Unless otherwise stated, data presented are the mean ± SD of at least three 
independent experiments. 
2.3.18 Histopathological examination of toxicity to the nasal mucosa 
All porcine nasal mucosa specimens were fixed in neutral buffered formalin for 12 h then 
dehydrated by incubating sequentially for 1 h in 70 %, 80 %, 96 % and 100 % alcohol. The 
tissue samples were subsequently incubated in methyl benzoate for 24 h then embedded in 
paraffin. 4 µm sections were cut using a rotary microtome (Leica Jung RM 2025). The 
sections were stained with hematoxylin and eosin and examined under the light microscope 
(Olympus Corporation, Tokyo, Japan). The freshly cut porcine nasal mucosa was used as 
negative control while nasal mucosa treated with 100 µL of 37 % v/v nitric acid served as 
positive control250 for the porcine nasal mucosa studies. Sections were analyzed for any 
pathological changes in cell morphology and tissue organization by personnel blinded to the 
experimental conditions. 
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2.3.19 Olfactory deposition of TSP-microparticles in 3D printed human nasal 
cast 
A human nasal replica cast designed from data obtained by magnetic resonance imaging 
scans (80 cross sections spaced 1 mm apart) of a healthy, non-smoking, adult male 
constructed using a 3D printer (Dimension Elite 3D printer, Stratasys, USA) with a 
resolution of 0.178 mm was provided by Auckland Institute of Bioengineering. The airway 
model encompassed the complete nasal passages from the nostrils to the posterior 
nasopharynx. The approximate location of the olfactory region where microparticle 
deposition was quantified is located in the dorsal posterior region of the nasal cavity, starting 
at the anterior middle turbinate and extending along the septal walls towards the back of the 
nose as shown in Figure 2.3251. 
 
Figure 2.3 A 3D printed cast of the human nasal cavity showing the left (A) and right nasal passage 
(B). The approximate location of the olfactory region where deposition of microparticles was 
determined is shown in the dotted region. 
A schematic of the experimental setup used for particle deposition experiments is shown 
in Figure 2.4. The sectioned nasal replica was coated with a layer of mucin solution 
(2 % w/v), assembled, and placed on a metal clamp. The throat side of the nasal cast was 
connected to a vacuum pump, and the inhalation flow rate was adjusted to ~20 L/min, 
measured with an anemometer. An air compressor system loaded with microparticles was 
brought to the right nostril. The microparticles were nebulized into the nasal cast using the 
air compressor system for 2 sec. Then the air compressor system was removed from the 
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nostril. Subsequently, the nasal replica cast was disassembled, and microparticles deposited 
in the olfactory region were carefully collected and analyzed for FITC-Dextrans or phenytoin 
content. TSP-microparticles of diameter 2 ± 1 µm prepared with spray-drying technique 
were used as a control in these experiments. The data is expressed as deposition efficiency 
(DE). Only deposition of microparticles in the olfactory region was considered in this study 
and is given by Equation 7 as below. 
𝐷𝐸( %) =  
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑑𝑒𝑝𝑜𝑠𝑖𝑡𝑒𝑑 𝑖𝑛 𝑡ℎ𝑒 𝑜𝑙𝑓𝑎𝑐𝑡𝑜𝑟𝑦 𝑟𝑒𝑔𝑖𝑜𝑛 (𝑚𝑔)
𝑇𝑜𝑡𝑎𝑙 𝑎𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑑𝑟𝑢𝑔 𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 𝑖𝑛𝑡𝑜 𝑡ℎ𝑒 𝑛𝑎𝑠𝑎𝑙 𝑐𝑎𝑣𝑖𝑡𝑦 (𝑚𝑔)
  |𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 7 
 
 
Figure 2.4 Schematic of the experimental setup used for particle deposition experiments. The 
microparticles were nebulized into the nasal cast using an air compressor for 2 sec. Arrows indicate 
the direction of air flow. 
2.4 In-vivo studies 
Six to eight week old male Wistar rats were used for all in-vivo studies. All in-vivo 
experiments were performed in accordance with an approved protocol by the Animal Ethics 
Committee (AEC 72/16), University of Otago, New Zealand. 
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2.4.1 Construction of insufflator for the intranasal delivery of microparticles 
An in-house custom insufflator was built for the purposes of administering solid 
microparticles to the rats as shown in Figure 2.5. The design of insufflator was inspired from 
PenncenturyTM dry powder insufflator reported for powder deposition in rat lungs252,253. An 
air syringe, three-way stopcock leur and a 21 gauge needle were used to build the insufflator. 
Microparticles were loaded into the chamber. Rotation of the handle to different positions in 
the three-way stopcock enabled the filling and compression of air in the syringe. Depressing 
the syringe plunger pushed air through the microparticle chamber and “insufflated” the 
microparticle dose, sending it out the needle to the target region. The needle was blunted and 
bent 1 cm from the tip at 45o to facilitate its reach to the olfactory region through the rat 
nostril. The average weight of microparticles loaded and expelled from the insufflator was 
determined to establish the efficacy of the device (Appendix D). In addition, quantity of 
microparticles expelled during each administration was obtained by measuring the difference 
in the insufflator weight before and after each insufflation. 
 
Figure 2.5 Custom built insufflator used for intranasal administration of solid microparticles to rats. 
Microparticles were filled at the base of the needle and were insufflated by compressed air released 
by turning the handle to the open position. 
2.4.2 Evaluation of nasal toxicity and drug-related behavioral adverse effects 
of phenytoin loaded TSP-microparticles. 
Rats were exposed to 5 % isoflurane for 3 min to induce short-term anesthesia. Once 
unconscious, the rats were held in the supine position with their head horizontal to the bench. 
Microparticles were administered into the nostril by the in-house built dry powder insufflator 
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described above. Rats were held in position for 15 sec after administration. Rats were 
monitored for any potential signs of nasal irritation such as frequent sneezing, noisy 
breathing, nose-rubbing, porphyrin (red) discharge, and general signs of pain/discomfort for 
60 min. 
Rats were euthanized 60 min after intranasal administration by guillotine decapitation. 
Following this, skin and excess tissue around the nasal passage were removed from the head. 
A blunt needle was inserted 0.5 cm into the posterior of the nasopharyngeal duct and used 
to flush the nasal passage with 10 mL of 10 % neutral buffered formalin (NBF) or sodium 
deoxycholate (positive control). The nasal passage was fixed in 50 mL of NBF for 48-72 h. 
The fixed nasal passage was subsequently decalcified in 10 % EDTA (pH 7.2) for 2-3 weeks, 
sliced coronally into blocks and embedded in paraffin. A microtome was used to cut 5 µm 
sections which were subsequently de-paraffinized, stained with hematoxylin and eosin, and 
cover-slipped with DPX mounting medium. Sections were imaged on an Aperio ScanScope. 
Images were analyzed by personnel blinded to the treatments using Aperio 
ImageScope v12.2.2.5015 software. A rat treated with saline was used as a negative control, 
and a rat nasal cavity flushed with sodium deoxycholate served as positive control. 
2.4.3 In-vivo drug administration 
Rats were divided into three treatment groups receiving intranasal phenytoin 
microparticles, intranasal phenytoin solution or IV phenytoin sodium injection under short-
term inhaled general anesthesia. The intranasal phenytoin microparticles were administered 
by the in-house custom built insufflator as described in Section 2.4.1. The dose of the drug 
was determined by weighing the microparticles emitted from an insufflator, an average dose 
of 1.5 mg phenytoin was administered as shown in Figure 2.6. Animals to whom 
administration was incomplete due to clogging of the microparticles in the needle were 
temporarily excluded. Considering the half-life of model drugs254–256 and logistics, animals 
were experimented with at a later date, at least 4 days later. 




Figure 2.6. Administration of phenytoin microparticles to the rat nasal cavity using the custom-built 
insufflator. 
The intranasal phenytoin solution was administered using a ‘rat intranasal catheter 
device’ (Impel Neuro Pharma, USA). The drug solution was administered to anesthetized 
animals in a similar to the procedure described in Section 2.4.2. Drug solution was loaded 
into a syringe with a piece of plastic tubing attached. The tubing was inserted about 1 cm 
into the rat nasal cavity to reach the olfactory region and depressing the plunger of the syringe 
delivered the drug solution through the tubing directly to the olfactory region. Phenytoin 
sodium solution was prepared by dissolving 100 mg of phenytoin sodium in 1 mL of 50 % 
ethanol-water mixture containing 10 µL of propylene glycol. Considering the limitation of 
solution volumes that the nasal cavity can accommodate, a volume of 15 µL solution, 
equivalent to 1.5 mg of phenytoin was administered to each rat. 
DBLTM Phenytoin injection (Hospira, Australia) was used for IV administration. The 
marketed formulation has a 50 mg/mL concentration of phenytoin sodium. A solution 
volume of 30 µL, equivalent to 1.5 mg of phenytoin sodium was administered IV by tail-
vein injection. 
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After administration, the rats were sacrificed at 15, 30, 45 and 60 min time points (n = 5 
for each time point) by decapitation as described in Section 2.4.2. Immediately after 
decapitation, trunk blood was collected into heparin tubes. The blood was centrifuged at 
2000 G for 5 min to collect the plasma. The brain was collected immediately and washed 
with fresh saline three times to remove any blood. The liver, spleen, kidneys, lungs, and heart 
were also collected and washed with saline. All the tissues and plasma were stored in a 
– 81 ºC freezer until further analysis. 
2.4.4 Analysis of phenytoin content in rat plasma and tissues by HPLC 
2.4.4.1 Equipment and chromatographic conditions 
An HPLC (Agilent technologies 1260 infinity) with UV detector, a C 18 column 
(150 X 4.6 mm) with 5 µm particle size and a C-18 guard cartridge (5 X 4.6 mm) 
(Phenomenex, California, USA) kept at 40 ºC were used for the analysis. The mobile phase 
consisted of a mixture of pH 5.8 phosphate buffer (10 mM) and acetonitrile that was 
regulated by a gradient profile programmed as follows: a linear gradient from 10 % 
acetonitrile to 50 % over 10 min; maintenance at 50 % for 2 min, a linear gradient from 50 % 
acetonitrile to 40 % over 1 min; maintenance of acetonitrile at 60 % for 3 min, then a linear 
gradient from 40 % acetonitrile to 10 % over 1 min. After each cycle, the column was 
conditioned with 10 % acetonitrile and 90 % phosphate buffer for 3 min. The flow rate was 
0.2 mL/min. The phenytoin derivative 5-(4-methylphenyl)-5-phenyl-hydantoin was used as 
the internal standard for the analysis of blood and tissues (referred to as ‘internal standard’ 
from now on in this thesis). The major metabolite of phenytoin in blood and tissues is 
‘5- (4-Hydroxyphenyl)-5-phenyl-hydantoin’ (referred to as ‘metabolite’ from here onwards 
in this thesis) was also quantified along with the phenytoin. The injection volume was 10 µL, 
and the UV detection wavelength was 210 nm. The chromatographic data analysis was 
performed using the OpenLAB software (Agilent Technologies, California, USA). The 
method was validated for its accuracy, selectivity, precision, and repeatability in plasma, 
brain, liver, spleen, kidneys, lung, and heart. Chromatographic conditions and the procedure 
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to extract phenytoin from plasma and tissue samples were optimized by modifying the 
reported methods257–259. 
2.4.4.2 Stock solutions 
Stock solutions of phenytoin, internal standard and metabolite were prepared in methanol 
at a concentration of 1 mg/mL. Working solutions (100 µg/mL and 10 µg/mL) were prepared 
by serial dilution of stock solutions with methanol. 
2.4.4.3 Plasma sample preparation 
For the construction of calibration curves, 200 µL aliquots of plasma were added to 
1.7 mL Eppendorf tubes. The samples were spiked with varying concentrations of phenytoin 
(0.1, 0.5, 1, 2.5, 5, 7.5, and 10 µg/mL) and metabolite (0.5, 1, 2.5, 5, 7.5, 10 and µg/mL) and 
a fixed concentration of the internal standard (10 µg/mL) using the working solutions and 
vortexed for 30 sec. Following that, 300 µL of chilled acetonitrile and 300 µL of tert-Butyl 
methyl ether were added to the spiked plasma samples to precipitate the proteins and extract 
the phenytoin from plasma. The samples were centrifuged at 13000 rpm at 4 ºC for 20 min. 
The supernatant was then separated and concentrated overnight by evaporation to dryness in 
a centrifugal evaporator. The concentrated samples were reconstituted in 200 µL of a mixture 
of pH 5.8 phosphate buffer and acetonitrile (60:40) and loaded into the auto sampler for 
HPLC analysis. 
For quantification of phenytoin from in-vivo studies: the 200 µL plasma samples were 
spiked with 10 µL internal standard (1 mg/mL) in Eppendorf tubes and vortexed for 30 sec. 
Following that, the same steps for sample preparation as for the calibration curves were 
followed and the samples were analyzed for phenytoin content. 
2.4.4.4 Tissue sample preparation 
All tissues were homogenized in 80 % ethanol solution in water to precipitate proteins 
and lipids. A volume of 6 mL of 80 % ethanol solution was used for every 1 g of tissue. 
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Tissue samples were spiked with varying concentrations of phenytoin (0.1, 0.5, 1, 2.5, 5, 7.5, 
10 µg/g) and metabolite (0.5, 1, 2.5, 5, 7.5, 10 µg/g) and a fixed concentration of the internal 
standard (10 µg/g) using the working solutions and vortexed for 30 sec. Tissue samples for 
constructing calibration curves were then prepared in the same way as the plasma sample 
preparations using of tissue homogenates equivalent to 200 µg tissue weight. However, 
multiple tissue aliquots were concentrated then pooled together and reconstituted with 
200 µL of a mixture of pH 5.8 phosphate buffer and acetonitrile (60:40) for analysis. 
For quantification of phenytoin from in-vivo studies: 1 g of tissue homogenates were 
spiked with 10 µL internal standard (1 mg/mL) in Falcon tubes and vortexed for 30 sec. The 
same steps for sample preparation as for the calibration curves were followed and the 
samples were analyzed for phenytoin content. 
2.4.4.5 Method validation 
The calibration curves were plotted using peak area ratio values obtained from the ratio 
of phenytoin to the internal standard. The unknown concentrations of phenytoin were 
determined from the calibration curves. Quality control (QC) samples consisted of low 
(1 µg/mL) medium (5 µg/mL) and high (10 µg/mL) concentrations of the phenytoin. 
2.4.4.5.1 Specificity 
The specificity of the method was determined by identifying and separating the 
phenytoin, the internal standard and the metabolite chromatographic peaks from each other, 
and from the endogenous materials in plasma, brain, and other tissues. The specificity of the 
HPLC method is demonstrated by comparing the chromatograms of plasma/tissue samples 
with no phenytoin, and plasma/tissue samples spiked with known amounts of phenytoin, 
internal standard, and metabolite. 




The linearity of the HPLC method was determined using standard solutions spiked with 
phenytoin and metabolite with final concentrations in the range of 0.1 to 10 µg/mL and an 
internal standard of 10 µg/mL. The calibration curves were plotted with peak area ratio 
values obtained from the ratio of phenytoin and metabolite to the internal standard. The linear 
regression coefficient (r2) values were calculated and reported. 
2.4.4.5.3 Sensitivity 
The sensitivity of the method is demonstrated by the lower limit of detection (LOD), and 
the lower limit of quantitation (LOQ) obtained from the standard deviation of the y-intercept 
and slope of the calibration curve. 
2.4.4.5.4 Accuracy and Precision 
The amount of phenytoin recovered from the tissue and plasma QC samples after sample 
preparation and HPLC analysis were compared to the theoretical values and used to report 
the accuracy of the method. The intraday variability was determined by replicate analysis of 
QC samples on the same day, by calculating and reporting the %co-variance (CV) and %bias. 
The accuracy and precision of the method were based on the %bias and %CV. 
The inter-day variability was measured to represent the repeatability of the method. QC 
samples were analyzed on different days with one replicate being analyzed each day and the 
%CV and %bias were calculated and reported. A %CV and %bias within ±15 % were 
considered as acceptable for the plasma and tissue samples. 
2.5 Statistical analysis 
All results are expressed as mean ± SD. Where applicable, statistical analyses were 
conducted using an unpaired t-test or ANOVA on Prism 6 (GraphPad, USA). A P-value of 
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3 Formulation and evaluation of TSP-microparticles 
As discussed in Chapter 1, this thesis aimed to develop a mucoadhesive microparticle 
system with specific size to efficiently target the olfactory region and enhance nose-to-brain 
delivery of drugs. In this Chapter, the selection of a mucoadhesive polymer, formulation of 
size tailored microparticles and the ability of such a microparticle system to load and release 
drugs was investigated. 
3.1 Selection of a mucoadhesive polymer 
Chitosan is the most popular polymer reported in the literature for the formulation of 
nose-to-brain micro and nanoparticle drug delivery systems (Table 5). It is proposed that the 
positively charged amino groups of chitosan interact with sialic acids in the mucous layers 
to form strong electrostatic bonds causing mucoadhesion. Also, chitosan can reversibly open 
the tight junctions by inducing changes in the transmembrane protein claudin-4 and the 
C-Jun NH2-terminal kinase-dependent pathway to increase the permeability of the epithelial 
cells231,260. These characteristics have made chitosan the first choice among all other 
polymers. However, there have been reports of acute mucosal toxicity261 believed to be due 
to the positive charge on chitosan, and there is very little known about the effect of long-term 
exposure to chitosan on the nasal mucosa. 
Recently, tamarind seed polysaccharide (TSP) has gained some attention in drug delivery 
applications due to its mucoadhesion properties, broad pH tolerance, biocompatibility and 
high drug loading capacity262,263. Moreover, unlike chitosan, TSP is uncharged under 
physiological conditions 264 and therefore is less likely to cause nasal toxicity. TSP is 
classified as a generally recognized as safe (GRAS) substance and is approved by the FDA. 
It is commonly used as an excipient in food and pharmaceutical preparations and is available 
in the market as an eye drop formulation for treating dry eyes264–266. TSP is a naturally 
occurring and readily available polymer. These distinctive advantages and characteristics of 
TSP make it a potential polymer for nose-to-brain drug delivery purposes and hence, this 




3.1.1 Tamarind seed polysaccharide (TSP)  
TSP is a high MW (720-880 kDa) polysaccharide isolated from the seed kernel of 
Tamarindus indica Linn. (Leguminosae)267 and composed of a cellulose-like 
(1→4)-β-D-glucan backbone substituted with sidechains of α-D-xylopyranose units at 1→6 
positions and β-D-galactopyranosyl units at 1→2 positions268 as shown in Figure 3.1 . TSP 
predominantly contains the sugars; glucose, galactose, and xylose in a molar ratio of 
2.8:1:2.25269,270. The MW of TSP is based on the chain length which can vary from 300 to 
3000 glucose units271. 
 
Figure 3.1 Chemical structure of TSP with xylose and galactose side chains attached on to the 
glucose backbone. 
As a result of inter-chain interactions promoted by the cellulose like β (1→4) backbone, 
TSP is a highly hydrophilic polymer. However, macromolecules in TSP are not adequately 
hydrated. Consequently, supramolecular aggregated species are present even in dilute 
solutions235. Xylose and galactose side chains are more hydrophilic than the glucose units 
and significantly affect the solubility of TSP. For example, removal of galactose side chains 
significantly decreases the solubility of TSP272. Given that modification of side chains shows 




functional relationship may have potential in controlling the release of drugs when 
formulated using TSP. 
The mucoadhesive properties of TSP are believed to be due to the secondary hydroxyl 
(OH) groups present in the molecule, which can interact with mucus to form hydrogen bonds, 
and Van der Walls attractions221. Also, the mucin-like configuration of TSP imparted by its 
branched structure aids in the interpenetration of chains between TSP and mucus resulting 
in mucoadhesion275,276. Due to the advantages it can offer, TSP has been investigated in drug 
delivery applications. Table 5 lists the reported drug delivery applications of TSP and the 




Table 5. Drug delivery applications (preclinical and in-vitro) of TSP reported in literature grouped according to the formulation type. 






 Enhanced drug absorption compared to simple suspensions was 
reported with TSP formulations in rabbits.  
277 
Timolol 
 High ocular and low systemic drug concentrations compared to 




 TSP significantly prolonged the drug residence in the precorneal 





 Synergistic action between TSP and hyaluronic acid was utilized to 
prolong the residence time of drugs in the tear fluid of rabbits.  
280 
Rufloxacin 
 A significant increase in the intra-aqueous penetration and the 
bioavailability of rufloxacin was reported by TSP formulations in rabbits.  
281,282 





 Modified-TSP was used as polymer: 44 % of galactose residues 
were removed from TSP by β-galactosidase to obtain thermally reversible 
gels. 
 Sustained Drug release was reported from TSP formulations 
283 




Mitomycin Intraperitoneal 286 
Indomethacin & 






 TSP + Pluronic F 127 combination was used as the polymer. 











 TSP was modified by grafting with polyacrylamide. 
 Significant enhancement in controlled release of aspirin was 
reported with grafted TSP formulations.  
290 
Aceclofenac Oral 
 TSP + Chitosan blend was used for the preparation of 





 TSP and tamarind kernel powder (TKP) were compared. TKP was 






 TSP and TKP were used to prepare the tablets. 
 TSP formulations were found to remain in the stomach for 12 h. 
293 
Simvastatin Oral 
 TSP was modified with cysteine to form thiomer. 














 In-vitro drug dissolution studies showed the release of theophylline 
was sustained by TSP  
 The release of drug from tablets was directly proportional to the 







 Diclofenac sodium 
Oral-Spheroids 
(690 µm) 
 Microcrystalline cellulose + TSP combination was used as the 
polymer.  




(710 to 1330 µm) 
 TSP + sodium alginate combination was used as the polymer 




(752 to 948 µm) 
 TSP + sodium alginate combination was used as the polymer  
 The TSP beads were able to control the release of drug for 12 h 




(1063 to 1269 µm) 
 TSP + sodium alginate was used as the polymer. 






 TSP + Pectin combination was used as the polymer. 






 TSP + sodium alginate combination was used as the polymer. 





(1000 to 1560 µm) 
 TSP + Gellan gum combination was used as the polymer. 






(490 to 621 µm) 
 TSP + Chitosan combination was used as the polymer. 
 The release of the drug was sustained over 10 h and sustained anti-




(3 to 6 µm) 







(0.9 to 6 µm) 
 Modified TSP was used as polymer: 47 % of galactose units were 
removed. 




Rizatriptan benzoate Buccal  TSP + Carbopol combination was used as the polymer. 307 
Nystatin Vaginal  The sustained release was reported  308 





Tropicamine Ocular  Increased drug absorption was reported in the in-vitro cell studies 311 
Doxorubicin NA/in-vitro 







 Modified-TSP was used as polymer: removal of galactose residues 
 Sustained release of drugs by TSP gel was reported in rats. 
313 
Metronidazole 
 Thiol-functionalized TSP was used as the polymer. 
 Mucoadhesion was increased by 6.85 folds after functionalization 
268 




Reports in the literature showcase the potential of TSP as an excipient and an active 
ingredient in drug delivery applications. The chemical modification of TSP with 
polyacrylamide315, methyl methacrylate316, polycaprolactone317,318 and PLA319 has been 
investigated for drug delivery purposes. Semi-synthetic derivatives of TSP such as 
thiolated-TSP268,276,320 and carboxymethylated-TSP321 have also been investigated for drug 
delivery applications. Several patents on the use of TSP as a polymer for drug delivery in 
opthalmic322,323, topical324 and cosmetic325 areas have been filed. In addition to the drug 
delivery applications, TSP has also been shown to have wound healing326, anti-tumor327–329, 
anti-myocardial infraction330 and immunomodulatory properties329,331.Patent has also been 
filed for the use of TSP as a protecting agent for epithelial cells of the respiratory tract from 
damages induced by smoking332. TSP has been tested clinically with positive results for the 
treatment of dry eye syndrome333 and is used in commercially available Visine Intensiv 1% 
eyedrops (Europe)266. 
The analysis of literature has shown some interesting trends in the use of TSP for drug 
delivery applications. 
1. The drug carrying capacity of TSP in oral and ocular routes was well characterized 
in the reported publications (Table 5). However, the ability of TSP to act as a drug 
carrier via the nasal route has not been well reported. 
2. The potential of TSP as a carrier of drug molecules with high MW has not been 
explored yet. 
3. About 60 % of the reported publications have formulated TSP either with a 
combination of another polymer or modification of its structure with an aim to change 
properties like mucoadhesion and drug release. Consequently, this has resulted in 
considerable variations in reported drug release profiles ranging from 2 h to 
four days. Controlled release of drugs formulated in TSP in combination with other 
polymers or by chemical modification has been shown for at least 10-12 h in-vitro 
(Table 5). While this may be useful for other drug delivery purposes, for the 
nose-to-brain delivery purposes, the likelihood that any formulation is retained in the 
nasal cavity for periods longer than 12 h despite its mucoadhesive nature is unlikely 




decrease the time required to release the encapsulated drugs, offering advantages for 
nose-to-brain drug delivery purposes. 
3.1.1.1 TSP as a carrier for nose-to-brain drug delivery 
Two investigations have reported the potential of TSP as a carrier for brain targeting 
drugs via the nasal cavity. Kumar et al.,275 formulated two anti-migraine drugs zolmitriptan 
and ketorolac tromethamine into thermally reversible gels using a blend of TSP, 
Pluronic F127 and PEG. The formulations were found to be mucoadhesive and sustained 
release of both drugs. The histopathological evaluation of sheep nasal tissue treated with the 
formulations suggested the formulations were safe to administer. In-vivo studies in rabbits 
compared the pharmacokinetic profiles of drugs between intranasal (gel), IV and oral 
(solutions) administrations. The TSP formulations were reported to have an almost 1.3-fold 
increase in absolute bioavailability compared to the oral route. 
In the second study, Mahajan et al.,334 reported the formulation of the anti-nausea agent 
ondansetron in a TSP thermally reversible gel. TSP was modified by the β-galactosidase 
enzyme to remove 45 % of the galactose units. The removal of galactose units imparted TSP 
with thermosensitive gel properties. The formulations were found to be mucoadhesive with 
sustain drug release over 6 h. Histopathological evaluation of rabbit nasal tissue treated with 
the formulations has shown no evidence of damage. In-vivo absorption studies compared 
intranasal (gel) and oral (solution) administration. TSP formulations were reported to 
produce an almost two-fold increase in absolute bioavailability. 
In both studies, TSP was either chemically modified or used with another polymer. Both 
studies reported the safety of TSP for nasal administration and the ability of TSP 
formulations to improve residency of drugs in the nasal cavity. However, the drug 
concentrations in the brain were not quantified. 
The capability of TSP as a mucoadhesive and safe polymer for nasal administration has 
been reported. Therefore, due to the advantages and potential of TSP, this thesis utilizes TSP 





3.2 Method of preparation of microparticles 
Freeze drying206,207, emulsification-cross linking137,208, and emulsification-solvent 
evaporation193,205 are some of the methods reported in the literature for the preparation of 
microparticles for nose-to-brain delivery. Spray-drying has been the most popular method 
with about 70 % of the reported publications utilizing spray-drying for the formulation of 
microparticles intended for nose-to-brain delivery. The high yield rate and simple 
methodology of spray-drying are the main reasons for its popularity. 
3.2.1 Spray-drying 
Spray-drying is a process where a liquid (feed) is converted to a powdered solid (product) 
by spraying the feed into a gaseous drying medium335. It has been utilized in the food and 
pharmaceutical industry for the production of powders since its first patent in 1872336. There 
are three phases involved in the spray-drying process: first, the atomization phase where the 
pumped feed is sprayed as small droplets through the nozzle by the force of a compressed 
air/gas. The second is the drying phase where the droplets interact with hot gas in a chamber 
to evaporate the solvent, and third, a separation phase where the particles are separated from 
the gas for collection by filter or cyclone337. 
Spray-drying is a one-step method and produces reasonable yields of microparticles338. 
By controlling the spray-drying parameters, microparticle characteristics such as particle 
size, shape and density can be tailored to suit the requirements339. The parameters of 
composition of feed solution, velocity of the feed solution being pumped, velocity of the 
compressed air/gas (atomizing air flow), nozzle type, velocity of the drying gas (aspiration) 
and temperature of the drying gas (inlet temperature) can be examined. 
As reported in Chapter 1 and previous sections spray-drying is the most widely used 
method to produce microparticles, which this can be attributed to the numerous advantages 
of spray-drying compared to the other methods. For example, compared to a commonly 
employed method, freeze-drying, it is economical and less time consuming due to the fact 




energy340–342.Hence, spray-drying is being explored as an alternative to freeze-drying343,344. 
In addition, particle size and distribution can be well controlled by spray-drying compared 
to emulsification, solvent extraction, and crosslinking methods employed in the literature. 
Hence, a spray-drying method promises successful bench-to-bedside translation of 
microparticle produciton345.  
Although spray-drying has numerous advantages, low yield and loss of nano-sized 
particles are major limitations of the spray-drying process345. Low yields are generally 
associated with loss of particles in the walls of equipment and smaller particles passing into 
exhaust346. The production of nanometer-sized particles by spray-drying is a challenging task 
due to the low separation capacity of the cyclone and low forces of liquid 
atomization345,347,348. While few studies reported an increased capacity of the cyclone at 
industrial settings, more studies are required to address these challenges345,349. 
Due to the ability of spray-drying to control the particle size, this thesis employs spray-
drying to investigate the optimum parameters to produce the 10 µm sized particles with TSP 
as a mucoadhesive polymer. 
3.3 Design of experiments (DOE) 
Rational DOE decreases the total number of experiments required to extract critical 
information of a complicated process and saves significant experimental time238. In this 
thesis variables of an experiment that may have an effect on the characteristics of the end 
product are termed ‘independent factors,’ the characteristics that are being affected are 
termed ‘responses.’ This chapter employs spray-drying to formulate size tailored TSP 
microparticles. The effect of spray-drying parameters at different levels on the particle size 
needs to be tested for these purposes to identify the optimum parameters. The relationship 
between one or more responses and one or more independent factors can be studied using 
response surface methods350. 
Central composite design and Box–Behnken experimental designs are two widely 




response238,239. The central composite experimental design has axial points beyond the 
design space leading to increased levels of the independent factors to be tested. Due to the 
nature of the independent factors tested in this chapter, it might not be beneficial to test points 
beyond the design space. In contrast, Box-Behnken design does not require the axial points 
beyond design space to be tested. Also, it is experimentally more convenient as it requires 
fewer experiments to be performed. The Box-Behnken experimental design also ensures that 
all individual factors are not tested at their highest levels, simultaneously putting the 
experiments in a safe operating zone350. Thus, in this chapter, Box-Behnken experimental 
design is employed to examine and identify the optimum parameters to produce the 10 µm 
sized particles with TSP using the spray-drying method. 
3.4 Model drugs 
In this Chapter, the ability of TSP to load drugs and the release of drugs from the 
formulated microparticles are examined by incorporating fluorescein isothiocyanate-labeled 
dextran’s (FITC-Dextrans) with MW of 3–5, 10, 20 and 40 kDa as model drugs. Use of 
FITC-Dextrans to study the drug release from the formulations and permeation across the 





Figure 3.2 Structure of FITC-Dextran. The MW depends on the number of dextran molecules linked 
to each other. Figure adapted from website https://www.sigmaaldrich.com 
Dextran is a polymer of anhydroglucose as shown in Figure 3.2 It is comprised of 
approximately 95 % straight-chain α-D-(16) glycosidic linkages and the remaining 
α -D-(13) glycosidic linkages account for the branching of dextran354. The FITC is 
randomly conjugated to the free hydroxyl groups of the dextran at a frequency of 0.003 to 
0.02 moles of FITC per mole of glucose. The number of dextran molecules determines the 
MW of the FITC-Dextrans and hence they are available in different MW. The FITC portion 
is responsible for the fluorescence of the compound, and hence it is utilized in permeation 
and release studies. It fluoresces with an excitation and emission wavelength of 498 nm and 
520 nm, respectively. 
3.4.1 Spray-dried TSP microparticles 
As discussed in the previous sections, the advantages TSP can offer, its unexplored 
potential as a carrier of macromolecules and the ability of spray-drying to control the particle 
size combined poses the research question of whether drug loaded 10 µm sized TSP-particles 




3.5 Hypothesis  
The overall hypothesis tested in this chapter is that drug formulated into 10 µm 
TSP-microparticles will have increased olfactory targeting and residence. 
3.5.1 Chapter aims 
1. To formulate 10 µm sized TSP-microparticles loaded with high MW drugs by 
spray-drying. 
2. To measure the mucoadhesion of the TSP-microparticles in-vitro and ex-vivo. 
3. To establish the drug release profile from the TSP-microparticles. 
4. To assess the safety of TSP-microparticles for nasal administration. 





3.6.1 Extraction of TSP from tamarind seed gum 
TSP was extracted from tamarind seed gum with an average yield of 51 ± 11 %. The 
infrared (IR) spectra and x-ray diffractograms of the extracted TSP were analyzed and 
compared with the published data355. 
The IR spectra of TSP presented the characteristic broad peaks for stretching of the –OH 
group on the glucan backbone at 3331.62 cm-1 and 3282.07 cm-1 and the OH bending peaks 
were observed at 526.61 cm-1. The alkane C-H stretching was observed by the peak at 
2922.80 cm-1. The cyclic ethers (C-O-C) stretching peak was observed at 1026.24 cm-1. 
These peaks (Figure 3.3 A) indicate the characteristic functional groups of TSP and are 
agreement with the reported literature355. The x-ray diffractograms of TSP are presented in 
Figure 3.3 B. In agreement with the published literature for TSP, no sharp peaks were 





Figure 3.3 IR spectrum (A) and X-ray diffractogram (B) of TSP extracted from the tamarind gum. 





The surface morphology of TSP was observed under SEM and found to be similar to the 
published literature356. 
 
Figure 3.4 Representative micrograph showing the morphology of TSP (powder obtained from the 






3.6.2 Formulation of 10 µm sized TSP-microparticles loaded with 
FITC-Dextrans 
3.6.2.1 Pilot studies 
Pilot studies were conducted by trial and error to examine the ability of TSP to form 
microparticles. Initially, the process variables that might affect the characteristics of resultant 
particles were identified. These are referred to as formulation parameters (independent 
factors) in this thesis. The identified formulation parameters were: total solids (%) (w/w) in 
the feed solution, FITC-Dextran content (%), spray-drying conditions (atomizing airflow 
(L/h), inlet temperature and aspiration (%)). Formulation parameters employed in the 
preliminary studies and the resulting microparticle size and yield are presented in Table 6. 
















1.0 742 130 100 2.1 ± 0.2 21 ± 4 
1.5 742 130 100 2.8 ± 0.9 53 ± 1 
2.0 742 130 100 2.2 ± 0.1 69 ± 4 
1.0 246 100 20 NA NA 
1.5 312 110 30 16.3 13.0 
2.0 384 120 40 13.2 35.0 
2.0 425 130 50 11.9 67.0 
TSP concentration higher than 2 % made the feed solution too viscous for spray-drying. 
Therefore, a 2 % TSP concentration (total solids content) was employed to prepare the feed 
solutions in subsequent studies. The % yield of the microparticles was found to increase with 




The levels of other formulation parameters were too many to test with trial and error. 
Hence a DOE approach was followed to identify the significant formulation parameters 
affecting the particle size. 
3.6.2.2 Optimization of formulation parameters using DOE 
Box-Behnken experimental design was used to optimize the formulation parameters to 
produce a mode size of 10 µm sized TSP-microparticles.  
A total of 29 combinations of different levels of formulation parameters were tested, the 
different levels of the formulation parameters and the resultant particle mode sizes are 
presented in Table 7. The effect of formulation parameters at different levels on the mode 




Table 7 Box-Behnken design of experiments to optimize the formulation parameters. 













1 494 50 0.10 110 12.99 
2 246 60 0.20 120 12.98 
3 494 60 0.10 120 9.48 
4 494 60 0.20 110 8.63 
5 494 70 0.20 100 8.61 
6 494 60 0.20 110 7.27 
7 246 50 0.20 110 11.32 
8 742 60 0.10 120 4.79 
9 742 70 0.20 110 5.24 
10 742 60 0.20 100 5.24 
11 494 50 0.25 110 14.14 
12 742 50 0.20 110 5.47 
13 494 60 0.20 110 12.96 
14 494 60 0.10 100 9.46 
15 494 60 0.25 120 12.40 
16 494 60 0.25 100 6.27 
17 742 60 0.20 120 5.47 
18 494 60 0.20 110 10.32 
19 494 50 0.20 120 12.96 
20 246 60 0.20 110 8.23 
21 494 60 0.20 110 10.32 
22 494 50 0.20 100 11.28 
23 494 70 0.20 110 10.32 
24 246 60 0.20 110 10.80 
25 742 60 0.25 110 8.23 
26 494 70 0.25 110 7.89 
27 494 60 0.10 110 11.84 
28 246 60 0.25 110 12.39 




ANOVA was performed to determine the validity of the experimental design used and 
the effect of each of the independent factors on mode size of the particles. The sequential 
model sum of squares and lack of fit tests were performed to determine whether the 
experimental design model is valid to navigate the design space. Lack of fit provided a mean 
response and an estimate of real experimental uncertainty and was found to have a value of 
P = 0.5613 (Table 8). An insignificant P-value for lack of fit indicates that any errors caused 
by design were too insignificant to influence the desired outcome.  
Table 8 Effect of independent factors on mode size of the microparticles and the validity of design 
model was determined by ANOVA. DF: degrees of freedom. *P-value of < 0.05 was taken to be 
significant. 
Source Sum of Squares DF Mean square F-value P-value  
Model 128.64 4 32.16 7.49 0.0005*  
Atomizing Airflow 92.47 1 92.47 21.53 0.0001*  
Aspiration 35.16 1 35.16 8.19 0.0086*  
TSP:FITC-Dextran 1.97 1 1.97 0.46 0.5051  
Inlet Temperature 3.50 1 3.50 0.81 0.3759  
Residual 103.07 24 4.29    
Lack of Fit 81.42 19 4.29 0.99 0.5613  
Pure Error 21.65 5 4.33    
Cur Total 231.71 28     
The atomizing airflow and aspiration were found to significantly influence microparticle 
size, with P-values of 0.0001 and 0.0086, respectively (Table 8). The three levels of inlet 
temperature used in the study were high enough to dry the microparticles in the spray-drying 
chamber and did not influence the mode size. Additionally, the amount of FITC-Dextran did 
not have a significant effect on the size of the microparticles. The 2D contour plots 





Figure 3.5 Contour plots showing the effect of the atomizing airflow and aspiration on the mode size 
of TSP-microparticles (A) which was further optimized to obtain microparticles with a mode size of 
10 µm (B). A plot showing the correlation between the predicted mode of TSP-microparticles sizes 
against experimentally determined values (C). 
Response surface methodology was used predict the optimal formulation parameters 
required to produce 10 µm sized microparticles based on their effect on the size. A 
correlation between the predicted mode size of TSP-microparticles and experimentally 
determined values was found to exist and is presented in Figure 3.5 C. The desirability plot 
shown in Figure 3.5 B, constructed based on the predictions of response surface 
methodology shows the desirable regression ranges for the atomizing airflow and aspiration 
to produce 10 µm microparticles. Optimum values of atomizing airflow and aspiration, to 
produce 10 µm microparticles were determined to be 547 L/h and 55 %, respectively, while 





All predicted values were validated by preparing the microparticles using the optimized 
spray-drying conditions, and the mode size of the particles was determined. Further, the 
microparticles loaded with different MW FITC-Dextrans were prepared using the optimized 
spray-drying conditions. The mode size of all microparticles formulated using optimized 
process variables as described above are presented in Table 9 
Table 9 Mode size of formulations containing FITC-Dextran’s prepared using optimized 
spray-drying conditions. Data presented is the mean of three independent experiments ± SD. 
Formulation Mode size (µm) 
F5 10.5 ± 0.2 
F10 10.3 ± 0.4 
F20 10.1 ± 0.2 
F40 10.2 ± 0.2 
The formulations were identified as F5, F10, F20, and F40, with the numerical value 
representing the MW of the dextran (in kDa). The mean diameters of the microparticles were 
in the range of 9 to 12 µm as shown in Figure 3.6 indicating uniformly sized formulations 
suitable for nasal administration226,236. 
 
Figure 3.6 Representative particle size distribution of TSP-microparticles spray-dried using 




3.6.2.3 Morphology of TSP-microparticles 
The morphology of the microparticles was investigated using SEM. The spray-drying 
conditions used in pilot studies were able to produce microparticles successfully as shown 
in Figure 3.7. The TSP-microparticles were spherical and corrugated in shape. The majority 
of the larger particles (> 15 µm) were spherical as shown in Figure 3.7 A and the smaller 
particles (< 5 µm) were corrugated in shape (Figure 3.7 B). All particles had a smooth 
surface. 
 
Figure 3.7 Representative SEM micrographs from the pilot studies showing the microparticle 
formation with TSP alone. Huge variation in particle size (large >15 µm (A) and small < 5 µm (B)) 




The morphology of TSP-Microparticles containing FITC-Dextrans obtained by 
spray-drying with optimized formulation parameters is shown in Figure 3.8. Addition of 
FITC-Dextrans also produced microparticles with corrugated shape and smooth surface. No 
significant morphological differences were observed with the particles containing different 
FITC-Dextrans. 
 
Figure 3.8 Representative SEM micrographs of TSP-microparticles containing FITC-Dextran 
(A) 5 kDa, (B) 10 kDa, (C) 20 kDa and (D) 40 kDa. All the formulations were similar in appearance 





Microparticles were physically broken using a mortar and pestle and observed under 
SEM to examine their core. The TSP-microparticles produced were hollow (Figure 3.9 B). 
 
Figure 3.9 Representative electron micrographs of TSP-microparticles showing the smooth rupture 
free surface (A) and showing the hollow core (B). The microparticles were physically broken and 
examined under SEM to reveal the hollow core. 
3.6.2.4 FITC-Dextran content 
Quantification of FITC-Dextrans encapsulated in TSP-microparticles was carried out by 
fluorescence spectroscopy. A series of standard curves were prepared with FITC-Dextrans 
and used to calculate the fluorescence of unknown samples, as presented in Figure 3.10. The 





Figure 3.10 Standard curves and r2 values of FITC-Dextrans with a MW (A) 3-5 kDa, (B) 10 kDa, 
(C) 20 kDa and (D) 40 kDa. (AU = arbitrary units) 
The fluorescence was used to quantify the amount of FITC-Dextran entrapped in the 
microparticles. Table 10 presents the entrapment efficiency (%) and drug loading (%) of 
microparticles for all the FITC-Dextrans used. 
Table 10 Drug loading and encapsulation efficiency of 3-5 kDa (F5), 10 kDa (F10), 20 kDa (F20) 
and 40 kDa (F40) FITC-Dextrans in TSP-microparticles. Data presented is the mean of three 
independent experiments ± SD. 
Formulation Drug loading (%) Encapsulation efficiency (%) 
F5 20.6 ± 0.1 82.6 ± 0.5 
F10 19.8 ± 0.3 79.3 ± 1.1 
F20 24.2 ± 0.6 75.7 ± 0.5 




The FITC-Dextran loading of TSP-microparticles was also determined qualitatively 
under fluorescence microscopy. The green fluorescence produced by the FITC is shown in 
Figure 3.11. 
 
Figure 3.11 Representative fluorescence micrographs (20X magnification) of TSP-microparticles 
containing FITC-Dextran; (A) 5 kDa; (B) 10 kDa; (C) 20 kDa; and (D) 40 kDa. Representative 
overlapped fluorescence and light micrographs of TSP-microparticles containing FITC-Dextran (E) 
and Blank TSP-microparticles (F). FTIC-Dextran loaded in microparticles produces green 
fluorescence when excited with the fluorescence illuminator suggesting its incorporation into the 
TSP-microparticles. However, the green fluorescence is not observed in the blank microparticles 




3.6.3 The mucoadhesive potential of TSP-microparticles  
A combination of in-vitro and ex-vivo techniques was used to investigate the interaction 
of TSP-microparticles with mucin as an indicator of mucoadhesiveness. The percentage of 
FITC-Dextran that remained adhered to a piece of filter paper saturated with mucin after 
application of an air load was quantified and expressed as a percentage of the original amount 
of FITC-Dextran applied (Figure 3.12 A). Applying an air load is a useful way to determine, 
in-vitro, the effect breathing may have on the clearance of microparticulate formulations 
from the nasal cavity (‘nasal retention’) after administration. The percentage of 
FITC-Dextran that remained adhered to the filter paper was comparable across all 
microparticle formulations. However, it was higher when compared to unformulated FITC-
Dextran powders, which were used as controls (P < 0.001). Mucoadhesive strength was 
determined ex-vivo using porcine mucosa and a tensile strength apparatus and the results are 
shown in Figure 3.12 B. The strength required to detach (mucoadhesion strength) the 
microparticles from the mucosa was significantly (P < 0.0001) higher than the 
mucoadhesion strength of unformulated FITC-Dextran powders. The mucoadhesion strength 
of all the formulations containing different MW FITC-Dextrans was comparable and also 







Figure 3.12 Mucoadhesive properties of FITC-Dextran containing TSP-microparticles (triangle) or 
unformulated FITC-Dextrans (square) in-vitro (A) and ex-vivo (B) as a function of the MW of the 
FITC-Dextran. Data presented is the mean of three independent experiments ± SD. (***P < 0.001 
and **** P < 0.0001). 
3.6.3.1 Mechanism of mucoadhesion determined by cryo-FESEM 
The interaction of TSP-microparticles with mucin was investigated microscopically by 
plunge freezing a sample of mucin with microparticles deposited on it. Samples were viewed 
at pre-determined time intervals under the cryo-FESEM (Figure 3.13). The time-series 
cryo-FESEM micrographs show the initial contact (Figure 3.13 B, white arrowhead) 
followed by gradual formation of a gel-like layer due to the interaction between the 
TSP-microparticles and the mucin layer (Figure 3.13 C and D, white arrows). The rough 
surface features of the mucin layer as shown in Figure 3.13 A gradually changes to a 







Figure 3.13 Representative cryo-FESEM micrographs of a 2 % w/v solution of mucin only (A) or 
mucin over 60 min (T0-T60) after deposition of TSP-microparticles on it (B-D). The initial contact 
stage between mucin and TSP-microparticles (B, arrowhead) is followed by interaction of the 
microparticles with the mucus layer (consolidation stage, white arrows) and gradual formation of a 





3.6.4 The release of FITC-Dextrans from TSP-microparticles 
Any drug incorporated into the microparticles must first be released from it to permeate 
across the nasal mucosa to have a biological effect in the CNS. In-vitro permeability studies 
are a useful tool for understanding the drug release potential of a formulation. Cumulative 
release profiles of FITC-Dextrans (3-40 kDa) from TSP-microparticles across a cellulose 
acetate membrane are shown in Figure 3.14. The unformulated FITC-Dextran solution was 
used as a control. It is evident from the data that incorporation into TSP-microparticles 
sustains the release of the FITC-Dextran molecules (P < 0.01) particularly over the first hour 
(Figure 3.14 inset). However, the release profiles of formulated and unformulated 
FITC-Dextrans were comparable after 2 h, and the effect of the MW of FITC-Dextrans on 
release was insignificant. The initial burst release of FITC-Dextrans from TSP microparticles 
reported within the first 15 min is likely a result of the desorption of a small proportion of 
FITC-Dextrans weakly associated with or adsorbed to the surface of TSP-microparticles 
upon contact with the dissolution medium. 
 
Figure 3.14 Cumulative release over time of 3-5 kDa (circle), 10 kDa (square), 20 kDa (triangle) 
and 40 kDa (diamond) FITC-Dextrans formulated in TSP-microparticles (solid lines) or as an 
unformulated solution (dotted line). The inset shows release within the first 60 min of the study. Data 




The in-vitro drug release results for the first hour were fitted into zero-order, first-order, 
Higuchi, and Korsymeyers-Peppas models to determine the release kinetics and presented in 
Table 11. 









F 5 0.865 0.874 0.996 0.996 
F 10 0.902 0.879 0.998 0.915 
F 20 0.905 0.749 0.948 0.822 
F 40 0.948 0.691 0.876 0.985 
3.6.5 Permeability of FITC-Dextrans across a porcine nasal mucosa  
Ex-vivo studies were conducted to determine if drug released from TSP-microparticles 
can then permeate across the nasal mucosa. Freshly acquired porcine nasal mucosa was used 
in these studies due to its morphological similarities with the human nasal mucosa357. The 
permeability of FITC-Dextrans formulated in TSP-microparticles across the porcine nasal 
mucosa shown in Figure 3.15 A-D was significantly slower compared to a solution of the 
FITC-Dextrans (P < 0.05). The cumulative amount of FITC-Dextran from 
TSP-microparticles penetrating the mucosa per unit area (cm2) versus time was plotted.The 
steady state flux (Jss) was calculated from the slope of the linear portion of the curves and is 
shown in Figure 3.15 E. The plot shows that Jss of FITC-Dextran incorporated in 





Figure 3.15 Permeability across porcine nasal mucosa over time of 3-5 kDa (A), 10 kDa (B), 20 kDa (C) and 40 kDa (D) FITC-Dextrans formulated 
in TSP-microparticles (solid lines) or as an unformulated solution (dotted line). Flux (Jss) as a function of the MW of FITC-Dextrans across porcine 




3.6.6 Olfactory deposition of 10 µm sized TSP-microparticles containing FITC-
Dextrans 
To determine if 10 µm sized TSP-microparticles are capable of depositing in the 
olfactory region of humans after intranasal administration, they were nebulized under normal 
breathing conditions and administered into a 3D printed cast of a human nasal passage, the 
experimental setup constructed, validated and used for the deposition studies is shown in 
Figure 3.16. 
The nasal cast was air sealed except for the nostrils and throat. The vacuum pipe was 
inserted into the throat of the nasal cast. The vacuum pump was adjusted to produce 
~20 L min-1 inhalational airflow rate. The flow rate was monitored before and after the 
experiment by an anemometer. The microparticles were nebulized for 2 sec in one of the 
nostrils using an air compressor acting at low airflow rates (~5 L min-1). Consequently, the 
nasal cast was disassembled and the particles deposited in the olfactory region were carefully 
collected. The FITC content was quantified using fluorescence spectroscopy and used to 
calculate the deposition efficiency. 
 
Figure 3.16 Experimental set up used for particle deposition experiments. [anemometer: AR, vacuum 
pipe: VP connected to a vacuum pump, nasal cast: NC, and air compressor: AC]. The equipment 




The deposition of microparticles in the 3D printed human nasal cast after nebulization is 
shown in Figure 3.17. The amount of FITC-Dextrans was used to indirectly quantify the 
extent of microparticle deposition in the olfactory region of the nasal cast. 
 
Figure 3.17 Representative picture showing the deposition of TSP-microparticles containing 
FITC-Dextrans in the nasal cast, the yellow color observed was due to the FITC. 
All formulations were compared against 2 µm sized TSP-microparticles containing 
FITC-Dextrans. Powder-based formulations of 2 µm in size are known to deposit 
preferentially in the lung due to their smaller size, therefore used as a control213. The 





Figure 3.18 Deposition efficiency of 10 µm versus 2 µm TSP-microparticles containing 5 kDa (A), 10 kDa(B), 20 kDa(C) and 40 kDa(D) 
FITC-Dextrans in the olfactory region of a human nasal replica 3D printed cast when nebulized under normal breathing conditions (20 L/min). 





Deposition in the olfactory region is reported as deposition efficiency and the data is 
presented in Figure 3.18. Deposition efficiency ranged from 0 to 1.9 % with 10 µm 
microparticles as compared to 0 to 0.7 % with 2 µm microparticles. In some experiments, 
olfactory deposition of microparticles was negligible, so for these experiments, the 
deposition efficiency is reported as zero. Consequently, a large number of independent 
experiments were conducted to ensure reproducible and statistically robust data. Overall, 
microparticles with a mode size of 10 µm showed significantly higher deposition efficiency 
(****P < 0.0001) in the olfactory region compared to the 2 µm particles. 
3.6.7 Safety of TSP-microparticles for nasal administration 
Histopathological analysis of porcine nasal mucosa at the completion of the ex-vivo 
studies (Section 3.6.5) is shown in Figure 3.19. Freshly acquired, untreated nasal mucosa 
was used as a control as shown in Figure 3.19 A. Mucosal structures such as the surface 
epithelium, the underlying connective tissue, and serous glands are evident in the 
micrographs as shown in Figure 3.19 B-E. The cylindrical appearance of epithelial cells 
retaining their overall polarity is a good indicator of structural integrity250. No visual 
evidence of epithelial cells detached from the mucosa or large vacuolated regions, necrosis, 
hemorrhage or ulceration (large red colour spots), were identified in tissues treated with 
TSP-microparticles as shown in Figure 3.19 B-E and these were comparable to the negative 
control. Marked alterations to the epithelium with a detachment of the epithelial layer, the 
presence of rounded epithelial cells and loss of polarity could be seen in the histopathology 
of the positive control as shown in Figure 3.19 F. The histopathlogy of nasal mucosa in this 






Figure 3.19 Representative light micrographs of porcine olfactory nasal mucosa after exposure to TSP-microparticles containing FITC-Dextran 
(B) 5 kDa, (C) 10 kDa, (D) 20 kDa and (E) 40 kDa. Freshly acquired nasal mucosa was used as negative control (A) while mucosa treated with 
37 % v/v nitric acid served as a positive control (F). (SG: serous glands). The arrows and arrowhead indicate histopathology of the olfactory 
epithelium and large vacuoles, respectively. (Scale bar = 100 µm). 




The potential advantages that TSP formulated as microparticles can offer to the 
nose-to-brain delivery of drugs, the unexplored potential of TSP as a macromolecular drug 
carrier, and the understated nasal drug carrier properties of TSP are the driving factors for 
the research presented in this Chapter. 
The majority of the literature has followed the extraction of TSP described by 
Rao et al233. Since it is an easy and straightforward method, it was used in this chapter for 
the extraction of TSP from tamarind seed gum. The IR spectrum of extracted TSP produced 
characteristic functional group IR peaks, and the x-ray diffractograms showed no sharp peaks 
indicating the amorphous nature of the TSP. The IR spectrum and the x-ray diffractograms 
were comparable to the data available in literature355. Furthermore, the SEM observation of 
TSP revealed a smooth surface and was similar to the published literature356. In addition, no 
batch variation was observed between TSP extracted on different days, x-ray diffractograms 
and IR spectrum were identical. Published scientific reports identified similar properties for 
polysaccharides with no batch variation when a similar method of extraction has been 
used360,361. 
Formulating TSP as microparticles and optimizing the microparticle size to 10 µm was 
one of the research aims of this chapter. In this thesis, the size of particles is reported as 
“mode size” the most common size within a particle population. Pilot studies and a DOE 
approach (Box-Behnken experimental design) was employed to optimize the formulation 
parameters. The effect of formulation parameters on the microparticle size was analyzed by 
ANOVA to understand their effect and atomizing airflow and aspiration were found to be 
significant factors affecting the particle size. The velocity of the compressed air passing 
through the nozzle (atomizing air flow) can significantly affect the particle size by 
determining the size of droplets formed from the feed solution339,362. The velocity of the 
drying gas (aspiration) determines the time of droplet drying in the chamber which might 
have affected the size of the particles339. Among the formulation parameters tested, 
FITC-Dextran concentration and inlet temperature did not significantly affect particle size. 
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The reason for this can be attributed to the low amount of FITC-Dextrans used in this study 
and that the temperatures were higher and sufficient to dry the solvent (water) quickly, 
resulting in an insignificant effect on the resultant microparticle size. 
To identify the optimal levels of formulation parameters to produce the 10 µm particles 
the Design Expert software was used. Design Expert provides a user interface to target the 
particle size to a specific range manually and predicts the optimal levels of formulation 
parameters required to produce the target range of particle size. The particle size target was 
set to 10 µm and the predictions of formulation parameter levels acquired from Design 
Expert. The levels of two significant parameters: atomizing airflow and aspiration, were 
predicted to be 547 L/h and 55 % respectively, in order to produce 10 µm sized particles. 
These predictions were tested practically and resultant particle size was measured. The 
optimized levels of formulation parameters were found to produce the 10 µm sized particles 
reproducibly. FITC-Dextran with MW 3-5 kDa was employed for these studies. 
Microparticles were prepared using the optimized levels of formulation parameters with all 
the other FITC-Dextrans. The MW of the FITC-Dextran did not show any effect on the 
particle size. This could have been be due to the constant amount of the FITC-Dextrans 
(0.25 % w/w) used in all the formulations. Spray-Drying TSP with FITC-Dextrans of 
different MW at the optimized levels of formulation parameters produced 10 µm sized 
TSP-microparticles containing FITC-Dextrans. 
Spray-dried TSP-microparticles containing FITC-Dextrans were corrugated in shape and 
hollow. Corrugated particle shape has been reported to lower the true area of contact between 
the particles thereby reducing the cohesiveness between particles which is the desired quality 
for intranasal administration363,364. Hollow particles improve the dispersibility of the solid 
microparticles339 which can be a desirable property for intranasal delivery end use aimed for 
in this thesis. The surfaces of the microparticles observed were rupture free, which is 
desirable as such microparticles have been reported to have proper deposition and delayed 
clearance from the nasal cavity365. There were no significant differences observed between 
the morphology of the TSP-microparticles containing different MW FITC-Dextrans. 
The FITC-Dextran content in the microparticles was determined by fluorescence 
spectrophotometer. The results indicated that TSP could successfully load high MW dextran 
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molecules up to 40 kDa. The molecular interactions of dextran chains with TSP and the low 
drug loss in the spray-drying process might have contributed to the high encapsulation 
efficiency of the TSP-microparticles. The green fluorescence of the FITC in 
TSP-microparticles observed with fluorescence microscopy confirmed the loading of 
FITC-Dextrans. These results suggest that TSP can be a potential macromolecular drug 
carrier for drug delivery applications. 
One of the beneficial features of TSP for intranasal drug delivery is its potential ability 
to resist mucociliary clearance. The mucoadhesive potential of TSP was evaluated to identify 
the potential of TSP-microparticles to increase their residence time in the nasal cavity. In the 
present study, two in-vitro approaches and an ex-vivo approach were used to confirm the 
mucoadhesive properties of FITC-Dextran loaded TSP-microparticles. Firstly, the amount 
of TSP-microparticles containing FITC-Dextran that adhered to a piece of filter paper 
saturated with mucin after application of an air load was determined by quantifying the 
amount of FITC-Dextran and represented as in-vitro mucoadhesion. It is a quick and useful 
approach to determine the effect of air-flow on nasal clearance of microparticulate 
formulations after their administration into the nasal cavity. Previously reported techniques 
for in-vitro mucoadhesion had applied the air load only one-way to simulate the process of 
inhalation but not exhalation209. In, the current study, respiration was simulated by 
incorporating the airflow from two directions in an attempt to better represent the respiratory 
conditions when a formulation is inhaled. In-vitro, TSP-microparticles showed significantly 
higher mucoadhesion compared to the unformulated FITC-Dextran powders. The 
mucoadhesive potential of TSP can be attributed to the hydrogen bonding capacity of –OH 
groups on the side chains of TSP. These functional groups interact with other electronegative 
atoms in mucin and form a hydrogen bond. Furthermore, van-der-Waals bonds may also 
arise due to the dispersion forces in TSP contributing to the mucoadhesion. 
Ex-vivo mucoadhesion studies using the tensile strength apparatus complemented the 
in-vitro study and demonstrated the potential of TSP-microparticles to adhere to the mucosa 
in the nasal cavity. Tensile strength is, a widely employed method for the assessment of 
mucoadhesion366. In this chapter, the force required to detach the microparticles from porcine 
nasal mucosa was represented as mucoadhesive strength. Assessing mucoadhesion of 
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microparticles is challenging due to the small size of the particles. In this study, an industrial 
grade strong adhesive epoxy was employed to ensure the firm adhesion of microparticles to 
the probe. This prevented the loss of microparticles onto mucosa when the probe measured 
the detaching force. The exclusively designed mucoadhesion rig minimized any equipment 
errors. TSP-microparticles demonstrated significantly high mucoadhesion strength 
compared to the unformulated FITC-Dextran powders. Mucoadhesive properties were 
comparable across all microparticle formulations in in-vitro and ex-vivo studies and are most 
likely the result of the constant amount of polymer and FITC-Dextran used in each of the 
formulations investigated (2 % of total solids)367. 
Cryo-FESEM was used to investigate the interaction between TSP-microparticles and 
mucin. This work is the first electron microscopy study to identify the two critical stages 
which have been hypothesized to occur during the mucoadhesion process; contact and 
consolidation221. In the initial contact stage, contact between microparticles and the mucus 
layer was visible, and no apparent changes were seen in the morphology of the microparticles 
or the mucin. In the following consolidation stage, the interaction of TSP-microparticles with 
the mucus layer was evident. The interaction is most likely due to the moisture present in the 
mucin, which allows the TSP to swell and penetrate the mucin layer. Subsequently, the TSP 
conforms to the shape of the mucin by forming a gel-like layer most likely by weak Van der 
Waals attraction and hydrogen bonding 221,228. 
While controlled release of a drug molecule is considered ‘gold standard’ in formulation 
science, the optimal release profile of a drug from an intranasal delivery system is dependent 
on several parameters, in particular, the drug molecule itself, the therapeutic indication and 
the required dose. Controlled release of drugs formulated in TSP in combination with other 
polymers has been shown for at least 10 to 12 h in-vitro. However, the release of drug 
molecules from TSP-only formulations was reported to be relatively quicker 
(approximately 6 h)300,316. The likelihood that any formulation is retained in the nasal cavity 
for periods as long as 10 to 12 h despite its mucoadhesive nature is unlikely and often not 
desired. Therefore, in the present chapter, release studies over a 4 h period were considered 
as a practical time frame which would most likely encompass the timeframe of any nasal 
clearance that occurs in-vivo. The mechanism of FITC-Dextran release was found to be 
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diffusion controlled as the data fit well with the Higuchi model of drug release. The 
mechanism of drug release from TSP can be compared to hydrogels as, the microscopy 
studies and previous reports in the literature show that TSP forms a gel-like viscous layer on 
contact with the mucin by absorbing water and simultaneously releasing the FITC-Dextrans 
loaded in the microparticles via diffusion368,369. However, the drug release from the F40 
formulation fitted a Korsmeyer-Peppas model indicating that the drug release is by both 
diffusion controlled and erosion controlled mechanisms. Why this was the case for the F40 
remains unclear. 
Furthermore, ex-vivo studies using porcine nasal mucosa were conducted as such studies 
provide useful data about the permeability of drug molecules across a mucosal barrier before 
testing in-vivo. The permeation of FITC-Dextrans released from TSP-microparticles was 
dependent on MW. The FITC-Dextrans employed in this chapter were ≤ 40 kDa in size and 
their ex-vivo permeation flux decreased with increase in MW as their permeation across the 
mucosa was diffusion dependent. It has been reported that FITC-Dextrans with MW lower 
than 40 kDa cross biological barriers primarily by diffusion and in small amounts by 
pinocytosis370. 
Collectively, the in-vitro data suggest that release of hydrophilic molecules (≤ 40 kDa) 
from TSP-microparticles was independent of MW and followed a typical biphasic profile. 
The initial burst release reported was most likely surface-associated molecules that dissolved 
quickly upon contact with the solvent. This is supported by the near 100 % release reported 
with FITC-Dextrans in solution. However, unlike FITC-Dextrans in solution, the release of 
FITC-Dextrans formulated in TSP-microparticles was significantly slower which was most 
likely because the FITC-Dextrans had to diffuse through the gel layer which is rapidly 
formed when TSP-microparticles interact with mucin, as was seen by cryo-FESEM. The 
ex-vivo studies show that permeability of molecules across the nasal mucosa is strongly 
dependent on their MW. The size-dependent permeability of FITC-Dextrans across the 
olfactory mucosa and into the brain after intranasal administration has been demonstrated 
in-vivo 371. 
Another objective of this Chapter was to investigate the deposition of 10 µm sized 
particles in the olfactory region of the human nasal cavity. A 3D human nasal replica cast 
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coated with 2 % w/w mucin solution inside the nasal passages was employed for this 
purpose. Deposition of particles in the geometrically complex human nasal cavity has been 
shown to be influenced by particle size, the inhalational flow rate and the position in the 
nasal cavity from where the drug is administered76. Particles 10 µm in size have recently 
been demonstrated to have an optimum deposition in the olfactory region of the nasal 
cavity215. TSP-microparticles (2 and 10 µm) were nebulized at the nostrils in a 3D printed 
human nasal cast under a normal inhalational flow rate (20 L/min). Such in-vitro studies 
provide useful data on the regional nasal deposition of particles before human testing. The 
influence of size on particle deposition in the olfactory region was reported in the present 
study, with 10 µm-sized microparticles showing better deposition than 2 µm-sized 
microparticles. The better deposition can be attributed to the inertia of the particles, where 
particles with 10 µm size have the optimum inertia to reach the upper narrow olfactory 
region. Deposition of microparticles was independent of the MW of the incorporated 
FITC-Dextrans. This study demonstrated that formulating microparticles to 10 µm size can 
enhance their deposition in the olfactory region of the human nasal cavity. In this chapter, 
the safety of TSP-microparticles containing FITC-Dextrans was assessed ex-vivo on the 
porcine nasal mucosa. Structural integrity and epithelial cell structure were preserved in the 
mucosae treated with TSP-microparticles demonstrating the safety of TSP-microparticles for 
intranasal administration. These results agree with the previously reported safety data of TSP 
for intranasal applications275,334.  
Collectively, this Chapter evaluated the potential of TSP as a nasal drug carrier and 
macromolecular drug carrier. The combined formulative approach of formulating 
mucoadhesive microparticles as 10 µm particles improved their deposition in the olfactory 
region and the mucoadhesive potential of TSP may increase the intranasal residence time of 
the drug. A significant advantage of TSP is that it is structurally very similar to mucin and 
demonstrates mucoadhesive properties. Furthermore, the established tolerability of TSP in 
humans makes it a great candidate for a nasal preparation266.  
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3.8 Key findings 
This chapter of the thesis tested a simple formulative approach of incorporating drug 
molecules in 10 µm-sized mucoadhesive microparticles to target them to the olfactory region 
of the nasal cavity. Collectively, the data reported in this chapter suggest that the TSP can 
act as a carrier for the high MW drugs and can be formulated as 10 µm-sized particles by 
spray-drying technique. TSP-microparticles have the potential to increase the residence time 
of drugs in the nasal cavity by mucoadhesion and are safe to the nasal mucosa after acute 
nasal administration. The 10 µm-sized TSP-microparticles can improve the olfactory 
deposition at normal inhalation rates. 
3.9 Future directions 
Although enhanced olfactory deposition with size tailored particles has been reported in 
this study, further human studies are required to correlate increased deposition efficiency 
with the biological relevance. Critical research quesitons such as, does increased depositon 
in the olfactory region affect brain uptake of drugs? Is the increase in depositon sufficient to 
produce a biological effect? need to be answered in future studies. 
Although the safety of TSP has been reported ex-vivo, further studies investigating the 
safety and tolerability of TSP-microparticles in-vivo after acute and chronic intranasal 
administration are required to progress this drug-delivery platform. The drug release and 
permeation across the nasal mucosa to reach the brain have to be examined in-vivo to further 
understand the potential of TSP-microparticles in nose-to-brain drug delivery. In addition, 
the FITC-Dextrans used as model drugs in this study are hydrophilic and the MW tested is 
only till 40 kDa. Such limitations of this study raise research questions on the potential of 
the TSP-microparticle delivery system for use with larger and or hydrophobic drugs, which 
need to be addressed by future studies. Also, study of effect of the surface charge of particles 
on drug delivery and mucoadhesion needs to be addressed in future work.  
Several drug delivery devices that aim to target drug formulations to the olfactory 
mucosa are already in various stages of clinical trials. While still at a conceptual stage, it 
would be interesting to explore if this formulative approach used in combination with an 
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intranasal device can augment olfactory targeting and enable enhanced delivery of 



























Formulation and In-vivo characterization of 


















4 Formulation and in-vivo characterization of TSP-
microparticles loaded with phenytoin  
4.1 Introduction 
Results from Chapter 3 demonstrate that TSP can be formulated as mucoadhesive 
microparticles. This chapter investigates the ability of the TSP microparticle system to load 
and release an anti-epileptic drug (AED) phenytoin in-vitro and its biodistribution in rats 
following intranasal administration. 
4.1.1 Sub therapeutic brain concentrations of drugs in epilepsy 
More than 70 million people worldwide are affected by epilepsy, making it one of the 
most common neurological disorders372,373. Unprovoked and recurrent seizures are observed 
in epileptic patients which are either focal or general in nature374. AEDs are the first line of 
treatment in controlling seizures. However, about one-third of epilepsy patients suffer from 
uncontrolled seizures despite treatment with at least two or three AEDs. Such a condition is 
termed ‘drug-resistant epilepsy’375. 
One possible reason for treatment failure is inadequate levels of AEDs reaching the brain 
due to overexpression of the multidrug efflux transporter P-glycoprotein (Pgp) at the 
blood-brain barrier (BBB) in the tissues surrounding the epileptic focus 376–378. Along with 
Pgp various types of multidrug efflux transporters present at the BBB are shown in Figure 
4.1. It is hypothesized that in patients with drug-resistant epilepsy, multidrug efflux 
transporters at the BBB efflux AEDs at a significantly higher rate, which results in lower 
brain concentrations of the AEDs376,377,379. Overexpression of such efflux transporters 
severely limit the AED penetration into the brain so that the concentrations of AEDs in the 
brain cannot become sufficiently high for therapeutic efficacy380,381. Consequently, AEDs 
fail to control the seizures in drug-resistant epilepsy. To improve the efficacy of AEDs 




long-term use of Pgp inhibitors can be associated with several intolerable side-effects and 
development of resistance to the Pgp inhibition383. 
 
Figure 4.1 Localization of multidrug efflux transporters at the BBB. The efflux transporters at the 
luminal side are mainly responsible for the restriction of drug entry into the brain. However, 
transporters at the abluminal side can sometimes act in conjunction with the transporters on the 
luminal side to enhance the extrusion of drugs from the brain. Arrows indicate the direction of 
transport of drugs. BCRP, breast cancer resistance protein; MRP, multidrug resistance protein; 
OAT3, organic anion transporter 3; OATP2/3, organic anion transporting polypeptide 2/3 and Pgp, 
P-glycoprotein. Figure modified with permissions from Loscher et al381. 
4.1.2 Strategies to enhance the brain concentrations of drugs in epilepsy 
In order to overcome the BBB and the effect of multidrug efflux transporters, drugs are 
administered to the brain by several strategies. Direct brain delivery of drugs by invasive 
methods such as intrathecal378, intracerebral implants384, and BBB disruption techniques385 
are reported. However, invasive methods have been reported to have significant 
disadvantages such as local toxicity, poor and unpredictable distribution, and low patient 
compliance385. Non-invasive methods such as chemical modification of drugs386,387, 
receptor-mediated delivery, cell penetrating peptide-mediated delivery, and intranasal 
delivery are reported in the literature. As discussed in Chapter 1, neurological pathways in 
the olfactory region can deliver the drugs to the brain while bypassing the BBB and 
multidrug efflux transporters. Hence, intranasal delivery of AEDs can be advantageous. For 




to produce enhanced anti-seizure effect compared to IV diazepam in humans388,389. 
Administering the AED lamotrigine390 and clobazepam391 intranasally has been reported in 
literature to achieve higher in-vivo brain concentrations. Also, intranasal administration of 
lorazepam demonstrated favorable pharmacokinetics in humans in relation to IV and IM 
routes392. 
Formulation strategies to improve AED bioavailability for effective anti-seizure activity 
has been reported in the literature. For example, formulation of carbamazepine as a 
β-cyclodextrin-carbamazepine complex has been shown to significantly improve the 
anti-epileptic activity and bioavailability in rats compared to unformulated AED after 
intraperitoneal and oral administrations393,394. Co-polymerization and co-precipitation of 
AEDs with polymers have been reported to improve the dissolution and solubility profiles 
consequently enhancing the bioavailability395,396. Formulating AEDs such as stiripentol,397 
carbamazepine,398–400 rufanimide401 and phenytoin402 as solid dispersions has been shown to 
improve their dissolution profiles. 
Delivery of AEDs formulated as nanoparticles have been reported with promising results 
towards increasing the bioavailability of AEDs403,404. For example, polysorbate-80 coated 
nanoparticles of gabapentin have shown an enhanced concentration in the brain after 
intraperitoneal administration405. Another study where clonazepam was formulated as solid 
lipid nanoparticles demonstrated improved anticonvulsant activity by enhanced BBB 
permeability of nanaoparticles406. Wang et al. reported that hydrogel nanoparticles of 
phenytoin sodium improve antiepileptic effects by enhancing the brain concentrations407 and 
on-demand delivery of phenytoin sodium into the brain by electro responsive nanoparticles 
in generalized tonic-clonic seizures408. 
Combining formulation strategies with intranasal administration has been reported to 
produce high brain targeting of AEDs in the literature. For example, Eskandari et al. reported 
that intranasal administration of valproic acid formulated into nanostructures could enhance 
the brain concentration and consequently produce high anti-seizure activity compared to 
intraperitoneal administration409. Sharma et al. demonstrated enhanced brain delivery of 
lorazepam incorporated into nanoparticles after intranasal administration compared to 




mucoadhesive microemulsions could significantly increase the direct nose-to-brain transport 
of clonazepam compared to a solution or non-mucoadhesive microemulsions, into rabbit 
brain. The brain targeting efficiency of mucoadhesive microemulsions was tested by 
measuring the radioactivity of administered 99mTc‐labeled clonazepam. Mucoadhesive 
microemulsions produced higher radioactivity in the brain demonstrating the high targeting 
efficiency of the mucoadhesive microparticles411. 
Interestingly, the reports on AEDs formulated as intranasal microparticles are scarce. 
One study reported spray-dried microspheres loaded with phenytoin. The in-vitro 
characteristics of the formulation and the sustained release of phenytoin from microspheres 
was reported, but no in-vivo data was provided412. In another study, alginate-chitosan 
microparticles of phenytoin were formulated. Nonetheless, the study did not report any 
significant advantage of formulating phenytoin as alginate-chitosan microparticles and 
concluded that the formulation requires more modifications413. 
Considering the advantages of intranasal administration of AED formulations and the 
potential of mucoadhesive microparticles as discussed in Chapter 1, this chapter 
investigates the formulation of an AED (phenytoin) into microparticles and its intranasal 
administration in rats. Phenytoin was selected as a model drug as it is an effective first-line 
AED and is a substrate of the Pgp multidrug efflux transporter. Over expression of Pgp in 
drug-resistant epilepsy severely limits the uptake of phenytoin into the brain leading to sub 
therapeutic levels and treatment failure414. Therefore this Chapter utilizes phenytoin as a 
model drug for formulation into the intranasal mucoadhesive microparticles. 
4.1.3 Phenytoin 
Phenytoin (Figure 4.2) was first developed during the 1930s, and it is still in use for the 
treatment of epilepsy despite the invention of many new AEDs415. In addition to its use as 
an AED, phenytoin is also used as antiarrhythmic416. Recently, neuroprotective activity of 
phenytoin in optic neuritis in patients with multiple sclerosis has been tested with positive 




Phenytoin exhibits anti-epileptic activity by blocking inactive sodium channels and reducing 
voltage-gated sodium and calcium channel currents418,419.  
 
Figure 4.2 Chemical structure of phenytoin sodium (phenytoin). 
Due to its poor water solubility (80 µmol/L), its sodium salt, phenytoin sodium, and ester 
prodrug, fosphenytoin, are used clinically420,421. Phenytoin (Sodium 2,5-dioxo-
4,4-diphenylimidazolidin-1-ide) belongs to Class II of the Biopharmaceutics Classification 
System with low solubility and high permeability422. Phenytoin is available as a parenteral 
preparation solubilized at 50 mg/mL with 40 % propylene glycol (PG) and 10 % ethanol421. 
Sodium salt of phenytoin is a low MW (274.25 Da) crystalline powder, which converts into 
phenytoin when administered and exhibits its pharmacological activity. Phenytoin undergoes 
metabolism in the liver by cytochrome P450 enzymes to form its major metabolite 
‘5-(4-Hydroxyphenyl)-5-phenyl-hydantoin’423. The amide groups (-NH) in the phenytoin 
molecule (Figure 4.2) are reported to interact with excipients by hydrogen bonding and 
improve the solubility of phenytoin394,421,424. 
4.1.4 TSP-microparticles loaded with phenytoin for nose-to-brain delivery 
It is evident from a review of literature that there is still a need for studies to explore the 
potential of formulation strategies combined with intranasal administration for AEDs. With 
the advantages mucoadhesive microparticle formulation can provide as discussed in 




TSP-microparticles with 10 µm size could have the potential for enhancing nose-to-brain 
drug delivery of phenytoin and therefore forms the focus of this chapter. However, the low 
solubility and high crystallinity of phenytoin pose research questions:  
 Whether phenytoin can be formulated as 10 µm sized TSP-microparticles?  
 Whether phenytoin can affect the mucoadhesive potential of TSP-microparticles?  
 How stable are the microparticle formulations?  
 How much phenytoin administered as intranasal microparticles can reach the brain? 
4.2 Hypothesis 
The overall hypothesis of this chapter is that incorporating phenytoin into 10 µm sized 
TSP-microparticles can enhance nose-to-brain delivery of phenytoin in a rat model. 
4.2.1 Chapter Aims 
1. To formulate and optimize 10 µm sized TSP-microparticles loaded with phenytoin 
by spray-drying. 
2. To assess the mucoadhesive potential and phenytoin release profile of 
TSP-microparticles. 
3. To assess olfactory deposition efficiency of 10 µm sized TSP-microparticles loaded 
with phenytoin. 
4. To assess nasal mucotoxicity of TSP-microparticles loaded with phenytoin in rats. 
5. To assess the stability of microparticle formulations. 
6. To develop an HPLC method to accurately quantify phenytoin in rat plasma, brain, 
and other tissues. 
7. To quantify the uptake of phenytoin in plasma, brain, and peripheral tissues 
following intranasal administration of phenytoin in TSP-microparticles, IV and as 





4.3.1 Formulating 10 µm-sized TSP-microparticles containing phenytoin by 
spray-drying 
4.3.1.1 Optimization of formulation parameters 
The initial experimental trials were based on the optimized conditions for the TSP 
FITC-microparticles from Chapter 3. The effect of formulation parameters: total solids (%), 
TSP:phenytoin ratio, PG (%), and spray-drying conditions (Q-flow (L/h) & aspiration (%)) 
on particle size was examined. The inlet temperature was kept constant at 120 ºC. Table 12 
lists various formulation parameters and the resulting particle size. A total of 
12 combinations of different levels of formulation parameters were tested. 
The optimized formulation parameters from Chapter 3 failed to produce the same 
particle size when the FITC-Dextran was replaced with phenytoin. Instead an increased 
particle size of 14 µm was observed. It has been reported that factors like the properties of 
drug, excipients, and drug to excipient ratio can affect the spray-drying process362,425. 
Phenytoin is a poorly soluble crystalline drug, unlike amorphous hydrophilic dextrans and 
the addition of PG may have affected the spray-drying process. Thus suitable formulation 
parameters to produce 10 µm sized TSP-particles containing phenytoin were identified by 
trial and error. 
The analysis of the spray-drying results from Chapter 3 revealed that atomizing airflow 
and aspiration are two significant factors that control particle size. As a first step, the 
atomizing airflow was changed, and the size of the resultant particles was analyzed. A 
decrease of atomizing air flow < 547 L/h lead to larger particle size (> 14 µm). Furthermore, 
the phenytoin was not completely formulated into microparticles as identified by SEM 
(Figure 4.3). Increasing the atomizing airflow to the next possible level (> 547 L/h) resulted 
in very fine atomization of the feed solution and consequently a decrease in the particle size 
(6 ± 0.3µm) and its distribution. Hence, the atomizing airflow rate was kept constant at 




analyzed. An increase in the velocity of the drying gas decreased particle size gradually, and 
at the maximum level of aspiration (100 %), the particle size was 11.6 ± 0.2 µm.  
As the amount of drug and excipients can also affect spray-drying, the total solid contents 
in the feed solution was decreased from 2 % to 1.5 % without changing the TSP:phenytoin 
ratio. This further decreased the particle size to 11.2 ± 0.1 µm. Further decrease in total 
solids was not considered due to its potential implications on the mucoadhesive potential and 
phenytoin content of the microparticles. Instead, PG content was decreased from 10 % to 
5 %, and the resultant particle size was analyzed. These conditions produced the required 
10 µm particles. The optimized conditions are presented in Table 12 and are highlighted 





Table 12 List of formulation parameters tested. Highlighted cells in gray color indicate the optimized, 
most suitable formulation parameters to obtain microparticles with a size of 10 µm. Particle size 














2.0 3:1 425 55 10 17.8 ± 0.3 
2.0 3:1 487 55 10 17.8 ± 1.0 
2.0 3:1 547 55 10 14.0 ± 1.0 
2.0 3:1 607 55 10 6.0 ± 0.3 
2.0 3:1 668 55 10 4.2 ± 0.1 
2.0 3:1 547 60 10 19.4 ± 0.1 
2.0 3:1 547 75 10 14.3 ± 0.8 
2.0 3:1 547 95 10 12.2 ± 0.5 
2.0 3:1 547 100 10 11.6 ± 0.2 
1.5 3:1 547 100 10 11.2 ± 0.1 
1.5 3:1 547 100 5 
9.8 ± 0.4 
10.1 ± 0.1 
10.3 ± 0.3 
1.5 1:1 547 100 5 9.7 ± 0.7 
1.5 1:3 547 100 5 11.0 ± 1.0 
The optimized conditions were validated by analyzing the particle size data obtained 
under these conditions on three different days and during three different times within a day. 
Statistical analysis of these results by a student t-test identified no significant difference in 
the particle size (P>0.05) confirming that these conditions were suitable to produce 
10 µm-sized TSP-microparticles containing phenytoin. Then, with an aim to further increase 




25 % to 50 % and 75 %. These changes did not result in significant particle size changes 
(P >0.05). 
Figure 4.3 A & B show the morphology of the unformulated phenytoin powder (A) and 
spray-dried phenytoin (B). Figure 4.3 C-F show representative SEM micrographs of 
TSP-microparticles containing phenytoin where the effect of formulation parameters can be 
observed in the morphological features of the particles. The effect of spray-drying 
parameters are shown in Figure 4.3 C & D and indicate that the larger particles are produced 
at lower atomizing air flow (≤ 487 L/h) rates. Also, at these levels, phenytoin was not 
completely incorporated into TSP-microparticles. The unformulated phenytoin crystals 
could be observed as shown in C. Higher atomizing airflow (≥ 607 L/h) led to particles with 
smaller size as shown in Figure 4.3 D. Figure 4.3 E & F demonstrate the effect of the 
TSP: Phenytoin ratio on microparticles. With increases in the concentration of phenytoin 
(50 %), the surface of the microparticles shows crystalline fractions of the phenytoin as a 
textured surface, as shown in Figure 4.3 E. Further increase in phenytoin level (75 %) results 
in increased fractions of crystalline phenytoin on the surface of the microparticles as shown 
in Figure 4.3 F. Large variations in the particle size and presence of crystalline phenytoin in 
the formulations and on the surface of microparticles observed under SEM emphasize the 






Figure 4.3 Representative micrographs of (A) crystalline unformulated phenytoin powder and (B) 
spray-dried phenytoin. Representative micrographs of TSP-microparticles demonstrating the effect 
of spray-drying parameters: (C) unformulated crystalline phenytoin observed after spray-drying with 
TSP and (D) smaller particle size at the higher levels (≥ 607 L/h) of spray-drying parameters. 
Representative micrographs of TSP-microparticles demonstrating the effect of an increase in 




Figure 4.4 shows the morphology of TSP-microparticles containing phenytoin produced 
using the optimized spray-drying conditions. These microparticles had uniform size 
distribution compared to the microparticles produced with non-optimized formulation 
parameters (Figure 4.3). The particles had corrugated shape. The surface appeared smooth 
and with no visible fractions of crystalline phenytoin as shown in Panel B. 
 
Figure 4.4 Representative micrographs showing the morphology of TSP-microparticles containing 
phenytoin (C) and corrugated microparticles with smooth the surface (D). 
These TSP-microparticles with a mode size of 10 µm, containing phenytoin produced 
with optimized spray-drying conditions were used for further studies. They are, herein 





4.3.1.2 Analysis of phenytoin content in TSP-microparticles 
The amount of phenytoin incorporated in TSP-microparticles was analyzed by a 
previously validated HPLC method (Younus et al, unpublished data). Figure 4.5 A, shows 
the peak for separation and identification of phenytoin. Phenytoin was quantified using the 
standard curve in Figure 4.5 B (r2 = 1). The encapsulation efficiency of optimized 
microparticle formulations was found to be 96.13 ± 0.37 %, and the drug loading was 
24.20 ± 0.02 %. 
 
Figure 4.5 (A) HPLC chromatogram showing the phenytoin (PHT) peak with a retention time of 
4.4 min. (B) A standard curve of phenytoin where data presented are the mean of three independent 




4.3.2 Mucoadhesive properties of TSP-microparticles containing phenytoin 
The mucoadhesiveness of TSP-microparticles containing phenytoin was investigated 
using the in-vitro and ex-vivo methods described in Chapter 3. Phenytoin solution and 
unformulated phenytoin powders were used as controls. 
Figure 4.6 shows that TSP-microparticles show significantly higher mucoadhesion 
under both the in-vitro (P < 0.01) and ex-vivo conditions (P < 0.001) compared to the 
unformulated phenytoin powder and phenytoin solution. Interestingly, there was no 
significant difference between the ex-vivo mucoadhesion strengths of phenytoin solution and 
phenytoin powder. 
 
Figure 4.6 In-vitro (A) and ex-vivo (B) mucoadhesive properties of TSP-microparticles containing 
phenytoin compared to the unformulated phenytoin sodium powder and solution. Data presented is 





4.3.3 Release of phenytoin from TSP-microparticles in-vitro 
The cumulative release profile of phenytoin from TSP-microparticles across a cellulose 
acetate membrane is presented in Figure 4.7. Unformulated phenytoin powder and 
phenytoin solution were used as controls. The results suggest that the microparticles 
significantly sustain the release of phenytoin. The initial burst release of phenytoin from 
microparticles and faster release in the first 5 min was observed compared to the phenytoin 
powder. 
 
Figure 4.7 Cumulative release of phenytoin as a function of time from solution (triangle, dotted line), 
unformulated powder (square, dashed line) and microparticles (circle, solid line). The inset shows 
the initial burst release from the microparticles due to the amorphous surface drug releasing 
instantly upon contact with the medium and sustained release of phenytoin over the first 60 min. Data 
presented is the mean ± SD of three independent experiments (* P < 0.05). 
The in-vitro drug release results for the first hour were fitted into zero-order, first-order, 
Higuchi, and Korsymeyers-Peppas models to determine the release kinetics. The release was 




The results from in-vitro drug release suggest that phenytoin from microparticles is 
slowly released during the first 60 min. In addition, an initial burst release of phenytoin was 
observed. Whilst in-vitro and in-vivo correlations are not always accurate, based on these 
results it is hypothesized that any brain uptake of phenytoin should be observable within 60 
min after administration of intranasal-microparticles in-vivo. Using this data in combination 
with the average nasal residence time of 8-15 min in healthy humans48,52,426 the time points 
of 15, 30, 45 and 60 min were established for the in-vivo study described in this chapter. 
4.3.3.1 Investigating the spray-drying induced change in physical state of phenytoin  
The initial faster release of phenytoin from microparticles could be due to a change in 
the physical state of phenytoin due to spray-drying with TSP. The XRPD diffractograms of 
phenytoin powder and microparticle formulations were obtained to investigate any changes 
in the physical state of phenytoin. Figure 4.8 A shows the XRPD diffractograms of 
unformulated phenytoin powder containing crystalline peaks. Figure 4.8 B shows 
representative XRPD diffractograms of TSP-microparticles containing phenytoin. The 
absence of any crystalline peaks in the microparticles indicates that the spray-drying has 
converted crystalline phenytoin to an amorphous phase in the microparticle formulations. 
Representative DSC thermograms in Figure 4.8 C show the thermal behavior of 
unformulated phenytoin powder with microparticles. The absence of a thermal peak in the 






Figure 4.8 XRPD diffractograms of unformulated phenytoin powder (A) and TSP-microparticles containing phenytoin (B). DSC thermograms 




4.3.4 The permeability of phenytoin across porcine nasal mucosa ex-vivo 
Permeation of phenytoin across the porcine nasal mucosa was studied to determine if 
drug released from TSP-microparticles can then permeate a biologically relevant mucus 
barrier. Unformulated phenytoin powder and phenytoin solution were used as controls. The 
permeability of phenytoin as shown in Figure 4.9 from microparticles during the first 2 h 
was significantly slower compared to the powder and solution (P < 0.05). The steady state 
flux (Jss) of phenytoin permeation across the porcine mucosa released from 
TSP-microparticles was calculated to be 55.9 ±2.808 µg cm-2 h-1. The Jss of phenytoin 
solution and phenytoin powder was found to be 210.10 ± 68.89 and 87.99±40.77 µg cm-2 h-
1 respectively. 
 
Figure 4.9 Permeability of phenytoin across porcine nasal mucosa over time. The permeation of 
phenytoin formulated as TSP-microparticles (circle, solid line) was compared with phenytoin 
solution (triangle, dotted line) and unformulated phenytoin powder (square, dashed line). Data 





4.3.5 Olfactory deposition of TSP-microparticles containing phenytoin 
The extent of olfactory targeting by microparticles under normal breathing conditions of 
20 Lmin-1 was determined by the amount of phenytoin depositing in the olfactory region of 
the 3D nasal cast. The 4 µm sized microparticles produced from one of the trial runs in the 
formulation optimization process was used as a control due to their ability to escape 
deposition in the nasal cavity. The deposition efficiencies of microparticles are reported in 
Figure 4.10. In some experiments, olfactory deposition of microparticles was negligible, so 
for these experiments, the deposition efficiency is reported as zero. Overall, microparticles 
with a mode size of 10 µm showed significantly higher (P < 0.0001) deposition efficiency 
in the olfactory region compared to the 4 µm particles. The results are comparable to the 
deposition of TSP-FITC-Dextran microparticles described in Chapter 3. 
 
Figure 4.10 Deposition efficiency of 10 µm versus 3 µm TSP-microparticles containing phenytoin in 
the olfactory region of a human nasal replica 3D printed cast when nebulized under normal 
breathing conditions (20 L/min). Data presented is the mean ± SD of ten independent experiments. 




4.3.6 Stability of TSP-microparticles containing phenytoin 
The stability of TSP-microparticles containing phenytoin was tested according to the 
ICH guidelines for finished products248. Phenytoin content, moisture content and XRPD 
diffractograms of all microparticle formulations stored at specified conditions were recorded 
at predetermined points. Table 13 shows the drug and moisture content of the formulations. 
No significant difference in encapsulation efficiency and moisture content of microparticles 
was observed over six months of storage. 
Table 13 Drug and moisture contents of TSP-microparticles containing phenytoin over a period of 
six months. 
Storage conditions Day Encapsulation efficiency 
(%) 
Moisture content (%) 
Freshly prepared 0 96.54 ± 0.25 1.73 ± 0.15 
25ºC and 60 % RH 
30 96.83 ± 1.47 3.20 ± 0.77 
60 94.95 ± 2.11 3.73 ± 1.22 
90 94.74 ± 2.01 3.68 ± 1.02 
180 94.04 ± 1.21 4.51 ± 1.01 
    
40ºC and 75 % RH 
30 95.21 ± 2.01 4.87 ± 1.91 
60 94.87 ± 1.95 4.66 ± 0.85 
90 95.07 ± 1.76 4.80 ± 1.02 
180 94.11 ± 2.87 4.61 ± 0.21 
Figure 4.11 A & B show the XRPD diffractograms of TSP-microparticles containing 
phenytoin after a storage period of three months. Figure 4.11 A represents 
TSP-microparticles stored under ambient conditions whilst Figure 4.11 B represents 
TSP-microparticles stored under accelerated conditions. The XRPD diffractograms in 
Figure 4.11 C & D show that crystalline peaks began to reappear after six months. In 
addition, the intensity of the peaks also increased. This can be attributed to the 





Figure 4.11 Representative XRPD diffractograms of TSP-microparticles containing phenytoin stored at 25 ºC and 60 % RH for three (A) and six 




4.3.7 Evaluation of nasal toxicity and drug-related behavioral adverse effects 
of phenytoin loaded TSP-microparticles after intranasal administration 
The effect of TSP-microparticles loaded with phenytoin on rat nasal mucosa was 
examined in-vivo. No potential signs of nasal irritation such as frequent sneezing, noisy 
breathing, red (porphyrin) discharge, nose-rubbing or general signs of pain/discomfort were 
observed over the time between administration and euthanasia. The histological micrographs 
of the olfactory mucosa of rats 1 h after administration of TSP-microparticles containing 
phenytoin is shown in Figure 4.12. The olfactory mucosa of a rat treated with saline was 
used as a negative control and is shown in Figure 4.12 A. The structural integrity of the 
olfactory mucosa treated with microparticles is evident in the micrographs as shown in 
Figure 4.12 B. The structure and appearance of the epithelial cells and tissue integrity is 
comparable to the negative control. No evidence of necrosis or structural damage exists, 
unlike in the positive control (Figure 4.12 C) which was rat nasal mucosa treated with 
sodium deoxycholate. Damage to the epithelial cells, rupture of the epithelial tissue and large 
vacuoles are observed in the positive control tissues. These studies suggest that the 
TSP-microparticles loaded with the phenytoin do not cause any nasal mucosal toxicity in 





Figure 4.12 Representative light micrographs of rat nasal mucosa treated with saline (A) (negative control), phenytoin containing 
TSP-microparticles (B), and sodium deoxycholate (C) (positive control). The arrows indicate histopathology of the olfactory mucosa. A, B, C were 
captured at 4X magnification (scale bar (blue) = 400 µm) and their zoomed micrographs were captured at 10X magnification 
(scale bar (green) = 100 µm).
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4.3.8 In-vivo characterization of TSP-microparticles containing phenytoin 
4.3.8.1 Development of an HPLC method for quantification of phenytoin 
A reliable analytical method to quantify phenytoin in blood and tissues was a vital part 
of characterizing the formulations in-vivo. The aim of this part of the chapter is to develop 
and validate an HPLC method to quantify the phenytoin in rat plasma, brain, and other 
tissues. Due to high selectivity and sensitivity, HPLC can enable quantification of phenytoin 
in the presence of complex matrices. 
4.3.8.1.1 Optimization of chromatographic conditions  
The HPLC conditions such as mobile phase, pH of the mobile phase, column 
temperature, flow rate, injection volume, runtime and UV detection wavelength were 
optimized based on literature values257,258 and by trial and error. The effect of all these 
conditions was tested and the optimal conditions for separation and quantification of 
phenytoin and metabolite peaks were identified. The optimized chromatographic conditions 
are presented in Table 14. 
Table 14 Optimized chromatographic conditions for the identification and quantification of 
phenytoin and its metabolite (5-(4-Hydroxyphenyl)-5-phenyl-hydantoin). 
Chromatographic parameters Optimized conditions 
Mobile phase Phosphate buffer (10 mM) and acetonitrile (pH 5.8) 
Column temperature 40 ºC 
Flow rate 0.2 mL/min 
Injection volume 10 µL 
Runtime 22 min 
UV detection 210 nm 
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At these optimized conditions, phenytoin and metabolite peaks were identified and 
separated as shown in Figure 4.13. Retention time for the phenytoin peak ranged between 
13.4 to 13.6 min, the metabolite peak between 10.4-10.6 min and the internal standard peak 
between 14.6 min and 14.8 min in various tissues and plasma. 
4.3.8.1.2 Validation 
The assay was validated in plasma, brain tissue and peripheral tissues such as lung, liver, 
spleen, heart, kidney, and spleen. The plasma and brain tissue validation data are presented 
in detail in this chapter, and the validation data in other tissues is given in Appendix E. 
4.3.8.1.2.1 Specificity 
The specificity of the HPLC method was determined by comparing the chromatograms 
of plasma and brain samples with no phenytoin, metabolite and internal standard to those 
obtained from plasma and brain samples spiked with known amounts of phenytoin, 
metabolite and internal standard. The blank samples had no peaks at the retention times 
expected for phenytoin, metabolite or internal standard as shown in Figure 4.13 A & C. The 
spiked samples had separate peaks for phenytoin, metabolite or internal standard as shown 





Figure 4.13 HPLC chromatograms of (A) blank plasma (B) plasma sample spiked with metabolite, phenytoin (PHT) and internal standard (IS), (C) 
blank brain tissue and (D) brain sample spiked with metabolite, phenytoin (PHT) and internal standard (IS). The chromatograms show clear 




Plasma and brain standard samples were measured with the HPLC method to determine 
the linearity of the peak ratio. The peak ratio of the standard samples was a linear function 
of the phenytoin and metabolite concentration in the range of examined concentrations as 
shown in Figure 4.14. The linear regression correlation coefficient (r2) values for metabolite 
and phenytoin in plasma and tissue were all > 0.998 and the y-intercepts did not significantly 
deviate from zero (P > 0.05). 
 
Figure 4.14 Standard curves of phenytoin and metabolite in rat plasma (A) and brain (B). Data 





The LOD and LOQ are used to assess the sensitivity of the HPLC assay. These were 
calculated from the slope and the SD of the y-intercepts from the standard curves. The LOQ 
and LOD for phenytoin were 0.016 µg/mL, and 0.048 µg/mL in plasma, and in brain were 
0.027 µg/g, and 0.084 µg/g respectively. The LOQ and LOD for metabolite were 
0.061 µg/mL, and 0.185 µg/mL in plasma, and in brain were 0.140 µg/g and 0.441 µg/g 
respectively. 
4.3.8.1.2.4 Accuracy and precision 
The accuracy of the assay was determined by comparing the amount of phenytoin and 
metabolite recovered in quality control (QC) samples spiked with known concentrations. 
The precision of the assay was then determined by calculating the coefficient of variation 
(CV) and bias (%). Accuracy and precision of plasma and brain samples are reported in 
Table 15 and Table 16. Deviations from theoretical concentrations were less than 8 % for 
all the intraday and inter-day QC samples tested. The CV and bias for all QC samples tested 
were within 13 % for both the intraday and inter-day. These values for accuracy and 





Table 15 Intraday and inter-day accuracy and precision of phenytoin and its metabolite in plasma 







%CV  %bias  Accuracy % 
Intraday 
Metabolite     
1 0.9694 ± 0.118 12.19 3.05 96.94 
5 5.2133 ± 0.472 8.98 -4.11 104.10 
10 10.3010 ± 0.380 3.64 -3.03 103.01 
Phenytoin     
1 0.9237 ± 0.064 7.00 7.63 92.37 
5 5.1423 ± 0.301 5.82 -2.85 102.84 
10 10.3600 ± 1.050 10.17 -3.61 103.60 
Inter-day 
Metabolite     
1 0.8875 ± 0.081 9.80 11.24 88.75 
5 5.3347 ± 0.413 7.73 -6.61 106.69 
10 9.9878 ± 0.922 9.32 0.17 99.878 
Phenytoin     
1 1.0492 ± 0.074 7.17 -4.92 104.92 
5 5.2641 ± 0.500 9.50 -5.21 105.28 





Table 16 Intraday and inter-day accuracy and precision of phenytoin and its metabolite in brain 







%CV %bias Accuracy % 
Intraday 
Metabolite     
1 0.8883 ± 0.065 7.40 11.16 88.83 
5 4.7934 ± 0.497 10.25 4.22 95.86 
10 9.8697 ± 0.304 3.04 1.41 98.69 
Phenytoin     
1 1.0633 ± 0.035 3.32 -6.33 106.33 
5 4.9074 ± 0.561 11.41 2.00 98.14 
10 10.1891 ± 1.276 12.44 -1.77 101.89 
Inter-day 
Metabolite     
1 0.8795 ± 0.089 10.28 12.04 87.95 
5 5.0187 ± 0.514 10.18 -0.14 100.37 
10 10.1734 ± 0.600 5.82 -1.72 101.73 
Phenytoin     
1 1.0753 ± 0.084 7.81 -7.52 107.53 
5 4.7299 ± 0.491 10.34 5.53 94.59 




4.3.8.2 Uptake of phenytoin into the rat brain. 
The uptake of phenytoin into the brain 60 min after intranasal administration of 
phenytoin-loaded microparticles was compared with IV and intranasal solution 
administration and is shown in Figure 4.15. 
IV administration showed comparatively low brain uptake of phenytoin with a maximum 
phenytoin concentration of 0.21 ± 0.09 µg/g observed at 15 min post administration. 
Thereafter, no statistically significant difference between the brain concentrations of 
phenytoin over the remaining 45 min was observed. The highest phenytoin concentration of 
1.25 ± 0.44 µg/g in the brain was at 30 min after administration of intranasal solution. Again, 
like the IV administration, no statistically significant difference in the brain concentrations 
of phenytoin over the remaining 45 min was observed. Intranasal microparticles produced a 
continuous increase in the brain concentrations of phenytoin over time with a maximum of 
1.22 ± 0.39 µg/g at 60 min. Phenytoin concentrations in the brain were significantly higher 
at 60 min (**P = 0.0037) compared to initial time points. 
The efficiency of the formulation for nose-to-brain delivery of phenytoin was analyzed 
by comparing the brain concentrations obtained after administration of intranasal 
solution versus intranasal microparticles. The efficiency of the route of administration was 
analyzed by comparing brain concentrations after administration as IV 
solution versus intranasal solution and the results are reported in Table 17. The statistical 
analysis indicates that initially the administration of the intranasal solution led to 
significantly higher concentrations of phenytoin in the brain at the 15, 30 and 45 min time 
points compared to IV and at 15 and 30 min (P < 0.05) compared to intranasal microparticle 
administrations. However, at 60 min post administration, microparticles were shown to 
produce significantly higher phenytoin brain concentrations compared to the intranasal 
solution at 60 min. The analysis of phenytoin brain concentrations shows the intranasal route 
can offer high brain concentrations of phenytoin compared to the IV route and furthermore 
administration of phenytoin as intranasal microparticles can preferentially increase the brain 





Figure 4.15 Concentration of phenytoin (PHT) in the rat brains after IV solution administration 
(square), intranasal administration of solution (circle) and intranasal microparticles (diamond) over 
time. Data expressed are the mean of minimum three independent experiments ± SD with at least 
n=5 rats in each time point. 
Table 17 P-values indicating the statistical significance of brain phenytoin concentrations after (IN; 
intranasal and IV; intravenous) over time. 
 15 min 30 min 45 min 60 min 
IV solution vs  
IN solution 
*P = 0.0129 **P = 0.0074 *P = 0.0328 P = 0.1072 
IN solution vs  
IN microparticles 




4.3.8.2.1 Uptake of phenytoin in the olfactory bulb 
The concentration of phenytoin in the olfactory bulb after intranasal administration can 
be an indicator of direct nose-to-brain delivery. Figure 4.16 shows the concentration of 
phenytoin in the olfactory bulb after IV and intranasal administration of phenytoin as a 
solution and intranasal administration as microparticles. The olfactory bulb phenytoin 
concentration following IV administration could not be quantified. Consequently, only data 
from intranasal solution and intranasal microparticle experiments are presented here. 
Administration of phenytoin as an intranasal solution produced significantly higher 
concentrations in the olfactory bulb at initial points (15 and 30 min) with maximum 
phenytoin concentration of 0.83 ± 0.26 µg/g at 15 min. However, at 45 min there was no 
significant difference between an intranasal solution and intranasal microparticles. At 
60 min, intranasal microparticles produced significantly higher brain concentrations of 
phenytoin than the intranasal solution (Table 18) with maximum concentration of 
0.53 ± 0.09 µg/g. However, there was no significant difference observed between the 
maximum concentrations produced by intranasal solution (15 min) and intranasal 
microparticles (60 min) in the olfactory bulb (P > 0.05). The phenytoin concentrations in the 
olfactory bulb decreased significantly over time (**P = 0.0013) when administered as an 
intranasal solution while the concentrations increased significantly over time 
(***P = 0.0006) when administered as intranasal microparticles. These results indicate that 
the phenytoin concentrations in olfactory bulb increase with time when administered as 
microparticles and are in correlation with the increasing concentrations of phenytoin in the 





Figure 4.16 The olfactory bulb-time concentration curves of phenytoin (PHT) in rats after intranasal 
administration of solution (circle) and microparticles (diamond). Data expressed are the mean of 
three independent runs ± SD with at least n=5 rats in each time point. 
Table 18 P-values indicating the statistical significance of olfactory bulb phenytoin concentrations. 
(IN: intranasal) over time. 
 15 min 30 min 45 min 60 min 
IN solution vs  
IN microparticles 




4.3.8.3 The plasma-time concentrations of phenytoin 
The plasma concentration of phenytoin over a period of 60 min after IV, intranasal 
solution and intranasal microparticle administration was quantified and is shown in Figure 
4.17. A trend of increase in plasma concentration of phenytoin over time when administered 
as intranasal microparticles and intranasal solution was observed with maximum 
concentrations of 1.29 ± 0.36 and 0.97 ± 0.45 µg/mL at 60 min respectively. No significant 
difference was observed in plasma phenytoin concentrations for the time points tested with 
intranasal solution and intranasal microparticle administrations. 
With IV administration, the maximum phenytoin concentration of 2.74 ± 0.27 µg/mL 
was observed at the initial 15 min time point, then the plasma concentrations decreased over 
time reaching a minimum of 1.85 ± 0.32 µg/mL at 60 min. The plasma phenytoin 
concentration decreased significantly (*P = 0.0239) over 60 min after IV administration. 
Plasma concentrations of phenytoin with IV administration were compared with intranasal 
solution to determine the statistical significance between administration routes. Also, 
intranasal solution and intranasal microparticle administrations were compared to assess the 
effect of formulation strategy and the results are reported in Table 19. The statistical analysis 
revealed that as expected, IV administration led to a significantly higher phenytoin plasma 
concentration than the intranasal solution and intranasal microparticles at all the time points. 
Significantly higher phenytoin plasma concentrations for intranasal solution compared to 
intranasal microparticles for the first 30 min were observed, but intranasal microparticles 
were then able to produce similar phenytoin plasma concentrations. The plasma phenytoin 
concentrations show that the intranasal route reduces the plasma exposure when compared 
to the IV route and furthermore administering intranasal microparticles produces low plasma 





Figure 4.17 Plasma phenytoin (PHT) concertation in rats after IV solution administration (square), 
intranasal administration of solution (circle) and intranasal microparticles (diamond) overtime. 
Data expressed are the mean of minimum three independent experiments ± SD with at least n=5 rats 
in each time point. 
Table 19 P-values indicating the statistical significance of plasma phenytoin concentrations (IN; 
intranasal and IV; intravenous). 
 15 min 30 min 45 min 60 min 
IV vs  
IN solution 
**** P < 0.0001  ***P = 0.0003 ** P = 0.0023 * P = 0.0338 
IN solution vs 
microparticles 




4.3.8.4 The brain targeting efficiency of TSP-microparticles containing phenytoin 
The brain-plasma ratio can be used as a good indicator of the brain-targeting efficiency 
for intranasally delivered drugs428–430. The brain-plasma ratio at each time point was 
calculated as the ratio of phenytoin concentration in the brain (µg/g) to the phenytoin 
concentration in plasma (µg/mL) and presented in Figure 4.18. While calculating the 
brain-plasma ratio, the phenytoin concentration in the olfactory bulb was also considered as 
the phenytoin concentration in the brain. 
 
Figure 4.18 Brain-plasma ratios of phenytoin after administration as IV solution, intranasal (IN) 
solution and intranasal (IN) microparticles. Data presented are the mean of at least three 
independent experiments ± SD. (*P < 0.05, ***P < 0.001, and ****P < 0.0001). 
The brain-plasma ratio of phenytoin was significantly higher after intranasal solution 
during the first 30 min, however in the latter time points intranasal microparticles were found 
to produce a significantly higher brain-plasma ratio of phenytoin as shown in Figure 4.18 
suggesting a greater targeting of phenytoin to the brain due to the ability of microparticles to 
withstand mucociliary clearance.  
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4.3.8.5 Peripheral tissue distribution of phenytoin 
Figure 4.19 shows the peripheral tissue concentrations of phenytoin following IV 
solution (A), intranasal solution (B) and intranasal microparticle (C) administrations. The 
peripheral tissues (liver, lung, kidney, spleen, and heart) were analyzed for phenytoin 
content. The results show that the phenytoin administered as intranasal microparticles 
underwent reduced distribution to the peripheral tissues. 
Phenytoin was rapidly distributed into the liver following IV and intranasal solution 
administration with the highest concentrations of 1.41 ± 1.12 µg/g and 1.98 ± 0.84 µg/g at 
15 min which then decreased with time. However, intranasal microparticles produced a 
different profile. The initial concentrations of phenytoin in the liver were low at 15 min after 
administration of intranasal microparticles and increased with time reaching 
0.331 ± 0.21 µg/g at 60 min. 
The lungs received 0.68 ± 0.21, 0.58 ± 0.30, and 0.59 ± 0.09 µg/g concentrations of 
phenytoin with the IV, intranasal solution and intranasal microparticles at 15 min 
respectively. The concentration of phenytoin in the lungs was comparable between the time 
points with no significant difference for IV and intranasal solution administration. However, 
the lung concentration of phenytoin significantly decreased (****P < 0.0001) overtime for 
intranasal microparticle administration reaching to 0.14 ± 0.09 µg/g at 60 min. 
A maximum phenytoin concentration of 1.89 ± 0.43 µg/g in the kidney was produced by 
IV administration followed by intranasal solution (1.06 ± 0.25 µg/g) and intranasal 
microparticles (0.64 ± 0.55 µg/g) at 15 min. Concentrations of phenytoin in the kidney 
remained comparable with no significant difference over 60 min for all administrations. 
IV administration of phenytoin produced significantly higher concentrations 
(**P = 0.0042) in the heart at 30 min (~1.9 µg/g) post administration compared to intranasal 
solution (~1 µg/g) and intranasal microparticle (~0.14 µg/g) administrations. Concentrations 
of phenytoin in the heart remained unchanged with no significant difference over 60 min for 
all administrations. However, the intranasal microparticle administration produced 
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significantly lower concentrations (*P = 0.0264) of phenytoin in the heart than IV and 
intranasal solution. 
The spleen received a comparatively higher concentration of phenytoin following IV 
administration. The highest concentrations of 0.12 ± 0.06 µg/g, 0.07 ± 0.03 µg/g and 
0.05 ± 0.01 µg/g phenytoin in the spleen was observed at 30 min with IV, intranasal solution 
and intranasal microparticle administrations respectively. Concentrations of phenytoin in the 
spleen remained comparable with no significant difference over 60 min for all 
administrations. However, the intranasal microparticle administration produced significantly 
lower concentrations (*P = 0.0135) of phenytoin in spleen than IV and intranasal solution. 
The results from the peripheral distribution study show that phenytoin distribution in 
peripheral tissues is significantly decreased by administering it as intranasal microparticles 






Figure 4.19 Comparison of phenytoin distribution over time in peripheral tissues after administration as intravenous solution (A), intranasal solution 
(B) and intranasal microparticles (C). (PHT: phenytoin).




In Chapter 3 the formulation using spray-drying and the characterization of 
TSP-microparticles loaded with model drugs was presented. The aim of this chapter was to 
formulate TSP-microparticles containing phenytoin and study the in-vivo brain uptake and 
biodistribution of the phenytoin formulated into TSP-microparticles. 
Formulating TSP-microparticles loaded with phenytoin and optimizing their size to 
10 µm was one of the research aims of this chapter. TSP-microparticles containing phenytoin 
were produced with the spray-drying method, and particle size was optimized to 10 µm The 
SEM analysis of the microparticles produced at optimized formulation parameters identified 
microparticles with a corrugated morphology and smooth and rupture free surface. A 
corrugated shape and rupture free surface has been reported to be advantageous for intranasal 
administration of microparticles363–365. The shape and texture of the microparticles had 
comparable features to TSP-microparticles containing FITC-Dextrans (Chapter 3). The 
phenytoin content analysis showed very high encapsulation efficiency in the 
TSP-microparticles, and these results corroborate with the literature reporting high drug 
contents of spray-dried products431,432. 
Evaluating the mucoadhesive potential of TSP-microparticles containing phenytoin 
was an important research aim of this chapter. As in Chapter 3, in-vitro and ex-vivo methods 
were applied to investigate the mucoadhesive potential of the microparticles. In the in-vitro 
method, phenytoin microparticles have shown significantly higher mucoadhesion than the 
phenytoin powder or solution. The complementary ex-vivo studies also have shown similar 
results. These results demonstrate that the TSP-microparticles are mucoadhesive, the 
mucoadhesiveness of TSP might help microparticles to withstand mucociliary clearance in 
the nasal cavity. 
The mucoadhesive potential of TSP-microparticles containing phenytoin was 
compared with the TSP-microparticles containing FITC-Dextrans. The ratio of the ex-vivo 
mucoadhesive strength of the microparticles to the unformulated powders was used to 
compare the mucoadhesive potential between TSP-microparticles containing FITC-Dextrans 
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and phenytoin. Lack of a statistically significant difference between TSP-microparticles 
containing phenytoin or dextrans indicates that the mucoadhesive potential of 
TSP-microparticles did not change with the addition of phenytoin. 
Assessing phenytoin release from the microparticles represented the drug releasing 
behavior from TSP-microparticles and was one of the research aims of this Chapter. The 
in-vitro studies were performed for a duration of 4 h as it was hypothesized that the in-vivo 
formulation residence time in the nasal cavity was unlikely to be longer than this. Analysis 
of in-vitro drug release data revealed that the release of phenytoin from microparticles was 
diffusion dependent. The data best fitted to Higuchi’s model for drug release, indicating 
diffusion of drug through polymer matrix was the rate-limiting step in the release of 
phenytoin from TSP-microparticles433. These results are supported by the cryo-FESEM 
studies discussed in Chapter 3 where it was shown that TSP-microparticles form a gel-like 
layer on contact with mucin and the drug has to diffuse through this matrix. The formation 
of a gel-like layer during the mucoadhesion process is likely the key to the sustained release 
of phenytoin from TSP-microparticles compared to the phenytoin solution and phenytoin 
powder. TSP-microparticles significantly sustained the release of the phenytoin compared to 
the phenytoin solution or powder. About 60 % of the drug was released from the particles 
during the first 60 min and the drug release was sustained over 2 h. The drug release data 
from microparticles during the first 60 min was significantly slower compared to the solution 
and powder. 
In-vitro drug release studies were supported by the ex-vivo permeation study in the 
porcine nasal mucosa. Due to the morphological similarities of porcine nasal mucosa to the 
human nasal mucosa, it was used in this chapter to evaluate drug permeation357. Ex-vivo 
permeation data showed evidence for sustained permeation of phenytoin from microparticles 
compared to the solution and powder. Due to its hydrophobic nature, phenytoin 
predominantly relies on the transcellular pathway to permeate across biological 
membranes434. However, the permeability of phenytoin solution data obtained in this study 
was slightly higher than literature422, with the high JSS values observed in this study 
suggesting that the transport of phenytoin is supported by other mechanisms such as passive 
diffusion through paracellular pathways. The ability of solid microparticles to open tight 
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junctions was already reported and may have contributed to the drug permeation228. 
Collectively, the drug release data suggest that phenytoin was successfully released from the 
microparticles and is able to permeate across the nasal mucosa. 
The initial burst release of phenytoin observed from the microparticles in the in-vitro 
studies is most likely attributed to surface-associated phenytoin molecules that can undergo 
rapid dissolution. Interestingly, in the first 5 min, the drug release from the microparticles 
was higher than the drug release from the phenytoin powder. The hypothesis is that this 
phenomenon was due to changes in the physical nature of the phenytoin when formulated 
into TSP-microparticles. 
Phenytoin, when spray-dried with the polymers containing hydrogen donor and 
acceptor sites, is known to change from its crystalline state to an amorphous phase395,424. A 
change form a crystalline to an amorphous phase can improve solubility75 and permit faster 
drug release which may be the reason for the faster release of phenytoin from 
TSP-microparticles than the crystalline powder. 
Physical characterization of TSP-microparticles by XRPD and DSC revealed the change 
of crystalline phenytoin to a high-energy amorphous phase. The XRPD diffractograms of 
TSP-microparticles lack any crystalline phenytoin peaks, and the DSC analysis did not show 
any thermal peaks indicating an amorphous nature. The hydrogen donor and acceptor sites 
in polymers such as TSP can interact with the amide –NH protons in phenytoin and result in 
variation in nucleation and crystal growth inhibition395. TSP contains numerous -OH groups 
that can act as hydrogen bond donors or acceptors, which upon spray-drying with phenytoin 
can potentially interact with the amide groups and inhibit the association of drug molecules 
to form crystal nuclei and hold the drug in the amorphous phase234,395. Results from the 
stability studies demonstrate that phenytoin content and moisture content of the 
TSP-Microparticles did not change significantly over the period of six months (P > 0.05). 
However, the XRPD diffractograms showed that the phenytoin crystalline peaks begin to 
reappear after six months of storage. Phenytoin molecules have been reported to surface 
absorb and interact with the other phenytoin molecules via π-π interactions between phenyl 
rings and hydrogen bonding between amide and carbonyl groups during crystal growth435. 
A polymer with structurally similar hydrogen donor and acceptor groups can maintain the 
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amorphous phase for longer periods by competitive hydrogen bonding to inhibit the 
nucleation and crystal regrowth395. Hence it is reasonable to hypothesize that due to the lack 
of structurally similar hydrogen donor or acceptor groups in TSP the nucleation and crystal 
regrowth of phenytoin molecules occurred over time causing the reappearance of the crystal 
peaks in XRPD diffractograms. In future studies, it would be interesting to investigate how 
long TSP is able to retain the phenytoin in its amorphous phase, as it may have implications 
for the shelf life of TSP-microparticles. 
Formulating size specific microparticles to target the olfactory region was a key focus 
of this thesis. Due to size-dependent aerodynamics and suitable impaction, 10 µm-sized 
particles have previously been suggested to target the olfactory region, as was observed in 
this study with TSP-microparticles214. Smaller particles (4 µm) owing to their small size tend 
to follow the air streamlines and escape the nasal cavity without depositing. These results 
reinforce the importance of particle size on nasal deposition and corroborate the olfactory 
deposition data for TSP-microparticles containing FITC-Dextrans. 
Assessing the mucosal toxicity of formulations intended for mucosal applications is 
a crucial step in the formulation development process. Therefore, assessment of mucosal 
toxicity of TSP-microparticles containing phenytoin when administered intranasally was one 
of the research aims of this chapter. TSP has been reported to be nontoxic to the mucosa in 
previous reports in the literature326 and results from Chapter 3 corroborated these reports as 
TSP-microparticles containing FITC-Dextrans were found to be non-toxic to ex-vivo porcine 
nasal tissue. In this chapter, the safety of TSP-microparticles containing phenytoin following 
intranasal administration in rats was evaluated. The histopathological examination revealed 
no signs of necrosis or tissue damage and the olfactory mucosa treated with microparticles 
was comparable with the negative control. The structure of the nasal mucosa was well 
preserved and the olfactory epithelium displayed standard characteristics. Collectively, these 
results suggest that the TSP-microparticles containing phenytoin are safe for acute intranasal 
administration. 
In addition to the results of in-vitro and ex-vivo studies, data from in-vivo studies are 
essential to predict the clinical outcome of a formulation436. An accurate, reliable analytical 
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method is required to obtain robust in-vivo data. Thus a sensitive HPLC method was 
developed to quantify the data in rat plasma and biological tissues. 
As discussed previously, phenytoin is metabolized into its metabolite 
(5- (4-Hydroxyphenyl)-5-phenyl-hydantoin) in in-vivo, hence an HPLC assay that could 
simultaneously quantify phenytoin and its metabolite was developed. The chromatographic 
conditions were optimized by trial and error. The mobile phase reported by Potschka et al257 
was used and modified. The pH of the mobile phase was adjusted to 5.8 to facilitate the 
separation of phenytoin. The flow rate affected the retention time and a flow rate of 
0.2 mL/min ensured the separation of the biological matrix from the phenytoin and 
metabolite. Adjusting injection volume to 10 µL provided an acceptable peak shape. 
Sample preparation for HPLC analysis was optimized by trial and error. Use of 
perchloric acid to effectively solubilize lipids in the brain tissue to prepare HPLC samples 
has been reported in literature437. However, in this study, when perchloric acid was used, 
phenytoin recovery was low. The decreased pH caused by the addition of perchloric acid 
was likely causing the phenytoin to precipitate out resulting in the poor recovery. The 80 % 
ethanol solution and acetonitrile used to prepare the samples was sufficient to solubilize the 
lipids in the brain and other tissues effectively. In order to completely extract phenytoin from 
the plasma and tissues, tert-butyl methyl ether (TBME) was added to the extraction 
procedure for the samples. The HPLC assay developed in this chapter was validated for 
specificity, linearity accuracy and precision in plasma, brain, and other tissues prior to 
analysis of the in-vivo samples. 
Brain, plasma and peripheral tissue uptake of phenytoin following administration as an 
IV solution, intranasal solution, and intranasal microparticles were obtained from in-vivo 
studies in rats. Brain concentrations of phenytoin were significantly higher for intranasal 
solution compared to the IV solution for the first 45 min, indicating transport through direct 
pathways to brain via olfactory and trigeminal neurons in the nasal cavity. As the ‘rat 
intranasal catheter device’ (Impel Neuro Pharma, USA) used for administration of intranasal 
solution in rats delivered the phenytoin solution directly to the upper dorsal olfactory region 
of the rat nose, it might have prevented the loss of drug in the vestibule and helped to increase 
the phenytoin uptake to the brain. The uptake of phenytoin in the olfactory bulb followed a 
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similar trend as the whole brain uptake. Intranasal solution produced maximum olfactory 
bulb concentration by 15 min suggesting fast transport by direct neuronal pathways. The 
brain and olfactory bulb phenytoin concentration gradually decreased with time after 30 min 
and a sudden drop in phenytoin concentrations was observed between 30 min and 45 min. 
The decrease in phenytoin concentration in the brain and olfactory bulbs can be postulated 
to be due to mucociliary clearance. With time, the intranasal solution was cleared from the 
nasal cavity by mucociliary clearance and/or by dripping and being swallowed resulting in 
a reduced dose of phenytoin available at the olfactory region for direct transport. Also, the 
increase in plasma phenytoin concentrations observed over time with the intranasal solution 
administration supports the idea of a solution being cleared or lost to swallowing. Comparing 
the brain concentrations of phenytoin after IV and intranasal solution administration clearly 
demonstrate the potential of intranasal administration to enhance the brain uptake of 
phenytoin. 
The concentrations of phenytoin in the brain after intranasal microparticle and 
intranasal solution administrations were compared to evaluate the effect of formulation on 
the brain uptake of phenytoin. The brain concentrations administered as a solution were 
significantly higher than microparticles within the first 30 min post administration. The high 
brain concentrations in the initial time points with an intranasal solution can be linked to the 
phenytoin dose available at the olfactory region for direct transport. The intranasal solution 
in this chapter was directly delivered to the olfactory region with a special rat intranasal 
catheter device and was readily available for absorption resulting in high dose availability in 
the olfactory region. In contrast, although the microparticles were delivered to the olfactory 
region, release of phenytoin from the microparticles requires time as suggested by the 
in-vitro release studies in Section 4.3.3. Hence, the available dose of phenytoin at the 
olfactory region for absorption during the first 30 min was likely less than the 
intranasal solution. 
At the later time points, the brain and olfactory bulb phenytoin concentrations with 
intranasal microparticles steadily increased while the phenytoin concentrations from 
intranasal solution decreased. At 45 min there was no significant difference between solution 
and microparticle administrations. Then by 60 min, the brain and olfactory bulb 
          Chapter 4 
151 
 
concentrations of the phenytoin from microparticles were significantly higher than from the 
solution. This increase in the brain and olfactory bulb concentrations could have been due to 
the continued availability of phenytoin administered as microparticles at the olfactory region 
due to the mucoadhesive nature of the microparticles. As demonstrated in Section 4.3.2, 
TSP-microparticles are mucoadhesive and can withstand mucociliary clearance. Therefore 
it is possible that they provide a continuous release of phenytoin at the olfactory region 
whereas, the solution is likely to have been cleared from the nasal cavity by mucociliary 
clearance resulting in a reduced dose of phenytoin being available for absorption. The 
brain-plasma ratio results suggest an increase in drug targeting efficiency to the brain over 
the time with microparticles, which is likely due to their mucoadhesive nature. 
Within the olfactory bulb, a higher concentration of phenytoin was observed at 
15 min than 30 min with intranasal microparticles. This could have been due to the in-vitro 
burst release and the availability of phenytoin due to desorption of the phenytoin from the 
surface of the microparticles. Once the surface phenytoin was exhausted, the uptake was 
dependent on the phenytoin release from the microparticles. Thus at 30 min, lower olfactory 
bulb concentrations of phenytoin were observed. 
Interestingly, the brain concentrations of phenytoin from intranasal microparticles at 
60 min was comparable to the maximum brain concentration obtained by intranasal solution 
at 30 min (P = 0.9208). In-vitro release data reported approximately 60 % phenytoin release 
from microparticles at 1 h. Comparing the brain concentrations suggests that 60 % of 
phenytoin dose released from microparticles can produce the brain concentrations equivalent 
to 100 % of phenytoin dose from intranasal solution. This can be explained by the dose of 
the phenytoin available at the olfactory region. Due to the mucoadhesive nature of the 
microparticles, the phenytoin dose available at the olfactory region for direct transport to the 
brain might have been higher than the intranasal solution resulting in comparable brain 
uptakes. Since the blood volume in the brain is very low (47 ± 1µl/g)438 and the dose 
administered was also low (1.5 mg) the amount of phenytoin attributed to blood traces can 
be assumed to be very low and hence not considered in this study. In addition, in rats, for 
intranasal administration of small molecules, it has been reported that the blood-brain ratio 
is not significantly affected by perfusion of the brain439. 
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Collectively, these results suggest that the mucoadhesive nature of the microparticles 
can withstand mucociliary clearance ensuring drug (in this case phenytoin), available for 
brain uptake at the olfactory region whilst the intranasal solution is cleared quicker. 
Therefore, formulating drugs into TSP-microparticles has potential in nose-to-brain drug 
delivery. These results are in corroboration with previous works on mucoadhesive 
microparticles173–175,189,440. 
The plasma concentrations of phenytoin at all-time points were significantly higher 
following IV administration compared to intranasal solution and microparticles. Although 
phenytoin plasma concentrations showed a decreasing trend over time after IV 
administration, they did not vary significantly between the time points which is likely due to 
the ~64 min half-life of phenytoin in rats, which extends beyond the time points employed 
in this study441. IV administration is also expected to lead to accumulation of phenytoin in 
the peripheral tissues which is supported by the high phenytoin concentrations observed in 
the peripheral tissues in this study. 
The phenytoin plasma concentrations following intranasal solution administration 
were significantly higher for the first 30 min compared to those after intranasal microparticle 
administration. The amount of phenytoin available for absorption into blood is likely much 
higher when formulated as solution compared to microparticles where the amount of 
phenytoin is limited by its release from the microparticles. The high vasculature and surface 
area of the nasal cavity might have promoted the absorption of the administered phenytoin 
solution into the bloodstream. In addition, ethanol present in the phenytoin solution might 
have enhanced the phenytoin absorption by causing vasodilation which explains the steady 
increase in the plasma concentration over time after intranasal solution administration The 
peripheral tissue phenytoin concentrations following intranasal solution administration are 
comparable to those following IV administration which supports the hypothesis of phenytoin 
being lost to dripping, nasally absorbed or lost to swallowing and eventually entering the 
blood. 
Plasma uptake of phenytoin administered as intranasal microparticles steadily increased 
with time. The lower plasma levels of phenytoin from microparticles can be explained by 
the controlled release of phenytoin from the TSP-microparticles. Interestingly, plasma 
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concentrations of phenytoin after intranasal microparticles and intranasal solution did not 
show any significant difference at 45 min and 60 min. This can be correlated to the phenytoin 
dose available for the absorption into the blood at respective time points. The 
intranasal solution, as mentioned before may have been cleared from the nasal cavity before 
45 min and/or dripped and swallowed by the rat which would most likely lead to absorption 
into the blood. However, the mucoadhesive microparticles retain the drug in the nasal cavity 
and the dose of phenytoin available for the absorption might not have changed over time. 
Therefore, at the 45 min and 60 min time points the effective phenytoin dose available for 
absorption from both the formulations could have been similar. Consequently, this might 
have resulted in the comparable plasma concentrations of phenytoin from intranasal solution 
and intranasal microparticles. The hypothesis is supported by the comparable phenytoin 
concentrations in the kidney, liver, and lung observed with an intranasal solution and 
microparticle administrations at the 45 min and 60 min time points. 
The peripheral tissue phenytoin concentrations suggest that the systemic exposure of 
phenytoin can be reduced by administering the drug as intranasal microparticles. The 
increase in plasma concentrations over time with intranasal microparticle administration is 
correlated with the increase in phenytoin concentration in the peripheral tissues over time. 
The high phenytoin concentrations at 15 min following intranasal microparticle 
administration is a noteworthy observation in this study. This is possibly due to the 
deposition of microparticles in the lung while administering with the insufflator, resulting in 
high lung concentrations at 15 min. This might have affected the plasma concentrations of 
phenytoin, and it would be reasonable to expect much lower plasma concentrations of 
phenytoin from intranasal microparticles without the deposition in the lungs. Interestingly, 
the lung phenytoin concentrations at later time points were significantly lower than at 15 min 
(****P < 0.0001). With the ability of microparticles to sustain the release of phenytoin, if 
the microparticles are deposited in the lung, a steady increase of the phenytoin concentration 
is expected over time. However, the phenytoin concentration decreases significantly. One of 
the possible reasons could be the presence of surface phenytoin. Assuming only a small 
fraction of microparticles are deposited in the lungs, the presence of surface phenytoin which 
quickly dissolves could have spiked up the phenytoin concentration at 15 min. Nevertheless, 
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evaluation of the TSP-microparticle release in the lungs is required in future to progress this 
delivery system. 
4.4.1 Key findings 
Collectively, the data presented in this chapter suggests that TSP can be formulated as 
10 µm-sized particles containing phenytoin by a spray-drying technique. TSP-microparticles 
control the extent of release of phenytoin and improve the olfactory deposition at normal 
inhalational rates. TSP-microparticles are mucoadhesive and do not cause any nasal mucosa 
toxicity in rats. TSP-microparticles containing phenytoin were found to be stable up to 
3 months of storage. In-vivo studies identified the enhanced the brain uptake and direct 
nose-to-brain delivery of phenytoin when administered as intranasal TSP-microparticles. 
4.4.2 Future directions 
Considering the enhanced brain uptake of phenytoin from the TSP-microparticles, it 
would be interesting to explore the efficacy of such microparticles in a rat epilepsy model. 
Such studies can provide critical data for the translation of formulations from bench to 
bedside. In addition, this study considered drug concentrations due to blood traces in brain 
and other organs are negligible, however, it can be a limitation and future work needs to 
address this by employing techniques such as perfusion of blood. 
The stability data in this chapter revealed the recrystallization on storage of 
TSP-microparticles for 6 months. Chemical modification of TSP to incorporate more 
structurally similar hydrogen donor or acceptor sites similar to phenytoin might prolong the 
storage time for TSP-microparticles. Furthermore, drugs with structurally similar hydrogen 
donor or acceptor sites could be ideal candidates for microparticle formulation with TSP. 
Therefore, the data from this chapter provides evidence for a brain targeting effect of 
TSP-microparticles after intranasal administration. It would be interesting to further explore 
the organ toxicity, elimination profiles and pharmacokinetics of the drug absorbed 
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5 Computational measurements of microparticle deposition in 
human nasal cavities 
Results from Chapter 3 and Chapter 4 of this thesis demonstrated that size-specific 
microparticles could enhance deposition in the olfactory region. It would be beneficial to 
study this formulative approach in combination with an intranasal delivery device to 
augment olfactory targeting. Intranasal devices carry the significant advantage of self-
administration. This Chapter investigates microparticle deposition in three human nasal 
cavities using two conventional drug delivery approaches; firstly, a standard nebulizer that 
uses normal inhalational air flow, and secondly, a modern bi-directional air flow delivery 
technique. 
5.1 Introduction 
A recent 2017 report442 from the Food and Drug Administration (FDA) stressed the 
importance of in-silico models in drug delivery. The statement “It is the use of in-silico tools 
in clinical trials for improving drug development and making regulation more efficient,this 
enables safe and effective new therapeutics to advance more efficiently through the different 
stages of clinical trials” from this report highlight the importance of in-silico models in drug 
development. 
In recent years, in-silico experiments have suggested new lines of basic research and 
opened up new possibilities in various research areas like cardiovascular studies443, 
ophthalmology444, toxicology445, dermatology446, cancer studies447,448, genetic assays449, 
intra-cellular mechanisms450, bone remodelling451 and organ studies452. Computational 
simulations offer an inexpensive method to test a hypothesis which might be challenging to 
investigate experimentally in animals or human subjects453. 
Quantification of particle deposition in the olfactory region of the geometrically complex 
human nasal cavity is experimentally very hard to measure due to practical and ethical issues. 
Thus, in-silico methods such as computational fluid-particle dynamics (CFPD) offer a 
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practical, noninvasive and inexpensive means of predicting nasal particle deposition. CFPD 
allows prediction of particle deposition by varying physical conditions such as inhaled 
velocity profile454,455 and particle size. It also helps obtain information on regional deposition 
within the nasal cavity456–460. 
5.1.1 Nebulized (inhalation-driven) deposition in the nasal cavity 
Nebulizers have been commonly used for many years for the administration of drug 
solutions as aerosols. Nebulizers use a facemask, or a mouthpiece for the administration of 
drug aerosols and the driving force for drug administration is inhalation. Commonly 
available nebulizers in the market are divided into three types based on their working 
principle: jet nebulizers, ultrasonic nebulizers and mesh nebulizers. 
Nasal airflow characteristics determine the intranasal deposition of particles through 
nebulization. Nasal airflow patterns are well described in the literature. Laminar flows are 
observed at normal inhalational rates of 5-20 L/min 461 as shown in Figure 5.1. The majority 
of air flows through middle and inferior regions, while dorsal posterior regions like the 
olfactory region receive little air flow462. The results obtained from the simulations were in 
partial agreement with experimental results from cadavers463 and the nasal casts464–466. 
 
Figure 5.1 Schematic representation of airflow streamlines in the human nasal cavity obtained by 
computational simulations. (A) represents the simple flow lines from one of the early studies by 
Subramaniam et al.467 and (B) represents the flow lines from an advanced CFPD model, with the 
color map indicating the velocity of the airflow (Figure adapted with permissions from Subramaniam 
et al.467 and Zhao et al.468). 
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Alterations in nasal airflow patterns within human population have also been 
successfully characterized469–471. These results identified that 5 to 20 L min-1 are the 
physiological inhalation flow rates215,472. Zhu et al.473 identified the difference in airflow 
patterns between two nasal models based on different ethnic origins. The study reported a 
lower flow in the olfactory region for the Indian model (about 1 %) compared to the 
Caucasian (about 6 %) and Chinese (about 5 %) models. The Caucasian nasal model showed 
high flow (35 %) through the middle passage and high flow (about 34 %) in the inferior 
portion of the Indian nasal model. 
5.1.2 Particle deposition in the nasal cavity 
5.1.2.1 Experimental measurements 
Many studies have reported particle deposition in adult human nasal replica casts474,475 
at various air flow rates (4 to 50 L min-1) and particle sizes (4 nm to 12 µm)476–479. The 
results from these studies have observed a common trend defining deposition in the nasal 
cavity. Total deposition fraction of particles in the nasal passages is a function of inertial 
impaction. The inertial particle deposition increases with the particle mean diameter and air 
flow rate and is expressed in terms of impaction parameter (IP)480–482. 
𝐼𝑃 = 𝑑𝑎
2. 𝑄  𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 6 
Where da is the particle aerodynamic diameter and Q is the volumetric airflow rate. 
Hence, inertial particle deposition increases with the particle mean diameter and air flow 
rate. 
5.1.2.2 Computational simulations 
Computational simulations couple airflow and particle trajectories in order to compute 
deposition of particles in human nasal cavities. Airflow in the nasal cavities is typically 
solved using a set of coupled partial differential equations called the Navier-Stokes equations 
which yields air flow velocity and pressure. Microparticle movement is usually tracked using 
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the Lagrangian approach by taking into account various forces acting on a particle. For 
example, Li et al.483 investigated microparticle deposition during normal inhalation for 
health-risk assessments associated with particle inhalation. Shang et al.484 compared the 
deposition of microparticles between human and rat nasal cavities with an aim to improve 
extrapolation of particle deposition data between inter-subject species. The total nasal 
deposition under the effect of dynamic air flow was studied by Karakosta et al.458 and they 
identified that dynamic flow has a significant effect on the microparticle deposition. It has 
been applied successfully to examine deposition of particles from nasal sprays485–488 and the 
effects of ethnic groups489, spray orientation459 etc. 
Shanely et al.490 investigated region specific deposition of particles at inhalational air 
flow rates of 2 to 7 L min-1 in one healthy adult human subject. The nasal deposition was 
reported as a function of Stokes number in the vestibule, valves, and main airways. Liu et 
al.491 investigated deposition of 1.71 to 10.00 μm sized microparticles at higher inhalation 
flow rates of 30, 60 and 90 L min-1 in one healthy adult human subject. This study divided 
the nasal cavity into an anterior, middle and posterior region. Particle deposition was 
reported to be dependent on particle size and flow rates. This study reported a preferential 
deposition of 10 µm particles at approximately 60 % of the distance into the cavity (from 
nostrils) at an airflow rate of 30 L min-1. The particles between 5.77 to 10.00 µm were 
reported to significantly deposit in the first 30 % of the length of the nasal cavity at flow 
rates of 30, 60, and 90 L min-1. Ghalati et al.492 studied the deposition of microparticles 
(1 to 30 µm) at flow rates of 5, 10 and 15 L min-1 in one healthy adult human subject. This 
study predicted deposition in the vestibule, nasal valve, main airway, and nasopharynx 
regions of the human nasal cavity. Although these studies have reported critical data on 
region-specific deposition, the olfactory region was not identified. 
Shi et al.215 reported deposition of microparticles in the olfactory region. This study 
divided the nasal cavity into the anterior part, olfactory, middle meatus and inferior meatus 
and tested the deposition of microparticles at 7.5 and 20 L min-1. The results of this study 
reported that relatively more particles pass through the olfactory and lower middle meatus 
regions, compared to the inferior meatus region with an increase in particle size (from 2 µm 
to 20 µm) due to the centrifugal force effect. The effect of gravity is negligible for flow rate 
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≥ 20 L min-1 due to inertia dominating, and the effect of gravity is higher for lower flow rates 
≤ 7.5 L min-1 and particle size > 10 µm. This study identified that there is an optimal IP to 
enhance deposition in the olfactory region (Figure 5.2). 
 
Figure 5.2 The region-specific deposition of microparticles as a function of IP reported by Shi et al. 
Circle represents the identified optimal IP to enhance the deposition in different regions of the nasal 
cavity. (Figure adapted with permission from Shi et al.215). 
Xi et al.493 compared drug deposition in human nasal replica casts with different nasal 
devices (sprays and nebulizers). This study reported that only 4.6 % of the particles released 
from spray pumps had reached the olfactory region whereas up to 9 % release was observed 
near the olfactory region with the pointed release administration by nebulizers. 
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Schroeter et al214 reported detailed local deposition patterns in the human nasal cavity. 
Deposition of particles with size 2.6 to 14.3 µm at an inhalation flow rate of 7.5, 15.0, and 
30.0 L min-1 in one healthy adult human subject were examined. Both the computational 
simulations and nasal replica cast deposition studies were reported. This study divided the 
nasal cavity into six regions; 1) nasal vestibule containing the anterior portion of the nose, 
2) nasal valve region containing the anterior part of the nasal cavity with minimum 
cross-sectional area, 3) anterior turbinates encompassing the anterior sections of the middle 
and inferior turbinates, 4) olfactory region, 5) turbinates containing the middle and posterior 
parts of the inferior and middle turbinates, and 6) nasopharynx. Deposition efficiency as a 
function of particle size was reported in this study. The results from this study identified the 
optimal particle size for enhancing the deposition in specific regions of the nasal cavity. As 
stated in Chapter 1, this study identified that a particle size around 10 µm is optimal for 
maximizing the deposition in the olfactory region as shown in Figure 5.3. 
  




Figure 5.3 Deposition of microparticles in specific regions in the nasal cavity as a function of particle 
size. The solid line represents the data from computational simulations and symbol (diamond) 
represents the data from in-vitro nasal replica cast studies. The region-specific analysis identified 
the optimal particle size to maximize the deposition. Circle indicates the optimal size of particles for 
enhanced deposition in the olfactory region. (Figure adapted with permission from Schroeter et 
al.214). 
In summary, the particle deposition in the nasal cavity was shown to be a function of its 
size. Also, all these studies investigated the region specific deposition in only one human 
subject and did not account for the inter-subject variability. Hence, there is a need to 
investigate the variability of deposition in the olfactory region of more than one human 
subject to examine if the same particle size range is enhancing the deposition. Therefore, this 
Chapter examines the effect of particle size on the region-specific deposition of particles in 
three human subjects with emphasis on the olfactory region. 
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5.1.3 Modern targeting devices 
As mentioned in Chapter 1, POD technology, Kurve technology, and the OPTINOSE 
bi-directional delivery technique can improve the deposition in the nasal airways particularly 
near the olfactory region. Nebulisation often leads to a significant loss of the administered 
drug dose to the lungs resulting in low drug deposition in the olfactory region. Hence, the 
use of novel drug delivery device technologies for targeting formulations to the olfactory 
region is gaining traction. Among the targeting devices, the OPTINSOE ‘Bi-directional 
delivery technique’ shown in Figure 5.4 has been popular and the recently FDA approved 
drug sumatriptan powder (Onzetra Xsail®) for nose-to-brain delivery is based on this 
delivery technique. 
 
Figure 5.4 Illustration of breath powered bi-directional delivery technique. (A) OPTINOSE® device 
(B) with air flow into nasal cavity from the mouth through the device. (C) Steps involved in the 
delivery technique and (D) direction of air flow entering from one nostril and exiting from other. 
(Figure adapted with permission from Tepper et al.494). 
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Optinose Inc. (Oslo, Norway) developed the breath powered bi-directional delivery 
technique. The device consists of two parts: a sealing nosepiece and an adjustable 
mouthpiece. The nosepiece is inserted into one nostril, and the subject blows into the 
mouthpiece. Due to the positive pressure during exhalation, the soft palate closes and forms 
a communication pathway between two nostrils near the nasopharynx region. Under these 
circumstances, airflow enters via one nostril and leaves by the other, hence the name 
‘bi-directional delivery technique’ as shown in Figure 5.4. The closure of the nasopharynx 
also prevents the loss of drug molecules into the lungs495. 
The bi-directional delivery technique has shown the potential to improve drug delivery 
to the olfactory region and consequently enhance nose-to-brain drug delivery. The 
bi-directional delivery technique has been tested with successful results in the treatment of 
migrane494,496–498, nasal polyps499,500, rhinosinusitis501. It has also shown evidence for direct 
nose-to-brain transfer of oxytocin by decreasing the dose required in a human study to 
improve social-cognitive behaviour218 and might have implications in the treatment of 
complex CNS disorders502. 
Skretting et al.503 identified the deposition of radiolabelled particles in the human nose 
administered by bi-directional delivery technique and showed that the bi-directional delivery 
could improve deposition in deep regions of the nasal cavity. Djupesland et al.1 demonstrated 
an improved deposition in the upper nasal cavities and less deposition in the nasal valve and 
vestibule region using the bi-directional delivery technique. Djupesland et al.504,505 compared 
the depositions of traditional spray pump in the human nasal cavity with bi-directional 
delivery technique and concluded that the bi-directional delivery could significantly improve 
the deposition of particles in the upper posterior segment of the nasal cavity near to the 
olfactory region. 
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5.1.4 Computational simulations in literature 
Kleven et al.506 were first to simulate bi-directional delivery at 6 L min-1 and uniform 
particle size of 3.5 µm as a part of the development process of this delivery technique. The 
particles were released near the nasal valve in the form of a spray. Under these conditions, 
the bi-directional delivery leads to 55.4 % total nasal deposition. The air flow velocity was 
observed to be greatest at the nasal valve regions of exit nostrils. The velocity at the inlet 
nasal valve was not high due to the placement of the delivery device. This study also tested 
the deposition of 10 µm sized particles and reported that the whole nasal deposition 
improved to 69.2 % due to the increase in particle size. 
Xi et al.507 compared the deposition of particles from two nebulizers vibrating mesh and 
jet nebulizer in one healthy human subject by inhalational and bi-directional delivery 
techniques. The particles released at the nostrils with size 1.5-3.2 µm and the air flow rates 
tested were 6, 12, 18 L min-1. The nasal cavity was separated into the olfactory region and 
vestibule-turbinate region to estimate the deposition. The results of this study reported up to 
6 % of olfactory deposition using the bi-directional delivery technique.  
Recently, Dong et al.508 simulated and compared the deposition pattern of particles (1 nm 
to 10 µm) released near the nasal valve in one healthy human subject by inhalational and 
bi-directional delivery techniques. The airflow rates tested in this study were 7.5 and 
15 L min-1. The deposition of particles near the olfactory region and the effects of exhalation 
flow rate were investigated. The results of this study were also in agreement with increased 
deposition of particles in the olfactory region by bi-directional delivery technique. 
In summary, although bi-directional delivery was shown to improve the drug delivery in 
the olfactory region, no report has attempted to study the effect of particle size on the 
olfactory deposition by bi-directional delivery technique. Also, the detailed region-specific 
deposition of the bi-directional delivery that might have implications in toxicity and drug 
delivery studies has not yet been reported. Moreover, all these studies investigated the 
deposition in only one subject and did not assess variability between subjects.  
  




The computational simulations in this Chapter aim to study the effect of particle size on 
the regional deposition of particles in three human subjects and consequently the 
nose-to-brain delivery of the drugs. To this effect, the following are the two objectives of 
this chapter: 
1. To study the effect of particle size combined with inhalation-driven (nebulized) 
delivery on the region-specific deposition of microparticles in the human nasal cavity with 
emphasis on the olfactory targeting of microparticles and study the variability between 
subjects in this study. 
2. To study the effect of particle size combined with bi-directional delivery technique 
on the region-specific deposition of microparticles in the human nasal cavity with emphasis 
on the olfactory targeting of microparticles. 
5.2.1 Chapter aims 
The overall aim of this Chapter is to investigate the interaction between particle size 
and two different intranasal delivery mechanisms. 
1. To analyze olfactory particle deposition in three human subjects under nebulization. 
a. By reconstructing the human nasal cavities in-silico using CT-scan images. 
b. By simulating the inhalational airflow and dynamics of particle deposition 
within the nasal passage. 
c. By analyzing and comparing the regional deposition data to identify the 
similarity in the deposition of the particles between three human subjects. 
2. To identify the ideal particle size to improve the olfactory targeting under 
bi-directional delivery technique. 
a. By simulating the bi-directional airflow and dynamics of particle deposition 
at various particle sizes within the nasal passages. 
b. By analyzing the deposition data to identify the suitable particle size for 
enhancing the olfactory deposition.  




5.3.1 Subjects used in this study 
Axial head and neck computed tomographic (CT) scans of three adult normal healthy 
human subjects were used to reconstruct the anatomically accurate nasal airways. A Philips 
CT scanner was employed to obtain the scans. Scans were comprised of stacks of horizontal 
slices with 6.0000 pixels per mm resolution, and the voxel size was 0.1667x0.1667x0.5 mm3. 
Subject 1 was a 40-year-old healthy male, Subject 2 was an 88-year-old male, and Subject 3 
was a 60-year-old healthy male. Patients were imaged awake, in a supine position. CT scans 
were obtained following approval from New Zealand Health and Disability Ethics 
committee protocol NTX/08/12/26. All the raw image files of CT scans were provided by 
the Department of Surgery at the University of Auckland. Further processing of raw image 
files to generate in-silico nasal airways and simulation studies were performed at the 
University of Otago and Auckland Bioengineering Institute. 
5.3.2 Image-based reconstruction of human nasal airways and mesh generation 
Using ITK‑SNAP 3.5.0, CT‑scan images were segmented, and the airways in the nasal 
passage were identified. The segmented images were then converted to a 3D surface and 
smoothed using MESHLAB®. The resulting 3D nasal airways meshed with high-quality 
computational elements, surface and volume mesh were generated by ICEM‑CFD® 
(ANSYS, Inc., Canonsburg, PA) for numerical analysis. The final 3D geometry was divided 
into six anatomical regions similar to Schroeter et al.214 as shown in Figure 5.5 to identify 
the region-specific deposition of particles. 




Figure 5.5 A representative 3D nasal cavity identifying the regions; nasal vestibule and valve (NV), 
anterior turbinates (AT), turbinates (T), olfactory region (OR), and nasopharynx (NP). 
5.3.1 Governing equations 
Assuming steady, laminar, incompressible and isothermal flow, the governing equations 
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Where ui is the air velocity, ρ is the fluid density, 𝑝 is the pressure and 𝑣 is the air 
kinematic viscosity. 
One-way coupling between fluid and particle phase was assumed. This assumption 
implies that the fluid phase affects particle phase. However, the particle does not influence 
the fluid flow. This assumption is valid for dilute suspensions. The governing equations for 
the microparticle transfer are given by  














2𝐶𝐷(U⃗⃗ g − u⃗ p)|U⃗⃗ g − u⃗ p| +  𝐺 |𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛11 
Where, x⃗ p is the particle position; u⃗ P and U⃗⃗ g≡ ui is the particle and airflow velocity 
vectors, mp is the particle mass; ρg is the gas density; 𝐺  is the gravitational force; CD is the 
drag coefficient; and dp is the particle diameter, each particle represents the group of particles 
possessing the same characteristics215. 
The air flow and particle deposition simulations were conducted with an air density of 
1.225 kg/m3, dynamic air viscosity of 1.8 X 10–5 kg/m.sec, absolute air temperature of 293 K 
and a particle density of 1350 kg/m3. 
5.3.2 Simulation of airflow and particle deposition 
Steady incompressible, laminar and isothermal airflow was simulated in the three-
dimensional (3D) nasal airways. The inhalational airflow rates of 5, 10, and 20 Lmin-1 and a 
bi‑directional airflow rate of 6 Lmin‑1 were simulated in this study. For the inhalation 
simulations boundary conditions were defined as, rigid airway walls with no-slip and perfect 
absorption, zero pressure at the nostrils and a negative pressure at the outlet. Outlet pressure 
was specified to attain the required flow rate. 
Boundary conditions for bi-directional delivery technique were defined as follows: 
nostrils were defined as inlet and outlet. Each subject was simulated twice with one nostril 
serving as inlet once. Rigid airway walls with no-slip and perfect absorption, zero pressure 
at the outlet were specified. Airflow was simulated at 6 Lmin‑1 at an upward angle of 60° 
through the inlet. All the simulations were performed by numerically solving the 
incompressible Navier-stokes equations using the finite volume method with commercial 
software ANSYS-CFX V16.0® (Canonsburg, PA). 
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Particle sizes of 2, 4, 6, 8, 10, 12, 14, 16, 18 and 20 µm were simulated in this thesis. 
Particles of 2-20 µm were selected to represent ideal size range to target olfactory region. 
The numerical computations of particle dynamics were performed with the low Reynolds 
number k-ω model; this model has demonstrated accurate solutions for laminar airflow509. 
Particles were released at both the nostrils when simulating nebulization. Particles were 
released at one of the noses for bi-directional delivery. In both cases, particles were released 
from uniformly distributed points across a surface. Total nasal deposition fraction was 
computed as the ratio of some particles deposited in the nose to the number of particles 
released. Region-specific deposition fractions were computed as the ratio of the number of 
particles deposited in each region by the total number of particles released. All the 
simulations were performed with commercial software ANSYS‑CFX V16.0® (Canonsburg, 
PA). The deposition efficiency of particles according to the nasal regions was calculated, 
analyzed and reported. 
𝐷𝐸( %) =  
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 𝑑𝑒𝑝𝑜𝑠𝑖𝑡𝑒𝑑 𝑖𝑛 𝑡ℎ𝑒 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑛𝑎𝑠𝑎𝑙 𝑟𝑒𝑔𝑖𝑜𝑛
𝑇𝑜𝑡𝑎𝑙 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒𝑠 𝑟𝑒𝑙𝑒𝑎𝑠𝑒𝑑 𝑖𝑛𝑡𝑜 𝑡ℎ𝑒 𝑛𝑎𝑠𝑎𝑙 𝑐𝑎𝑣𝑖𝑡𝑦
  |𝐸𝑞𝑢𝑎𝑡𝑖𝑜𝑛 12 
5.3.3 Statistical analysis 
Where applicable, statistical analyses were conducted using an unpaired t-test or 
ANOVA on Prism 6 (GraphPad, USA). A P-value of < 0.05 was taken to be significant. 
  




5.4.1 Subjects used in this study 
Three 3D-human nasal cavity models created from the three CT-Scans are shown in 
Figure 5.6, and their respective geometrical surface areas are presented in Table 20. 
 
Figure 5.6 The 3D-human nasal replica model geometries of three subjects generated from CT-scan 
images. 
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Table 20 Geometrical surface area of the nasal regions in the 3D-human nasal cavity models. 
Anatomical region 
Surface area (cm2) 
Subject 1 Subject 2 Subject 3 
Nasal valve and vestibule 34.50 38.85 29.02 
Anterior turbinates 40.39 28.60 27.21 
Olfactory region 40.59 37.82 27.91 
Turbinates 96.49 102.91 113.47 
Nasopharynx 32.97 35.47 22.56 
Total 244.94 243.65 220.17 
Cross-sectional areas of the nasal passage (inferior/middle/posterior meatuses) of the 
individual subjects were compared with cross-sectional results published in the literature to 
assess deviation from population data510. The cross-sectional areas of the three subjects used 
in this thesis were compared to the cross-sectional areas of normal subjects available in the 
literature511–513 and are presented in Figure 5.7. Cross-sectional areas of all the three subjects 
were within the natural range of variation and, they reflect the trends of changing cross-
sectional area at different positions along the cavity. 




Figure 5.7 Comparison of the average cross-sectional area of the three individual subjects with 
published data from the literature. The horizontal axis is the distance from the anterior tip of the 
nostril. 
The nasal airways were divided into tetrahedrons (Volume mesh) by ICEM-CFD. This 
mesh generation helps solve fluid flow and particle motion. Also, near to the nasal wall, a 
prism mesh consisting of three-layer tetrahedral or pentahedral elements was generated as 
shown in Figure 5.8 to accurately calculate deposition and wall turbulence effects. The final 
mesh features about 89668 nodes, and 179086 elements for subject 1, 90000 nodes, and 
179726 elements for Subject 2, and 86528 nodes, and 172771 elements for Subject 3. 




Figure 5.8 Reconstruction of human nasal cavities in-silico. (A) Segmentation of nasal airways in a 
CT-scan image (B) reconstruction of surface and generation of surface mesh (C) reconstructed nasal 
cavity model showing complex airways and (D) volume mesh generated in the airways and a three-
layer prism mesh at the borders. 
5.4.2 Model validations 
Our predictions were overall in agreement with reported values from the literature. 
Particle deposition data from Kelly et al.481 and Schroeter et al.214 were selected to validate 
the data as they feature similar inlet conditions and anatomical descriptions of the regions in 
the nasal cavity. The whole nose deposition data as a function of IP from the current 
simulations were compared with the experimental data from nebulization simulations in a 
human nasal cast by Kelly et al.481 and shown in Figure 5.9. 




Figure 5.9 Whole nose deposition efficiency prediction of the three subjects for particle size between 
2 to 20 µm (inhalation flow rates ranging from 5 to 20 L min-1) as a function of IP compared to the 
published data from Kelly et al.481. 
Four inhalational flow rates (5, 7.5, 10, 15, and 20 L min-1) and particle sizes from 2 to 
20 µm were investigated in this study in each subject. The whole nasal deposition data of 
three subjects in this study were compared to the two nasal cast deposition data from Kelly 
et al. 481 as a function of IP. The total nasal deposition curve of all the three subjects was 
sigmoidal in shape and was in good agreement with experimental data. The minimum 
deposition of 4 % was observed with 2 µm particles at a lower airflow rate of 5 L min-1. The 
deposition fraction of 2 µm particles increased to 8 % at a higher airflow rate of 20 L min-1. 
The maximum deposition rate was 78 % for 20 µm particles at an airflow rate of 5 L min-1. 
Near 100 % deposition was achieved for 20 µm, 14 µm, 12 µm particles at 10 L min-1, 
15 L min-1 and 20 L min-1 airflow rates respectively. The preferential deposition in the 
anterior parts of the nasal cavity was observed with the increase in particle size as shown in 
Figure 5.10. 




Figure 5.10 Representative deposition patterns of microparticles in the human nasal cavity. At lower particle size of 2 µm (A) the particles show 
low and distributed deposition, when particle size reaches 10 µm (B) the deposition of particles is increased with preferential deposition at the 
middle and upper regions of nasal cavity and at a particle size of 20 µm (C) all the particles released are deposited within the nasal cavity with 
preferential deposition in the anterior region. (At an inhalational air flow rate of 20 L min-1).
                     Chapter 5 
178 
 
5.4.2.1 Agreement with published literature 
5.4.2.1.1 Results from nebulization 
The region-specific particle deposition data were compared with the experimental data 
from Schroeter214 to validate the computational predictions and presented in Figure 5.11. 
Results from the flow rate case of 15 L min-1 were used. The overall deposition in all the 
regions was in good qualitative agreement with the experimental data. For example, in 10 µm 
particles inhaled at 15 L min-1, the olfactory deposition fraction matched closely with 
Subject 3. 
5.4.2.2 Results from bi-directional delivery technique 
The data for whole nasal deposition from Kleven et al.506 was used to validate the 
deposition efficiency which had also used 6 L min-1. The whole nose deposition data from 
the current simulations were in reasonable agreement with the experimental data 
(62 vs 73.96 ± 21 %).




Figure 5.11 Comparision of computational predictions of microparticle deposition in three subjects (nebulization delivery technique) with the 




5.4.3 Simulation of airflow with nebulization and bi-directional delivery 
techniques 
The representative air velocity profile in the olfactory/turbinate region for nebulization 
is shown in Figure 5.12. With nebulization, higher velocities were observed in the middle 
and lower portions of anterior turbinates and turbinates, while lower velocity was observed 
in the upper region of anterior turbinates and the olfactory region. A recirculation zone 
(shown with a red arrow) is observed in the upper dorsal part of the nasal valve area of 
Subject 1 and 2. The recirculation zone is a result of sudden area expansion in cross-sectional 
and effective flow areas. Airflow towards the olfactory region increased as the velocity was 






Figure 5.12 Representative velocity profile of the air in the olfactory/turbinate region with 
nebulization at (A) 5 L min-1, (B) 10 L min-1, (C) 15 L min-1 and (D) 20 L min-1 inhalational air flow 
rates. Increased air flow in the olfactory region (Inset) can be observed with the increase in 
inhalational air flow rate. 
The representative air velocity profile in the olfactory/turbinate region for bi-directional 
delivery technique is shown in Figure 5.13. With the bi-directional method, the nasopharynx 
is closed. Hence airflow enters through one nostril and exits from another nostril. The 
velocity was maximum at the nasal valve region of the exit nostril. In this study, air flow 
was simulated at an upward angle of 60° which led to higher velocity in regions of superior 





Figure 5.13 Representative velocity profile of the airflow in the olfactory/turbinate region with bi-
directional delivery technique. Increased airflow in the olfactory regions (Inset) were observed. 
Fluid streamlines for an inhalation air flow rate of 20 L min-1 and bi-directional flow rate 
of 6 L min-1 is shown in Figure 5.14. Airflow was at the highest speed in the nasal valve 





Figure 5.14 Representative airflow streamlines of nebulization and bi-directional delivery methods in three subjects. Black arrows indicate the 
direction of airflow. (A),(B) & (C) represent the nebulization airflow streamlines at 20 L min-1. (D),(E) & (F) represent the bi-directional air flow 
streamlines at 6 L min-1. (D) represents the top view of airflow streamlines in bi-directional simulations. (E) & (F) represent a side view of airflow 
streamlines in bi-directional simulations. Red arrows indicate the regions of recirculation in the nasal cavity. The colour map indicates the velocity 




5.4.4 Results of particle deposition under nebulization 
Regional deposition data in three subjects were analyzed and compared with an aim to 
identify the variability in particle deposition pattern and presented as region-specific particle 
deposition data at the peak inhalation flow rate of 20 L min-1 in Figure 5.15. 
5.4.4.1 Nasal valve and vestibule 
Deposition in the nasal valve and vestibule area increased with increase in particle size. 
Maximum deposition of 61 % was observed for the 20 µm particles. The higher inertia of 
particles and filtering effect of the nasal valve due to its minimum cross-sectional area might 
have been the reason for the observed trend. The deposition patterns between the subjects 
were comparable without any statistically significant difference (P = 0.8690). 
5.4.4.2 Anterior turbinates 
Deposition in anterior turbinates increased with increase in particle size up to 20 µm for 
Subject 1 and the maximum deposition observed was 38 %. The maximum deposition of 
49 % was observed for the Subject 2 and Subject 3 at a particle size of 14 µm and then the 
deposition slightly decreased. The deposition of 10 µm or bigger particles in Subject 1 was 
about 15 % smaller than Subjects 2 and 3. However, the deposition patterns between the 
subjects were comparable without any statistically significant difference (P = 0.7658). 
5.4.4.3 Olfactory region 
All the three subjects demonstrated comparable particle deposition with particles of size 
10 µm showing highest deposition in the olfactory region. Interestingly, a narrow range of 
particle size was found to be optimum for enhanced deposition in the olfactory region: the 
deposition was maximum with the particle size of 8-12 µm for all three subjects. A maximum 




patterns between the subjects were comparable without any statistically significant 
difference (P =0.9795). 
5.4.4.4 Turbinates 
The turbinate region included all parts of the nasal passage past the anterior nasal passage 
to the nasal choana where the two nasal airways coalesce. This region presents the largest 
mucosal surface for drug distribution. The deposition pattern was comparable between the 
three subjects. Maximum deposition in turbinates of 14 % and 22 % was observed with 
14 µm particles for Subject 1 and Subject 2. For Subject 3, maximum deposition of 20 % 
was with 10 µm particles. For Subject 2 and 3, deposition fraction in the turbinates decreased 
for particles above 10 µm size. For Subject 1 the deposition fraction in the turbinates 
decreased for particles above 12 µm. The deposition patterns between the subjects were 
comparable without any statistically significant difference (P =0.1465). 
5.4.4.5 Nasopharynx 
Particles around 8 µm consistently showed maximum deposition in the nasopharynx 
region for all the subjects. The maximum deposition was 6.7 %, 16.95 % and 12.56 % with 
Subjects 1, 2 and 3 respectively. The deposition pattern was comparable between the three 






Figure 5.15 Regional specific deposition in nasal cavities of three human subjects at an inhalation rate of 20 L min-1. No significant difference in 




5.4.4.6 Other airflow rate simulations 
Results from computational simulations for lower inhalational rates of 5 L min-1 and 
10 L min-1 for all three subjects are presented in Figure 5.16. The deposition fraction 
increased with increase in the particle size, and flow rate in the nasal valve and vestibule 
region. The maximum deposition observed in this region was 51.93 % for 20 µm particles at 
10 L min-1 in Subject 2. The deposition pattern in the anterior turbinates region was similar 
and was a function of particle inertia. For air flow rates of 5 L min-1 and 10 L min-1, the 
deposition increased with increase in particle size until 20 µm. For the higher flow rates, a 
trend of decrease in particle deposition was observed in all the subjects at a particle size of 
14-18 µm. Deposition patterns were significantly different between subjects at 5 L min-1 
(P = 0.0080). Turbinates received increased deposition with an increase in particle size at 
5 L min-1 air flow rate and for other flow rates deposition was maximum with particle sizes 
up to 14 µm and then decreased. A significant difference of deposition pattern in turbinates 
between the subjects was observed at 10 L min-1 (P = 0.0361). The nasopharynx received 
comparatively low deposition in all the subjects despite large surface area; the deposition 
decreased with the increase in flow rates and a sharp increase in particle deposition was 
observed at 8-10 µm for all the subjects observed at all the flow rates. 
5.4.4.7 Particles escaped from the nasal passages 
The particles that escaped from the nasal passages were also determined. The particle 
size and airflow rate had a significant effect on the deposition of the particles. About 75 % 
to 90 % of the smaller particles (less than 6 µm) escaped the nasal cavity without depositing. 
The lower the airflow rate, the higher was the percentage of particles that escaped. Particles 
between 8 to 12 µm showed huge variations depending on the airflow rate. Around 76 % to 
85 % of particles escaped at the low 5 L min-1 airflow rate, and the number decreased to 50 
to 15 % at the high 20 L min-1 air flow rate. Particles greater than 14 µm in size had low 
escape percentage, with about 1 % of particles escaping at the higher flow rates, and between 









5.4.5 Identification of suitable particle size to maximize olfactory deposition 
with the bi-directional delivery technique  
Region-specific deposition in nasal cavities was assessed with a bi-directional delivery 
technique at an air flow rate of 6 L min-1 and presented in Figure 5.17 and Figure 5.18. For 
each subject, two protocols of simulations were run with a different nostril serving as an 
outlet each time and were referred as left to right and right to left indicating the direction of 
airflow. Results were analyzed to identify a suitable particle size to maximize the deposition 
in the olfactory region. Also, the results were compared to identify any variability in the 
deposition data between the subjects. Due to the particle release position located near the 
nasal valve, deposition fractions were not calculated in the vestibule and nasal valve region. 
5.4.5.1 Anterior turbinates 
Particle deposition followed a similar trend to the inhalational flow with an increase in 
deposition observed with increase in particle size. A maximum deposition of 47 % was 
observed with 20 µm particles for Subject 3. The deposition pattern between the subjects 
and the left and right protocols was comparable (P > 0.2). A significant difference in 
deposition pattern between the subjects (P = 0.0187) was observed. 
5.4.5.2 Olfactory region 
Deposition in the olfactory region was higher than by the nebulization delivery technique 
in all the subjects. Deposition increased with increase in particle size up to 18 µm and then 
decreased about 2-4 % in all the subjects with 20 µm particles. The greatest deposition of 
13.16 % was observed with the 16 µm particle in Subject 2 with the right to left protocol. 
The deposition pattern between the subjects and the left and right protocols was comparable 





With increase in particle size, the deposition in the turbinates region increased. The 
maximum deposition for all the subjects was ~30 % with particle size around 16-20 µm. 
There was no significant difference observed between left to right and right to left protocols 
of all the subjects or between the individual subjects (P > 0.2). 
5.4.5.4 Nasopharynx 
Bi-directional delivery technique produced higher deposition in the nasopharynx 
compared to nebulization. The increase in particle deposition was observed with increase in 
size. The maximum deposition of ~25 % was observed with 16 µm particles in Subject 1. 
There was a significant difference between left to right and right to left protocols and 
deposition data for Subject 3 (P = 0.0350) and in the deposition pattern between subjects 






Figure 5.17 Effect of particle size on region-specific deposition in the nasal cavities of three human 
subjects with bi-directional delivery technique at an air flow rate of 6 L min-1 when bi-directional 





Figure 5.18 Effect of particle size on region-specific deposition in the nasal cavities of three human 
subjects with bi-directional delivery technique at an air flow rate of 6 L min-1 when bi-directional 





5.4.5.5 Total nasal deposition 
The total nasal deposition with the bi-directional delivery technique was dependent upon 
the particle size. For smaller particles (less than 6 µm) the total deposition was around 
11 to 26 %. For particles between 8–12 µm the total nasal deposition was around 43-91 %. 
Almost 99 % total nasal deposition was observed after particle size reached 14 µm or higher. 
5.5 Discussion 
To exploit advantages of the nasal route to improve nose-to-brain drug delivery, targeted 
drug delivery to the olfactory region is very important214,215,509. Previous Chapters of this 
thesis have experimentally demonstrated the preferential deposition of particles in the 
olfactory region as a function of particle size. This Chapter utilizes computational 
simulations to investigate the effect of particle size on olfactory deposition by nebulization 
and bi-directional delivery techniques in human subjects. 
Anatomically accurate 3D-human nasal cavity models of three subjects were 
constructed, and steady laminar airflow was simulated at airflow rates of 5, 10, and 20 Lmin-1 
and a bi‑directional airflow rate of 6 Lmin‑1. For nebulization, the flow patterns did not 
change very much with an increase in the inhalational airflow rates. At the lower airflow rate 
(5 L min-1), the majority of the flow passes through the middle and lower portion of the nasal 
cavity resulting in low airflow towards the upper narrow olfactory region. With an increase 
in the inhalational airflow rate (20 L min-1) airflow bypasses the meatuses due to stronger 
momentum increasing the airflow towards the olfactory region. Increased airflow towards 
the olfactory region was evident for bi-directional delivery and could have been due to the 
simulation of airflow at an upward angle of 60º. Although the airflow was simulated at a 
particular angle, the characteristic geometry of the nasal cavity might have offered some 
resistance for alteration of the downstream flow pattern resulting in the majority of airflow 
through the middle and lower regions of the nasal cavity similar to the nebulization514. 
For the nebulization technique, whole nasal deposition was a function of particle size 




have shorter relaxation times and lack momentum to deviate from the airflow; thereby a low 
portion was deposited in the nasal cavity. Larger particles (> 8 µm) have high inertia, and 
consequently, high deposition rates; the whole nasal deposition rate increased with an 
increase in the particle size. The deposition rate increased with the increase in inhalational 
flow rate. This may have been due to the higher air momentum and increased secondary 
flows at the higher flow rates which contributed to the increased particle deposition rates in 
the nasal cavity215. At a particle size of 18 µm and flowrate of 20 L min-1 99 % of particles 
were deposited. 
For bi-directional delivery technique, the whole nasal deposition was a function of 
particle size. Although the smaller particles (less than 6 µm) escaped the nasal cavity due to 
lower inertia, the total deposition compared to the respective particle size by nebulization 
was higher with bi-directional delivery. The increased transit time of a particle in the nasal 
passages due to bi-directional airflow by the closed nasopharynx contributed to this 
improved deposition rates. Similarly, the larger particles showed higher deposition rates and 
when the particle size reached 14 µm 99 % percent of the particles were deposited. 
The region-specific deposition of particles with nebulization was analyzed and compared 
with the experimental results in a nasal cast (airflow rate of 15 L min-1) from Schroeter et al. 
214. The region-specific deposition predictions were in good agreement with the experimental 
data except for the valve and vestibule region. The trend of deposition was similar between 
the studies. The particle size resulting in maximum deposition in each region was 
comparable between simulation studies and the experimental data. The underprediction of 
the deposition in the nasal valve region and vestibule area could have been due to the 
geometrical complexity and narrow width of this region. Similar anatomical partitioning of 
the nasal cavity and the density of the particles used in both the studies were the reasons for 
the comparison.  
One of the primary objectives of this Chapter was to study the effect of the particle size 
on region-specific deposition with nebulization delivery. For the nebulization studies, the 
deposition patterns were dependent on particle size and flow rate in all of the regions. Inertia 
played an essential role in the region-specific particle deposition. The overall deposition was 




anterior turbinates at the lower flow rate (5 L min-1) between subjects was significantly 
different. This variability could have been due to the gravitational sedimentation effect of 
particles at lower inhalation rates coupled with the complex anterior turbinate geometry. The 
anterior turbinates have a very narrow width (~1 cm), and the geometry expands suddenly 
due to the formation of turbinates. A recirculation was observed in this region due to the 
geometrical complexity and might have augmented the different particle deposition patterns 
in this region between the subjects214. Secondly, a notable difference in a deposition in the 
turbinate area at a flow rate of 10 L min-1 occurred. 
Olfactory deposition in the nebulization delivery method was dependent on particle size 
and flow rate. At lower flow rates (5 and 10 L min-1) the particles sized 14-18 µm were 
shown to improve the olfactory deposition. The increased deposition was observed with the 
higher flow rate. At the higher flow rates (15 L min-1) and peak inhalational flow rate 
(20 L min-1) the optimum size of particles with enhanced olfactory deposition was found to 
be 10-11 µm. Shi et al.215 and Liu et al.487 have reported increased deposition of particles in 
the middle region of nasal cavity at a particle size of 10 µm. Schroeter et al.214 reported 
preferential deposition of 10 µm particles in the olfactory region. The geometric differences 
between human nasal cavities can cause variation in the deposition of microparticles481,482. 
Hence, there is a need to investigate the inter-subject variability in olfactory deposition to 
examine if the same particle size range identified in this study is suitable for enhancing the 
deposition. The results from the computational studies in this chapter showed no 
inter-subject variability between the olfatory deposition of the microparticles and are in 
agreement with the reported studies, which reinforce that particles with a size around 10 µm 
can have enhanced deposition in the olfactory region when nebulized. 
The second objective of this Chapter was to study the combined effect of particle size 
with bi-directional delivery on region-specific deposition in the nasal cavity. To the best of 
the authors knowledge, this was the first study to investigate region-specific deposition with 
bi-directional delivery. Therefore, the data from this thesis cannot be compared with any 
other experimental data. However, whole nasal deposition data in a human nasal cast has 
been reported in the literature by Kleven et al.506.The inlet conditions used in this study are 




the simulation and experimental studies. In this thesis, the region-specific deposition with 
two protocols, where a different nostril served as an outlet each time (referred as left to right 
and right to left, indicating the direction of airflow) has been analyzed. 
For bi-directional delivery, the particle deposition in the anterior turbinates was a 
function of particle size. However, due to the complex nasal geometry and gravitational 
sedimentation, significant variations in deposition between the subjects was observed. For 
Subject 1 the difference was notable between the left to right and right to left protocols. The 
deposition in the turbinates was a function of particle size. However, a decrease in the 
deposition was observed after particle size reaching 14-16 µm. The filtering effect of the 
nasal valve with larger particles could be a reason for this decrease. Bi-directional flow 
enhanced the deposition in the turbinate region compared to the nebulization due to the 
enhanced air penetration into these regions515.The deposition patterns between the two 
protocols and subjects were comparable. The deposition in the nasopharynx was dependent 
on the particle size. However, the deposition reached a plateau phase when the particle size 
was 12-14 µm and then there was a slight decrease in deposition with 20 µm particles. Also, 
significant differences in the deposition of particles at the nasopharynx between subjects 
were observed, which could have been due to the combined effect of airflow, inertia, and 
interception. In addition to the inertia, the interception of particles at the nasopharynx due to 
the change in airflow (i.e. changes of about 180° near the nasopharynx) can increase the 
number of particles depositing in this region. Due to the substantial change in the airflow 
direction, the chance of variation in particles depositing in this region can be high. Also, the 
notable difference observed between left to right and right to left protocols of Subject 3 can 
be attributed to the significant change in airflow direction and increased chances of 
interception. The bi-directional delivery significantly increases the deposition in the 
nasopharynx. 
Results of this study indicate that deposition in the olfactory region is a function of 
particle size. A suitable size of particles for targeting the olfactory region with the bi-
directional delivery was found to be 14-18 µm (Figure 5.19). The bi-directional delivery 
significantly enhanced the deposition of particles in the olfactory region compared to the 




to the combined effect of increased airflow to the olfactory region and the release position 
of the particles. The particles were released at the nasal valve in the bi-directional delivery. 
The release position prevented the deposition of particles in the nasal vestibule and enhanced 
the deposition in the olfactory region. Another reason could be the angle of air flow; the 60° 
upward angle increased the airflow towards the olfactory region thereby increasing the 
olfactory deposition. 
 
Figure 5.19 Comparison of maximum olfactory deposition by nebulization (20 L min-1) vs. bi-
directional delivery (6 L min-1) techniques. Particles sized 14-18 µm showed the highest deposition 
with bi-directional delivery technique. The data presented are the means of three individual 
subjects ± SD. 
When particle size increased to 20 µm, the olfactory deposition started to show a 
decreasing trend. At the higher particle size, the particle has higher inertia and is more likely 
to deviate from the main flow, hence, 20 µm particles were deposited more in the turbinate 
regions. If the simulations were to continue with higher particle size due to the increase in 
inertia of particles the trend of decreased olfactory deposition would continue. While 
particles between 14-18 µm had the right inertia to reach the olfactory region. Also, the 




larger particles and reduced their penetration to the upper dorsal regions of nasal cavity like 
the olfactory region. 
Results of this study corroborate with the results from by Djupesland et al.214,504,516 who 
demonstrated higher deposition efficiency in the upper nasal cavity with the bi-directional 
delivery technique. The high deposition can be attributed to increased airflow velocities and 
penetration in the upper nasal cavity with the bi-directional delivery technique. The region-
specific deposition patterns reported in this study identified the suitable particle size to 
maximize the deposition.The results from this study can help in optimizing the particle size 
of the powder formulations to target the region of interest in the nasal cavity. 
The computational simulations in this chapter assessed the variability in deposition 
pattern of the particle s between the subjects with nebulization and bi-directional delivery 
techniques. Anterior turbinates have shown a significant difference in particle deposition 
pattern with the nebulization technique. The anterior turbinates and nasopharynx region 
received the various deposition patterns in three individuals with the bi-directional delivery 
technique. Gravitational sedimentation and the effect of geometry were speculated to cause 
the variability in anterior turbinate deposition, and the bi-directional air flow was speculated 
to be the reason for the variability in the nasopharynx. 
Computational predictions of region-specific particle deposition patterns in this study 
can provide detailed insights into the effect of particle size and inter-individual variability 
which is otherwise difficult to observe experimentally. Geometry and particle size were 
shown to impact the region-specific deposition. Also, particle release position and airflow 





5.6 Key findings 
The computational simulations in this chapter suggests particles around 10 µm size show 
high deposition in the olfactory region of all three subjects studied under nebulization with 
no significant variability observed in the deposition pattern between subjects. Microparticles 
with 8 µm were found to improve deposition in the nasopharynx with the nebulization 
delivery technique. Microparticles sized between 14-18 µm are found to be suitable for 
enhanced drug delivery in the olfactory region with the bi-directional delivery technique. 
This study identified that the bi-directional delivery technique can enhance the olfactory 
deposition of microparticles compared to nebulization without any inter-subject variability 
and might be a desirable method to enhance nose-to-brain delivery of drugs. Anterior 
turbinates and nasopharynx were found to have significant variation in the particle deposition 
of particles. 
5.7 Limitations and future directions 
This study assumes particles are of uniform size; future computational simulations shall 
consider the effect of polydisperse particles on region-specific deposition in the nasal cavity 
especially the olfactory region, to further exploit the probability of enhancing delivery to this 
region. The olfactory region in this study contains some part of the meatuses due to the 
geometrical definition of regions. A better resolution of the 3-D structure can provide further 
details of olfactory deposition. Three human subjects were used in this study, but analyzing 
large population data might provide more insight into the inter-individual variability. In 
addition, future studies need to explore the potential of bi-directional delivery by changing 
the parameters such as particle release position and airflow angle which might have an 















































6 Summary and future outlook 
The inability of most of the drugs administered orally or IV to reach the brain at 
therapeutic levels due to the BBB has moved the focus to using the intranasal route of 
delivery to deliver drugs to the brain. The olfactory pathway in the olfactory region and 
trigeminal neural pathway in the nasal cavity can transport drugs directly to the brain as 
discussed in Chapter 1. Therefore, targeting drugs to the olfactory region has the potential 
to enhance nose-to-brain delivery517,518. However, targeted delivery to the olfactory region 
is difficult due to its location in the posterior uppermost part of the nasal cavity. Convoluted 
and narrow air passages limit drug delivery to the olfactory region, and most of the 
administered drugs are either filtered by the nasal valve region or lost to the lungs1,507. 
Furthermore, retaining drugs in the nasal cavity is a challenging task due to mucociliary 
clearance48. The clinical feasibility of nose-to-brain delivery of drugs is still challenging due 
to a very low dose of drugs reaching the olfactory region and thereby the brain. Given the 
increasing number of drugs being discovered for the treatment of complex CNS disorders, 
developing efficient delivery systems to enhance nose-to-brain drug delivery by targeting 
the olfactory region has become very topical 215,493,509. 
Various formulation strategies to enhance nose-to-brain drug delivery are under 
investigation. One promising strategy is formulating drugs as particulate delivery systems. 
Formulating drugs as particulate delivery systems can reduce side effects and enhance brain 
absorption of polar and large drug molecules which otherwise have minimal absorption into 
the brain230. Another strategy is the use of mucoadhesive polymers to improve their residence 
time in the nasal cavity197. In addition to these strategies, recent modeling studies suggest 
that particles around 10 µm size can target the olfactory region214,215, which can be beneficial 
to the nose-to-brain delivery of drugs. Therefore, the objective of this thesis was to examine 
the potential of combining these formulation strategies for enhancing nose-to-brain delivery 
of drugs. Features of microparticles that make them an attractive nose-to-brain drug delivery 
system were described extensively in Chapter 1 of this thesis and included the ability to 




Chapter 3 of this thesis examined the potential of size tailored mucoadhesive 
microparticles to target the olfactory region in-vitro and the potential of TSP as a 
mucoadhesive carrier of drugs. Designing appropriate in-vitro methods to test the objectives 
of this thesis was in itself challenging. Mucoadhesion of TSP-microparticles in the nasal 
cavity is vital for facilitating nose-to-brain drug delivery. Previously reported in-vitro 
methods were modified to mimic as closely as possible the human nasal environment and 
respiration. In this thesis, a combination of in-vitro and ex-vivo methods were employed to 
evaluate the mucoadhesion. This enabled one of the key identifications of the work presented 
in this thesis; the mechanism of mucoadhesion and visualization of the two critical stages 
involved in the mucoadhesion process; contact and consolidation221. TSP-microparticles 
were found to sustain drug release compared to their solution forms. The rate-limiting step 
of drug release from microparticles was found to be diffusion of the drug from the polymer 
matrix. The release studies served as a guide to their potential kinetics in-vivo. However, any 
in-vitro data has to be interpreted with caution due to the artificial nature of in-vitro 
experiments compared to the in-vivo environment.  
As discussed in Section 3.9 use of hydrophilic drugs in this study may be a limitation for 
the extrapolation of the data reported to different classes of drugs. The release behaviour of 
model drug from TSP-microparticles changed from diffusion controlled (Higuchi) to 
diffusion/erosion controlled (Korsmeyer-peppas) when the molecular weight reached 
40 kDa. Whether this is an effect of TSP-microparticles or the cellulose acetate membrane 
used for the in-vitro studies needs to be examined and poses the question of reliability of 
data extrapolation to release behaviour of large molecules (>40 kDa) from TSP-
microparticles. Mucociliary clearance and effect of other stimulations such as respiration 
and sneezing, which cannot be simulated in-vitro can affect drug release in-vivo resulting in 
a different release profile. 
Though selective deposition of the particles in different regions of the human nasal cavity 
as a function of particle size has been reported previously491, formulating particles to a 
specific size to enhance the deposition in the olfactory region, however, has not been 
previously examined. This thesis demonstrated preferential deposition of 10 µm particles in 




results of this study are only applicable for the peak normal inhalational airflow rate and 
when particles are released from the nostrils. Particle density can affect the deposition of 
particles in human nasal cavities519. The microparticles used in this thesis had a density of 
1.3 kg/m3 which is similar to other published report214 that demonstrated high deposition in 
the olfactory region with 10 µm particles, therefore, the effect of density on the deposition 
was not evaluated in this thesis. However, to translate the proposed delivery system to a 
clinical stage, future work will be required to examine the effect of particle density, effect of 
inhalational airflow rate individually and in combination with the particle size on the 
olfactory deposition of particles. Although this thesis provided evidence for enhanced 
deposition in the olfactory region, the critical question ‘whether this enhancement can 
produce any therapeutic effect?’ remains. Data correlating this enhancement with the 
biological relevance is the key for translation of such a microparticle system from lab to 
market and needs to be generated.  
Data from the animal studies are essential to understand the behavior of delivery systems 
in the dynamic in-vivo environment. Chapter 4 of this thesis examined the potential of 
mucoadhesive TSP-microparticles loaded with an AED phenytoin to enhance its 
nose-to-brain delivery in-vivo. 
The interesting observation with TSP-microparticles when phenytoin was loaded in to 
them was their drug release profiles. Though the release of phenytoin was sustained when 
incorporated into TSP-microparticles, the release of phenytoin within the first 5 min from 
the microparticles was significantly higher than phenytoin released from the unformulated 
powder due to the change in crystallinity. The change from a crystalline into an amorphous 
phase can aid nose-to-brain delivery of phenytoin by increasing its solubility520. This change 
in physical form is speculated to play an essential role in the shelf life of the microparticles. 
Therefore, a six-month stability study of TSP-microparticles containing phenytoin was 
conducted according to the ICH guidelines. The transformation of amorphous phase to 
crystalline nature was observed by six months. Since polymers with similar functional 
groups may prevent the recrystallization for more prolonged periods, it would be interesting 
to examine the effect of chemical modifications to TSP with an aim to control the 




correlation of such a change in physical state to the extent and rate of drug absorption and 
therapeutic efficacy are needed to further exploit the potential of TSP formulations.  
The concentrations of phenytoin observed in-vivo in the olfactory bulb and the brain can 
be correlated to the burst release of phenytoin from TSP-microparticles observed in-vitro, 
and the availability of phenytoin at the site of absorption (olfactory region). While the 
intranasal solution failed to achieve high concentrations at the olfactory region after 30 min, 
TSP-microparticles were hypothesized to withstand mucociliary clearance and show high 
levels of phenytoin at the olfactory region over 60 min and the concentrations of phenytoin 
were expected to increase beyond this period. Correlating the in-vitro and in-vivo data it can 
be hypothesized that, 50-60 % of the dose of phenytoin administered as TSP-microparticles 
was sufficient to produce equivalent or higher brain concentrations of phenytoin than 
phenytoin administered as intranasal solution. This reduction in dose can be correlated to the 
decreased systemic absorption and increased direct nose-to-brain delivery. The objective of 
this work presented in this thesis was to examine the potential of formulation strategies to 
enhance nose-to-brain delivery. The time points selected for the in-vivo studies demonstrated 
the potential of TSP-microparticles to increase drug delivery to the brain. The time points 
chosen in this study and the olfactory bulb phenytoin concentrations measured have provided 
insights into the initial stages of the drug release from TSP-microparticles.  
Nevertheless, to progress into a clinical trial stage, any future work will require data from 
more extended time periods to thoroughly understand the pharmacokinetic profile of the drug 
administered when formulated into TSP-microparticles. Furthermore, it will allow safety to 
be assessed further and the overall absolute bioavailability of the drug to be calculated. Also, 
future work will require the development of more sensitive assays so drug concentrations in 
specific regions of the brain can be quantified, which can provide valuable data for treatment 
of CNS disorders that are specific to an area in the brain. In addition, studies to investigate 
the biological efficacy in disease animal models are critical for the translation to a clinical 
stage and need to be included in the future work. 
In-silico methods have been shown complementary results from in-vitro and in-vivo 
studies521. They can provide insight and answer to experimentally tricky observations. The 




established a branch linking engineering and medical sciences. With continuous 
development both the fields complement each other and facilitate the complicated and 
tedious process of drug development. 
Chapter 5 of this thesis utilized in-silico techniques like CFPD to examine the 
experimentally challenging studies like the effect of inhalational airflow and never reported 
studies like the effect of inter-subject variability on the deposition of particles in the nasal 
cavity. The in-silico studies in this thesis suggested that the 10 µm sized particles were able 
to enhance the olfactory deposition rates in all the three human subjects examined without 
significant inter-subject variability. The bi-directional delivery technique has demonstrated 
higher olfactory deposition with no inter-subject variability. However, this is a small sample 
size including only male subjects, and future work will be required to assess the data from a 
larger population including different sex, race and geographical locations. Also, further 
resolution of anatomical models to clearly identify the olfactory region is required in the 
future work. Since in-silico studies can generate data on various experimentally difficult 
facets like particle release position, variable air velocity, geometrical complexity, etc. a 
comprehensive database needs to be developed to identify, compare and comprehend the 
results from different subjects which might help advance the liaison of two fields for faster 
drug development in nose-to-brain delivery. 
The formulative approach of administering size specific 10 µm particles increased 
deposition in the olfactory region. The observations from Chapter 3 and Chapter 4 posed 
an exciting research hypothesis that such a formulative approach used in combination with 
an intranasal targeting device can further augment olfactory targeting. Therefore in 
Chapter 5, a CFPD modeling technique was employed to answer this question with an aim 
to study the effect of particle size combined with bi-directional delivery technique on 
olfactory deposition. The results of this study provided an essential identification; 
microparticles sized between 14-18 µm showed significantly enhanced drug deposition in 
the olfactory region combined with the bi-directional delivery technique. The airflow 
direction in the bi-directional delivery technique was anticipated to be reason for increase in 




Many other targeting devices are being developed to improve olfactory deposition; it 
would be interesting to examine the particle size effect on these targeting devices and to 
identify if such a combined approach can further enhance olfactory targeting. Future studies 
will be required to acquire deposition data from a large population to determine any 
differences in deposition patterns between the subjects. Effect of surface modification of 
size-specific particles with olfactory neuron-specific proteins like lectins on nose-to-brain 
delivery of drugs could be an exciting research question for the future studies. While this 
thesis provides evidence to support that the size controlled particles increase deposition in 
the olfactory region, the biological relevance of this increased deposition needs to be 
investigated in future studies.  
In summary, the in-vitro, in-vivo and in-silico studies complement and refine each other 
and are essential to optimize a drug delivery system. This thesis utilized a formulation 
strategy, the development of a microparticle delivery system and integrated data from 
in-vitro, in-vivo and in-silico studies to refine and optimize the delivery system. Together, 
the data presented in this thesis provides evidence for the potential of a size tailored 
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A. Clinical trials on nose-to-brain drug delivery 
The PubMed database (http://www.ncbi.nlm.nih.gov/pubmed/) was searched with the 
specific keyword string for intranasal drug delivery to the brain. Clinical trials intended for 
the drug delivery to the brain via nasal route were identified after reading the titles and/or 
abstracts. While few of the important clinical trials are references in the Chapter 1 a full list 
is uploaded to the following web link. 
https://files.acrobat.com/a/preview/c4afac0e-4406-492b-bd01-0897060ecef6 
 
Search criteria: ("nose"[MeSH Terms] OR "nose"[All Fields] OR "nasal"[All Fields] 
OR "transnasal"[All Fields] OR "intranasal"[All Fields] OR "olfactory"[All Fields]) AND 
("brain"[MeSH Terms] OR "brain"[All Fields] OR "central nervous system"[MeSH Terms] 
OR "central nervous system"[All Fields] OR "cerebrospinal"[All Fields]) AND (“targeting” 
[All Fields] OR "delivery"[All Fields] OR "transport"[All Fields]) AND (“clinical trial” 
(Filter)). 
B. Calculation of %DTP values for microparticle formulations 
The PubMed database (http://www.ncbi.nlm.nih.gov/pubmed/) was searched with 
following keyword string to identify the suitable literature. The %DTP values for the 
individual studies identified are given in Table 21. 
 Search criteria: ("nose"[MeSH Terms] OR "nose"[All Fields] OR "nasal"[All Fields] 
OR "transnasal"[All Fields] OR "intranasal"[All Fields] OR "olfactory"[All Fields]) AND 
("brain"[MeSH Terms] OR "brain"[All Fields] OR "central nervous system"[MeSH Terms] 
OR "central nervous system"[All Fields] OR "cerebrospinal"[All Fields]) AND (“targeting” 
[All Fields] OR "delivery"[All Fields] OR "transport"[All Fields]) AND ("Microparticles 




Table 21 %DTP values calculated for the microparticle formulations from the reported literature. 











4210 0 583 3480 0 100 N6-
cyclopentyladenosine 4210 0 807 33495 6420.53 80.83 
Gavini  
et al. 2010 144 0 47 55 17.95 67.36 
Rokitamycin 
Sun  
et al. 2012 480.37 0 129.16 25.18 6.77 73.11 
Methotrexate 
Rassu  
et al. 2015 
145.10 NR 8.92 198.20 12.18 93.85 deferoxamine 
mesylate 145.10 NR 14.89 815.70 83.70 89.73 
Dalpiaz  
et al. 2014 
NR NR NR NR NA 100 (claimed) 
Zidovudine Prodrug 
NR NR NR NR NA 100 (claimed) 
Dilpiaz  
et al. 2015 
NR NR NR 354 NA 100 (claimed) 





C. Ex-vivo mucoadhesion apparatus 
 
Figure 8.1 Tensile strength apparatus used to measure the ex-vivo mucoadhesion strength of the 
TSP-microparticles. (A) TSP-microparticles containing FITC-Dextrans attached to the moving 
probe (MP) (B) Special mucoadhesion rig (MR) with porcine olfactory mucosa (C &D) Assembly 





D. Microparticle insufflation studies 
Average weight of microparticles being expelled from the insufflator device was 
established using a series of experiments (n = 5) where a constant volume of air (10mL) was 
sucked into the syringe and mass of the expelled microparticles is determined using an 
electronic balance. 
Table 22. Microparticle expulsion from insufflator device. Weight of empty insufflator (W1), weight 
of insufflator loaded with microparticles (W2) and weight of insufflator after expulsion of 

















SD (mg)  
19.4342 19.4451 19.4392 10.9000 5.9000 
5.8360 ± 0.3 
19.4342 19.4454 19.4397 11.2000 5.7000 
19.4342 19.4460 19.4404 11.8000 5.6000 
19.4342 19.4455 19.4400 11.3000 5.5000 
19.4342 19.4466 19.4401 12.4000 6.4800 





E. HPLC method validation data for peripheral tissues 
Table 23 Intraday and inter-day accuracy and precision of phenytoin and its metabolite in lung tissue 








Metabolite    
1 6.99 -9.17 107.26 
5 5.68 -11.41 112.30 
10 5.18 -5.01 103.56 
Phenytoin    
1 5.62 -12.01 112.99 
5 9.42 -6.81 108.58 
10 6.53 -2.41 100.86 
Inter-day 
Metabolite    
1 6.44 -4.47 104.47 
5 8.05 -10.42 110.42 
10 4.28 -9.70 109.70 
Phenytoin    
1 4.97 4.97 105.70 
5 5.06 -10.28 110.28 






Table 24 Intraday and inter-day accuracy and precision of phenytoin and its metabolite in liver tissue 








Metabolite    
1 6.02 -9.25 109.25 
5 6.48 -0.78 100.78 
10 2.98 4.21 95.79 
Phenytoin    
1 3.79 -13.34 113.34 
5 4.45 -2.66 102.66 
10 2.15 5.03 94.97 
Inter-day 
Metabolite    
1 6.05 -4.57 104.57 
5 6.63 -7.55 107.55 
10 3.32 -4.81 104.81 
Phenytoin    
1 3.48 3.48 104.58 
5 5.70 -2.97 102.97 






Table 25 Intraday and inter-day accuracy and precision of phenytoin and its metabolite in kidney 








Metabolite    
1 1.67 -10.19 110.19 
5 6.29 0.93 99.07 
10 7.49 5.61 94.39 
Phenytoin    
1 4.49 5.03 94.97 
5 8.92 -4.82 104.82 
10 7.42 12.65 87.35 
Inter-day 
Metabolite    
1 4.54 2.86 97.14 
5 8.25 -2.92 102.92 
10 8.07 -0.58 99.79 
Phenytoin    
1 4.94 4.94 98.99 
5 6.35 3.77 96.23 






Table 26 Intraday and inter-day accuracy and precision of phenytoin and its metabolite in spleen 








Metabolite    
1 2.40 3.99 96.01 
5 0.32 6.13 -4.01 
10 9.99 4.05 95.95 
Phenytoin    
1 5.89 -1.61 101.61 
5 7.16 4.47 95.53 
10 3.95 8.47 91.53 
Inter-day 
Metabolite    
1 5.66 8.57 91.43 
5 4.69 -3.30 103.30 
10 6.36 2.83 97.17 
Phenytoin    
1 10.71 10.71 97.75 
5 5.71 5.84 94.16 






Table 27 Intraday and inter-day accuracy and precision of phenytoin and its metabolite in heart 








Metabolite    
1 4.19 -5.61 105.61 
5 1.93 1.63 98.37 
10 5.82 8.11 91.89 
Phenytoin    
1 7.30 -13.60 113.60 
5 1.74 6.08 93.92 
10 3.78 -0.92 100.92 
Inter-day 
Metabolite    
1 9.81 6.23 93.77 
5 4.03 0.54 99.46 
10 4.56 3.57 96.01 
Phenytoin    
1 5.30 5.30 107.94 
5 3.15 5.07 94.93 





F. Airflow in nasal cavities of three human subjects at different nebulization velocities 
 
Figure 8.2 Representative airflow streamlines of nebulization and bi-directional delivery methods in three subjects at different nebulization airflow 
rates. Arrows indicate the region of recirculation. The color map indicates the velocity of air flow
 
 
 
 
